<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> IMMUNE PHARMACEUTICALS INC (Form: 10-K, Received: 03/30/2016 18:10:48) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_EXHIBIT_INDEX **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_SUBSEQUENT_EVENTS FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_21 **FIS_SUBSIDIARIES FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_23_2 **FIS_EXPERTS_CONSENT_2 FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="133">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="V434974_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	WASHINGTON, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	FORM&nbsp;10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	(Mark One)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Annual
	Report Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934
</B>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	For the Fiscal Year Ended&nbsp;December&nbsp;31,
	2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
<B>
	&uml;
</B>
</FONT>
<B>
	Transition
	Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	For the transition period from ____ to
	____
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Commission File No. 000-51290
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Immune Pharmaceuticals Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Exact name of registrant as specified in
	its charter)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 49%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 49%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	52-1841431
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	(State or other jurisdiction of incorporation or organization)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	(IRS Employer Identification No.)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	430 East 29th Street, Suite 940, New
	York, NY 10016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Address of principal executive offices)
	(zip code)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Registrant&rsquo;s telephone number, including
	area code:
<B>
	(646) 440-9310
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: CENTER">
<B>
	Securities registered pursuant
	to Section&nbsp;12(b)&nbsp;of the Act:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Title of each class
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name of each exchange on which registered
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Common Stock, par value $0.0001 per share
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	The NASDAQ Stock Market LLC
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT">
	Securities registered pursuant to Section&nbsp;12(g)&nbsp;of
	the Act:
<B>
	None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp; Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	is not required to file reports pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act.&nbsp; Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during
	the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
	subject to such filing requirements for the past 90 days. Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted
	and posted pursuant to Rule&nbsp;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
	was required to submit and post such files). Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark if disclosure of
	delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant&rsquo;s
	knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any
	amendments to this Form&nbsp;10-K.&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of
	&ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule&nbsp;12b-2
	of the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Large accelerated filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 47%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Accelerated filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-accelerated filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Smaller reporting company
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of June 30, 2015, the last business
	day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate market value of shares of common stock
	held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is
	an affiliate), computed by reference to the closing bid price of such shares on the NASDAQ Capital Markets was $39,353,570.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of March 24, 2016, the registrant had
	35,985,761 shares of common stock, par value $0.001 per share, outstanding
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following documents (or parts thereof)
	are incorporated by reference into the following parts of this Form 10-K: portions of the registrant&rsquo;s Proxy Statement for
	the 2016 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to
	the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) within
	120 days of the registrant&rsquo;s fiscal year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	TABLE OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 15%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A HREF="#V434974_10K_HTM_A_001">
	PART I
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 80%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 5%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;1.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_002">
	Business
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	1
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;1A.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_003">
	Risk Factors
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;1B.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_004">
	Unresolved Staff Comments
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	41
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;2.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_005">
	Properties
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	41
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;3.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_006">
	Legal Proceedings
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	41
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;4.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_007">
	Mine Safety Disclosures
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	42
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A HREF="#V434974_10K_HTM_A_008">
	PART II
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;5.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_009">
	Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	42
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;6.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_010">
	Selected Financial Data
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	43
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;7.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_011">
	Management's Discussion and Analysis of Financial Condition And Results of Operations
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	44
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;7A.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_012">
	Quantitative and Qualitative Disclosures About Market Risk
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	52
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;8.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_013">
	Financial Statements and Supplementary Data
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	52
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;9.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_014">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosures
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	52
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;9A.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_015">
	Controls and Procedures
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	53
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;9B.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_016">
	Other Information
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A HREF="#V434974_10K_HTM_A_017">
	PART III
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;10.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_018">
	Directors, Executive Officers and Corporate Governance
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;11.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_019">
	Executive Compensation
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;12.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_020">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholders
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;13.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_021">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;14.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_022">
	Principal Accounting Fees and Services
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART IV
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Item&nbsp;15.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<A HREF="#V434974_10K_HTM_A_023">
	Exhibits and Financial Statement Schedules
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 10.05PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A HREF="#V434974_10K_HTM_A_024">
	SIGNATURES
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	59
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	i
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING
	STATEMENTS
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	This Annual Report on Form&nbsp;10-K
	contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
	other than statements of historical facts contained in this Annual Report on Form&nbsp;10-K, or Form 10-K, including statements
	regarding our future results of operations and financial position, business strategy, prospective products, product approvals,
	research and development costs, timing and likelihood of success, plans and objectives of management for future operations and
	future results of anticipated products, are forward-looking statements.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	In some cases, you can identify forward-looking
	statements by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
	&ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;contemplate,&rdquo;
	&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo; or the
	negative of these terms or other similar expressions.
</I>
<I>
	These forward-looking statements are only predictions. We have based
	these forward-looking statements largely on our current expectations and projections about future events and financial trends that
	we believe may affect our business, financial condition and results of operations. All forward-looking statements speak only as
	of the date of this Form&nbsp;10-K, are expressly qualified in their entirety by the cautionary statements included in this Form&nbsp;10-K
	and are subject to a number of risks, uncertainties and assumptions, including those described under the sections in this Form&nbsp;10-K
	entitled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
	Operations&rdquo; and elsewhere in this Form&nbsp;10-K.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	These statements involve known and unknown
	risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
	different from any future results, performance or achievements expressed or implied by the forward-looking statements. These factors
	include, among others:
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to continue to meet our obligations under our existing debt agreements;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to obtain approval to market and commercialize any of our product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our dependence upon key personnel;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization
	of our product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory
	approval process;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to find partners for our products on attractive terms, on a timely basis, or at all;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our history of operating losses since our inception;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the highly competitive nature of our business;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to maintain the listing of our common stock on NASDAQ;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks associated with litigation;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks associated with our ability to protect our intellectual property;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks associated with our ability to raise additional funds;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to complete our planned clinical trials (or initiate other trials) in accordance with our estimated timelines due
	to delays
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to continue to operate as a going concern; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our liquidity.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Further, any forward-looking statement
	speaks only as of the date on which it is made. New risk factors and uncertainties may emerge from time to time, and it is not
	possible for management to predict all risk factors and uncertainties, or how they may affect us. Except as required by law, we
	do not intend to, update or revise the forward-looking statements in this Form&nbsp;10-K after the date of this Form&nbsp;10-K,
	whether as a result of any new information, future events, changed circumstances or otherwise. This Form&nbsp;10-K also contains
	market data related to our business and industry. This market data includes projections that are based on a number of assumptions.
	If these assumptions turn out to be incorrect, actual results may differ from the projections based on these assumptions. As a
	result, our markets may not grow at the rates projected by these data, or at all. The failure of these markets to grow at these
	projected rates may have a material adverse effect on our business, financial condition, results of operations and the market price
	of our common stock.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT>
<I>
	&nbsp;
</I>
</FONT>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<A NAME="V434974_10K_HTM_A_001">
</A>
<B>
	PART
	I
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT>
	&nbsp;
</FONT>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT>
<A NAME="V434974_10K_HTM_A_002">
</A>
<B>
	ITEM
	1. BUSINESS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 15.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune Pharmaceuticals
	Inc., together with its subsidiaries (&ldquo;Immune&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo; or the &ldquo;Company&rdquo;),
	is a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics
	in the fields of immuno-inflammation and immuno-oncology. On August 25, 2013, Immune Pharmaceuticals Inc. (formerly EpiCept Corporation),
	a Delaware corporation closed a merger transaction (&ldquo;Merger&rdquo;) with Immune Pharmaceuticals Ltd., a privately held Israeli
	company (&ldquo;Immune Ltd.&rdquo;), pursuant to a definitive Merger Agreement and Plan of Reorganization, dated as of November
	7, 2012, as amended, (&ldquo;Merger Agreement&rdquo;), by and among Immune, EpiCept Israel Ltd., (&ldquo;Merger Sub&rdquo;), an
	Israeli company and a wholly-owned subsidiary and Immune Ltd. Pursuant to the Merger Agreement, Merger Sub merged with and into
	Immune Ltd., following which Immune Ltd. became a wholly-owned subsidiary of Immune Pharmaceuticals Inc. and the former stockholders
	of Immune Ltd. received shares of Immune Pharmaceuticals Inc. that constituted a majority of the outstanding shares of Immune.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company focuses
	on a precision medicine approach to treatment of diseases by incorporating methods for better patient selection in its clinical
	trials and the potential for development of companion diagnostics. The Company&rsquo;s Immuno-inflammation product pipeline includes:
	bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation,
	a portfolio of clinical-stage immune oncology products and nanocyclo, a topical nanocapsule formulation of cyclosporine-A, for
	the treatment of atopic dermatitis and psoriasis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s
	current product portfolio is summarized in the table below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="WIDTH: 24%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-ALIGN: CENTER">
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Product(s)/
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Product Candidate(s)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 26%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Primary Indication(s)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 14%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Status
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 30%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Commercialization Rights
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	BERTILIMUMAB
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Bullous Pemphigoid
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	IBD (Crohn's and ulcerative&nbsp;&nbsp;colitis)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Atopic Dermatitis
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase I/II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	NASH
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase I/II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NANOCYCLO (cyclosporin-A)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Atopic Dermatitis, Psoriasis
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Preclinical
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	IMMUNO-ONCOLOGY
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Crolibulin
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Solid Tumors
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Azixa
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Glioblastoma multiforme
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NanomAbs
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Solid Tumors
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Preclinical
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Bispecific Antibodies
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Oncology
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Preclinical
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Ceplene
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Acute Myeloid Leukemia (in combination with IL-2)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase III/ (marketed in the EU by Meda AB)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Americas, Israel), Meda (EU, RoW)
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 8.8PT; TEXT-INDENT: -8.8PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	OTHER/ PAIN
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	AmiKet
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Neuropathic Pain
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase III (Ready)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	LidoPAIN
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Pain
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Phase II
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The
	Company&rsquo;s immuno-oncology pipeline includes Ceplene, a first-in-class small molecule targeting the Histamine-2 Receptor
	(&ldquo;H2R&rdquo;) to overcome immunosuppression in Acute Myeloid Leukemia (&ldquo;AML&rdquo;) and potentially other
	malignancies. Ceplene has completed Phase III clinical trials and is approved by the European Medicines Agency
	(&ldquo;EMA&rdquo;) and in Israel and is marketed by Meda AB. Azixa and crolibulin are Phase II clinical stage
	vascular disrupting agents (&ldquo;VDA&rdquo;). NanomAbs is a technology platform that allows the targeted delivery
	of chemotherapeutics into cancer cells and a novel technology platform for the construction of bispecific antibodies
	for immunotherapies. The Company continues to review opportunities relating to the Company&rsquo;s non-core assets for
	the treatment of neuropathic pain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Strategy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune&rsquo;s goal
	is to be a leading biotechnology company focused on the discovery, development and commercialization of novel immunotherapies for
	the treatment of diseases that currently lack effective therapies. The Company&rsquo;s work targets are primarily in severe inflammatory
	diseases in dermatology, gastro-enterology and cancer. The Company plans to achieve this by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	unlocking the value of its pipeline by allowing financing of specific asset groups such as but not limited to Immuno-Oncology
	through the establishment independently funded asset-centric subsidiaries;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Securing scientific expert collaborative partnerships with academia to develop its products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	accelerating clinical development of its products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	expanding its product portfolio through targeted acquisitions and through the development of new drug candidates utilizing
	the Company&rsquo;s proprietary nanoparticle and bispecific technologies; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	securing collaborative partnerships with other companies to co-develop and commercialize its products.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Products and Programs
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Bertilimumab
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s
	lead product candidate, bertilimumab, is a fully human monoclonal antibody that targets eotaxin-1, a chemokine involved in inflammation.
	Eotaxin-1 has been validated as a bio-marker of disease severity and a therapeutic target for several inflammatory diseases. In
	2015, the Company initiated and is currently enrolling patients in Phase II clinical trials, comprised of a placebo-controlled,
	double-blind study with bertilimumab for the treatment of ulcerative colitis (&ldquo;UC&rdquo;), a common form of inflammatory
	bowel disease (&ldquo;IBD&rdquo;), and an open label trial in newly diagnosed patients with bullous pemphigoid (&ldquo;BP&rdquo;),
	a rare auto-immune disease. The Company is also currently planning to expand the bertilumimab clinical development program to include
	severe atopic dermatitis (&ldquo;AD&rdquo;) and a series of preclinical and pilot clinical studies in multiple indications including
	liver disease such as nonalcoholic steatohepatitis (&ldquo;NASH&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In February 2015,
	Immune announced publication of new data on the role of eotaxin-1 in UC and Crohn's disease (&ldquo;CD&rdquo;). The article, published
	in Digestive Disease Science, presented results of an observational clinical study intended to characterize serum and intestinal
	wall eotaxin-1 levels in IBD patients, and explored the effects of targeting eotaxin-1 by specific antibodies in an animal IBD
	model. These studies were conducted under the oversight of Professor Eran Goldin, Chairman of the Digestive Diseases Institute
	at Shaare Zedek Medical Center of the Hebrew University School of Medicine in Jerusalem, and supported in part by an unrestricted
	grant from Immune. Professor Goldin, the principal investigator for the study, stated: &quot;The observational clinical study shows
	that tissue eotaxin-1 correlates with disease severity in both UC and CD. The Company believes that the results obtained in the
	clinical study support the role of eotaxin-1 as a target in IBD, a therapeutic area in which over half of patients fail to sustain
	remission. A first-in-class alternative to currently available therapies will offer a new treatment option.&rdquo; In 2013 Immune
	filed a patent for anti-eotaxin-1 monoclonal antibodies (&ldquo;mAbs&rdquo;) for the treatment of UC and CD.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In November 2015,
	Immune obtained clearance of its Investigational New Drug application from the Food and Drug Administration (&ldquo;FDA&rdquo;)
	allowing for expansion in 2016 of its phase II clinical trial in BP to multiple sites in the United States. Additionally, in November
	2015, the first patient was dosed in the Phase II clinical trials with bertilimumab in UC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Bertilimumab addresses
	large unsatisfied markets such as Crohns disease, UC and severe AD as well as an orphan indication,
	bullous pemphigoid (BP), with limited treatment alternatives. Upon successful development, regulatory approval and commercialization
	in multiple indications, bertilimumab has the potential to address the following markets based on research from GlobalData Plc
	(&ldquo;GlobalData&rdquo;) and on multiple analysts&rsquo; reports:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the $14.0 billion crohn&rsquo;s &amp; colitis market
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the $7.3 billion atopic dermatitis market
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the $1.6 billion bullous pemphigoid market.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s strategy is to enter into
	a strategic partnership with a large pharmaceutical or biotechnology company in order to accelerate the development of bertilimumab
	and maximize its commercial potential.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	NanoCyclo
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In January 2016, Immune entered into a worldwide exclusive licensing agreement with BioNanoSim Ltd., an
	Israeli company led by Professor Simon Benita, former Head of the Drug Research Institute at the Hebrew University of Jerusalem,
	for the development of a topical nanocapsule formulation of cyclosporine. NanoCyclo is the first stable formulation to leverage
	nanotechnology to ensure local dermal penetration of and minimize systemic exposure to cyclosporine, a drug used orally for the
	treatment of psoriasis and AD. NanoCylco has the possibility of development under a 505(b)2-regulatory submission, which is typically
	a faster process than the traditional 505(b)1 regulatory submission utilized by new chemical entities. Based on market research
	from GlobalData and multiple analysts&rsquo; reports,
	NanoCyclo could the estimated $7.3 billion AD market and the $5.3 billion psoriasis market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Immuno Oncology
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company's&nbsp;Immuno Oncology programs include the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
<B>
<I>
	Ceplene
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Ceplene&reg;
	(histamine dihydrochloride), the Company&rsquo;s lead oncology product candidate functions in AML by reducing the
	immunosuppressive effects of reactive oxygen species on T cells and Natural Killer (&ldquo;NK&rdquo;) cells, permitting their
	effective activation by Interleukin-2 (&ldquo;IL-2&rdquo;) in order to eliminate residual leukemic cells in patients who are
	in clinical complete remission. New findings emerging from work performed by the Company&rsquo;s scientific collaborators
	from the University of Gothenburg, Sweden, has led to the identification of a patient cohort, which is most likely to benefit
	from combination Ceplene/IL-2 immunotherapy treatment. The Company&rsquo;s current research is in delineating the value of
	combining Ceplene with immune checkpoint inhibitors, which should pave the way for future trials and label expansion. Celpene
	is already approved for marketing in Europe and Israel and has Orphan Drug status in the U.S and EU.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In March 2016
	the Company announced that new clinical pharmacology and outcomes data will be presented by Prof. Kristoffer Hellstrand, Dr.
	Anna Martner and their scientific colleagues from the University of Gothenburg and Universit&agrave; di Roma, Italy, at the
	upcoming American Association of Cancer Research annual conference to be held April 16-20, 2016, in New Orleans, LA. Results
	of a post-marketing clinical study using Ceplene in patients with AML will also be presented at the conference. The study
	showed that immunotherapy with Ceplene and low-dose IL-2 led to a re-distribution of cytotoxic T-cell subsets in blood
	towards a tumor-killing phenotype. These immunological properties of Ceplene and IL-2 therapy significantly predicted
	clinical outcomes such as relapse and survival. The results illustrated the potential for the use of T-cell bio-markers to
	accurately predict the efficacy of Ceplene and IL-2 in patients with AML, and to focus treatment on those patients most
	likely to benefit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In February 2016 the
	Company announced that it had filed a patent application directed to the treatment of AML and other cancers. The new invention
	provides methods of treating cancer by administration of Ceplene in combination with immune checkpoint inhibitors. The new patent
	also provides methods of predicting the efficacy of Ceplene and IL-2 therapy in patients with AML.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune
	intends to leverage recent data on predictive bio-markers and post-adhoc analysis of earlier studies to design and seek FDA
	guidance for a pivotal Overall Survival study in AML supporting a New Drug Application in the U.S. Immune is evaluating
	options for Ceplene in ex-U.S. territories where Ceplene is approved or could be approved based on the EU registration and
	where Immune has or may obtain the commercial rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
<B>
<I>
	Azixa
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Azixa
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	(verubulin) is a Phase II novel microtubular destabilizer that functions as a VDA. It evades multidrug
	resistance pumps, thus crossing the blood-brain-barrier and achieving high central nervous system concentrations. In Phase I and
	II clinical trials in glioblastoma multiforme (&ldquo;GBM&rdquo;), evidence of objective response was seen, including in patients
	who had failed previous bevacizumab (Avastin) therapy. Many scientists in the field of angiogenesis have suggested that the combination
	of anti-angiogenic and VDAs may be synergistic by both disrupting existing tumor vessels and inhibiting the formation of new vessels
	simultaneously. In addition, the Company is continuing preclinical work studying the potential advantages of combining Azixa with
	immune checkpoint inhibitors. If the results of these studies warrant further investigation, the Company may plan further clinical
	studies for GBM as well as other solid tumors. Azixa has Orphan Drug status for GBM in the U.S.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
<B>
<I>
	Crolibulin
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
	Crolibulin
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	is a novel small
	molecule VDA and apoptosis inducer for the treatment of patients with solid tumors and is a novel microtubule destabilizer that
	is selective for pathologic vasculature. Crolibulin is being studied by the National Cancer Institute in Phase I/II clinical trials
	for the treatment of anaplastic thyroid cancer (&ldquo;ATC&rdquo;). Crolibulin has shown promising vascular targeting activity
	with potent anti-tumor activity in preclinical in vitro and in vivo studies and in a Phase I clinical trial conducted in part by
	the National Cancer Research Institute and the Company. The molecule has been shown to induce tumor cell apoptosis and selectively
	inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts
	demonstrated crolibulin inhibits growth of established tumors of a number of different cancer types. In preclinical animal tumor
	models, combination therapy has demonstrated synergistic activity with cytotoxic drugs as well as anti-angiogenic drugs. This may
	support further development of crolibulin by the Company or with a partner in a variety of cancers other than ATC, including but
	not limited to refractory ovarian cancer and neuro-endocrine tumors. In a Phase I/II clinical trial of crolibulin in combination
	with cisplatin several complete responses were observed.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	NanomAbs
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s
	NanomAbs technology platform is an antibody-drug conjugate (&ldquo;ADC&rdquo;) platform potentially capable of generating novel
	drugs with enhanced profiles, as compared to stand-alone antibodies. The technology conjugates mAbs to drug loaded nanoparticles
	to target drugs to specific cells. NanomAbs selectively accumulates in diseased tissues and cells, resulting in higher drug accumulation
	at the site of action with minimal off-target exposure. The Company is currently attempting to build a longer-term pipeline of
	NanomAbs for the treatment of cancer and may seek to enter into collaborative agreements with other companies to acquire complementary
	drugs or technologies to potentially accelerate the development of NanomAbs product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Bispecific Antibodies
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In December 2015,
	the Company published data with a novel bispecific antibody in a poster presentation at the IBC Life Sciences Antibody Engineering
	&amp; Therapeutics Conference in San Diego, CA. Immune's poster presentation titled &quot;Design and Validation of a Novel Tetravalent
	IgG1-like BiSpecific Antibody Format&quot;. In this publication, the Company described positive study results with this novel
	platform for the production of tetravalent IgG1-like bispecific antibodies. The prototype bispecific antibody retained effector
	functions and mediated redirect killing of target cells by cytokine induced killer T cells demonstrating direct anti-cancer effects
	in vitro as well as anti-tumor activity and improved survival in a mouse xenograft model of disseminated leukemia. The Company
	believes that this newly developed platform may be further used to generate novel bispecific antibodies against immune-oncology
	targets. The poster was presented by Dr. Boris Shor, PhD, Executive Director Research &amp; Development, Immune Pharmaceuticals
	Inc. and Dr. Jean Kadouche, PhD, a scientific co-founder of Immune. This work was developed by a collaborative European consortium
	and funded by a European grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In March 2016, the
	Company announced the publication of preclinical data in support of its bispecific antibody platform in the Journal of Immunology
	by Dr. Jean Kadouche, scientific co-founder of Immune, and other collaborators from a consortium of academic centers. The authors
	described the design and validation of a novel platform for the production of tetravalent&nbsp;IgG1-like bispecific antibodies,
	including final in-vivo proof-of-concept data for the benchmark molecule targeting human leukocyte antigen class II histocompatibility
	antigen and cluster of differentiation 5 (&ldquo;HLA-DR/CD5&rdquo;) protein. This work has been funded in part by a European grant
	to the collaborative European consortium.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Going forward, the Company
	is focusing on the development of bispecific antibodies targeting two immune check points, an immune check point and tumor specific
	target and undisclosed novel targets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Other / Pain
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	AmiKet&trade;
</I>
</B>
<B>
<I>
	/ AmiKet Nano
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	AmiKet is a prescription
	topical analgesic cream containing a formulation of two FDA approved drugs: amitriptyline, which is a widely-used antidepressant;
	and ketamine, an N-methyl-D-aspartic acid (&ldquo;NMDA&rdquo;), antagonist that is used as an intravenous anesthetic. AmiKet has
	completed Phase I and II clinical trials involving 1,700 patients for the treatment of neuropathic pain. In 2010, the FDA granted
	AmiKet Orphan Drug status for the treatment of postherpetic neuralgia (&ldquo;PHN&rdquo;). The PHN Phase III clinical trial has
	been designed on the basis of two statistically significant Phase II clinical trials. The Company is currently developing a new
	improved formulation of the product utilizing nano-particle technology licensed from Yissum Research Development Company of The
	Hebrew University of Jerusalem, Ltd. (&ldquo;Yissum&rdquo;). AmiKet Nano is expected to provide patent protection until 2036 and
	allow for the development of additional indications including diabetic peripheral neuropathy chemotherapy-induced peripheral neuropathy
	and chronic back pain. In October 2015 Immune&rsquo;s Pain Scientific Advisory Board met to discuss a Phase III clinical trial
	aimed at seeking a broad neuropathic pain label and on the benefits of its novel nano formulation. The Company believes that the
	Advisory Board recommendation could serve as the basis for further development and commercialization for AmiKet/AmiKet Nano with
	a broader peripheral neuropathic pain indication, addressing an $8 billion market according to GlobalData. The Company continues
	to review strategic opportunities by seeking investors or potential corporate partners to unlock the value of its Pain franchise
	with a focus on Amiket Nano.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	License Agreements and other Collaborative Research and Development
	Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	BioNanoSim Ltd - Nano Cyclosporine-A
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In January 2016, Immune Pharmaceuticals
	Inc., through its wholly owned subsidiary, Immune Ltd. entered into a definitive research and license agreement with BioNanoSim
	Ltd., (&ldquo;BNS&rdquo;). The license was entered into pursuant to an existing binding MOU, dated June 10, 2015, by and between
	the Company and Yissum. Under the license, the Company obtained from BNS an exclusive, worldwide sublicense, with a right to further
	sublicense, for the development, manufacturing and commercialization of certain inventions and research results regarding Yissum&rsquo;s
	patents in connection with nanoparticles for topical delivery of cyclosporine-A (Nanocyclo), for all topical skin indications.
	In consideration for the License, the Company will pay BNS the following payments throughout the term of the License:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual maintenance fee of $30,000, commencing on January 1, 2021, which maintenance fee shall
	increase by 30% each year, up to a maximum annual maintenance fee of $0.1 million and may be credited against royalties or milestone
	payments payable in the same calendar year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a license fee in the amount of $0.5 million, to be paid in four equal installments to be made between
	January 4, 2016 and October 1, 2016;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	royalties on net sales of products (as such term is defined in the License) by the Company in the
	amount of up to 5%, subject to certain possible reductions in certain jurisdictions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Sublicense fees in the amount of 18% of any non-sales related consideration received by the Company
	from a sublicense or an option to receive a sublicense for the products and/or the licensed technology (as such terms are
	defined in the license); and
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	milestones payments of up to
	approximately $4.5 million and 250,000 shares of the Company&rsquo;s common stock upon the achievement of certain regulatory,
	clinical development and commercialization milestones, though in the event that the Company receives consideration from a
	sublicensee for any such milestones, the Company will pay to BNS the higher of either (a) the amount of the particular
	milestone payment or (b) the amount of the sublicense fees that are due for such sublicensee consideration paid to the
	Company. In addition, the Company shall reimburse BNS within 60 days for expenses relating to patent fees and will sponsor a
	12-month research program to prepare the program for investigational new drug (&ldquo;IND&rdquo;) submission.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Yissum &ndash;
	AmiKet Nano
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In June 2015, the
	Company entered into a definitive research and license agreement with Yissum. Under the license, the Company has obtained an exclusive,
	worldwide license from Yissum, with certain sublicensing rights, to make commercial use of certain of Yissum&rsquo;s patents and
	know-how in connection with a topical nano-formulated delivery of AmiKet for the development, manufacturing, marketing, distribution
	and commercialization of products based on the technology. In consideration for the license, the Company shall pay Yissum the following
	payments throughout the term of the license:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual maintenance fee of $30,000 commencing on June 25, 2020, which maintenance fee shall increase
	by 30% each year, up to a maximum annual maintenance fee of $0.1 million and may be credited against royalties or milestone payments
	payable in the same calendar year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	royalties on net sales of products (as such term is defined in the license) by the Company in the
	amount of up to 3%, subject to certain possible reductions in certain jurisdictions;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	milestones payments of up to approximately $4.5 million upon the achievement of certain regulatory,
	clinical development and commercialization milestone; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reimbursement of related patent fees
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Furthermore, the Company
	will fund an annual research program in the amount of approximately $0.4 million annually, plus VAT and any applicable taxes, commencing
	on October 1, 2015 (or such other time as mutually agreed between the parties). The results of the research, including any patents
	or patent applications shall automatically be licensed to the Company. As of December 31, 2015, the Company accrued the first installment
	of the annual research fee of $0.2 million, which was paid in the first quarter of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Yissum &ndash;
	NanomAbs
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In April 2011, the
	Company entered into a license agreement with Yissum that includes patents, research results and know-how developed by Professor
	Simon Benita related to the NanomAbs technology. Yissum granted the Company an exclusive license, with a right to sub-license,
	to make commercial use of the licensed technology in order to develop, manufacture, market, distribute or sell products derived
	from the license. As consideration for the grant of the license, the Company is required to pay the following consideration:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	royalties in the amount of up to 4.5% of net sales;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual license maintenance fee between $30,000 for the first year and up to a maximum of $0.1
	million from the first year through the sixth year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	research fees of at least $0.3 million for the first year and at least $0.1 million from the second
	year through the sixth year (but, not to exceed $1.8 million in the aggregate);
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	milestone payments up to $8.6 million, based on the attainment of certain milestones, including
	IND application submission, patient enrollment in clinical trials, regulatory approval and commercial sales;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	sub-license fees in amounts up to 18% of any sub-license consideration; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	equity consideration in the amount of 8% of the Company&rsquo;s shares of common stock on a fully
	diluted basis.&nbsp; The license expires, on a country-by-country basis, upon the later of the expiration of (i)&nbsp;the last
	valid licensed patent, (ii)&nbsp;any exclusivity granted by a governmental or regulatory body on any product developed through
	the use of the licensed technology or (iii)&nbsp;the 15-year period commencing on the date of the first commercial sale of any
	product developed through the use of the licensed technology.&nbsp; Upon the expiration of the license,&nbsp;the Company will have
	a fully paid, non-exclusive license to the licensed technology.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Atlante Biotech
	SAS (&ldquo;Atlante&rdquo;)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In December 2015,
	the Company entered into an exclusive license with Atlante to the patents and know-how for a new format of bispecific antibody
	platform. The technology, the result of a collaborative European consortium led by Dr. Kadouche and funded by a European grant,
	developed the novel platform for the production of tetravalent IgG1-like bispecific antibodies. A prototype bispecific antibody
	utilizing the platform was shown to retain effector functions and mediate redirect killing of target cells by cytokine induced
	killer T cells. Moreover, the bispecific antibody demonstrated direct in-vitro and in-vivo anti-cancer effects in tumor models
	and improved survival in a mouse xenograft model of disseminated leukemia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Dr. Jean Kadouche,
	and Alan Razafindrastita
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In December&nbsp;2011,
	Dr Jean Kadouche sold, assigned and transferred to the Company the entire right, title
	and interest for all countries, in and to any and all patents and inventions related to mice producing human antibodies and a method
	of preparation of human antibodies for nominal cash consideration paid to Dr. Jean Kadouche and 800,000 of shares of the Company&rsquo;s
	common stock&nbsp;(registered in the name of Dr. Jean Kadouche) and $20,000 (paid to Jean Kadouche and Alan Razafindrastita), collectively,
	the Human Antibody Production Technology Platform.&nbsp; Through the Human Antibody Production Technology Platform and additional
	laboratory work, human immune systems and specific cell lines were introduced in mice, enabling the mice to produce human mAbs.&nbsp;
	With additional laboratory work, the human mAbs can be produced in an efficient manner.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Shire Biochem
	Inc. (&ldquo;Shire Biochem&rdquo;)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In connection with
	the Merger, the Company acquired a license agreement for the rights to the MX2105 series of apoptosis inducer anti-cancer compounds
	from Shire Biochem, (formerly known as BioChem Pharma, Inc.). Under the agreement, the Company is required to provide Shire Biochem
	a portion of any sublicensing payments it receives if Immune relicense the series of compounds or makes milestone payments to Shire
	BioChem totaling up to $26.0 million, assuming the successful commercialization of the compounds by the Company for the treatment
	of a cancer indication, as well as pay a royalty on product sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Lonza Sales
	AG
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In May 2012, Lonza
	Sales AG (&ldquo;Lonza&rdquo;), granted the Company a sublicensable, non-exclusive worldwide license under certain know-how and
	patent rights to use, develop, manufacture, market, sell, offer, distribute, import and export bertilimumab, as it is produced
	through the use of Lonza&rsquo;s system of cell lines, vectors and know-how.&nbsp; If Lonza manufactures bertilimumab,&nbsp;the
	Company must pay to Lonza a royalty of 1% of the net selling price of the product, if the Company or one of its strategic partners
	manufactures bertilimumab,&nbsp;the Company must pay to Lonza approximately $0.1 million, annually during the course of the license
	agreement (first payable upon commencement of Phase II clinical trials) plus a royalty of 1.5% of the net selling price of the
	product, and if any other party manufactures the bertilimumab,&nbsp;the Company must pay to Lonza approximately $0.5 million per
	sublicense annually during the duration of such sublicense plus a royalty of 2% of the net selling price of the product.&nbsp;
	In addition,&nbsp;the Company must pay Lonza approximately $3,000 for the supply of certain cell lines, if the Company uses such
	cell lines.&nbsp; Notwithstanding the foregoing,&nbsp;Immune is not obligated to manufacture bertilimumab through the use of Lonza&rsquo;s
	system.&nbsp; The royalties are subject to a 50% reduction based on the lack of certain patent protections, including the expiration
	of patents, on a country-by-country basis.&nbsp; Unless earlier terminated (including, but not limited to, the reasons set forth
	below), the license agreement continues until the expiration of the last enforceable valid claim to the licensed patent rights,
	which began to expire in 2014 and will continue to expire between 2015 and 2016. The Company may terminate the license agreement
	for convenience upon 60 days prior written notice to Lonza.&nbsp; Either Lonza or Immune may terminate the license agreement by
	prior written notice if (i)&nbsp;the other party commits a breach that is not remedied within 30 days of notice of such breach
	requiring its remedy (if such breach is capable of being remedied) or (ii)&nbsp;the other party is unable to pay its debts, enters
	into liquidation, has a receiver appointed or ceases to carry on its business.&nbsp; Additionally, Lonza may terminate the license
	agreement if the Company knowingly, directly or indirectly, oppose, dispute or assist any third party to oppose or dispute the
	patents or patent applications, or the validity of such, with respect to any of the licensed patent rights.&nbsp; In addition to
	the license agreement, on June&nbsp;27, 2011, Immune and Lonza entered into an agreement for the manufacture of bertilimumab for
	use in certain of the Company&rsquo;s Phase II clinical trials.&nbsp; See &ldquo;Manufacturing&rdquo; below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 14.8PT">
<B>
<I>
	MabLife SAS (&ldquo;MabLife&rdquo;)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In March 2012,&nbsp;the
	Company acquired from MabLife, through an assignment agreement, all right, title and interest in and to the patent rights, technology
	and deliverables related to the anti-Ferritin mAb (&ldquo;AMB8LK&rdquo;), including its nucleotide and protein sequences, its ability
	to recognize human acid and basic ferritins, or a part of its ability to recognize human acid and basic ferritins.&nbsp; The consideration
	was as follows: (i)&nbsp;$0.6 million payable in six equal installments (total payments to date totaled $0.2 million); and (ii)&nbsp;royalties
	of 0.6% of net sales of any product containing AMB8LK or the manufacture, use, sale, offering or importation of which would infringe
	on the patent rights with respect to AMB8LK.&nbsp; The Company is required to assign the foregoing rights back to MabLife if it
	fails to make any of the required payments, is declared insolvent or bankrupt or terminates the agreement. In February 2014, the
	Company acquired from MabLife, through an irrevocable, exclusive, assignment of all rights, titles and interests in and to the
	secondary patent rights related to the use of anti-ferritin monoclonal antibodies in the treatment of some cancers, Nucleotide
	and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies
	or antibody-like molecules comprising these sequences. During the first quarter of 2015, MabLife informed the Company that it had
	filed for bankruptcy. The Company is considering its options relating to the MabLife assignment agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<B>
<I>
	iCo Therapeutics
	Inc. (&ldquo;iCo&rdquo;)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In December&nbsp;2010,
	iCo granted Immune an option to sub-license the use of bertilimumab from iCo, which obtained certain exclusive license rights to
	intellectual property relating to bertilimumab pursuant to a license agreement with Cambridge Antibody&nbsp;Technology Group Plc,
	a biotechnology company, dated December&nbsp;20, 2006, and to which the Company became a party. On June&nbsp;24, 2011,&nbsp;the
	Company exercised its option and obtained a worldwide&nbsp;license from iCo for the use and development of bertilimumab for all
	human indications, other than ocular indications, pursuant to a product sub-license agreement. The Company paid iCo upfront consideration
	of $0.5 million, plus common stock and warrants to purchase Immune common stock.&nbsp; In addition, iCo may receive from the Company
	up to $32.0 million in milestone payments plus royalties. These milestones include the first dosing in a Phase III clinical trial,
	filing a Biologics License Application/Marketing Authorization Application (&ldquo;BLA/MMA&rdquo;), approval of a BLA/MAA and the
	achievement of $100.0 million in aggregate sales of licensed products for use in IBD.&nbsp; The term of the license lasts until
	the expiration of all payment obligations on a country-by-country basis, at which point the license will be deemed fully paid,
	perpetual and irrevocable with respect to that country.&nbsp; However, iCo retains the worldwide exclusive right to the use of
	bertilimumab (iCo-008) for all ocular applications.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<B>
<I>
	Dalhousie University
	(&ldquo;Dalhousie&rdquo;)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In July 2007, Immune
	entered into a direct license agreement with Dalhousie,&nbsp;under which the Company was granted an exclusive license to certain
	patents for the topical use of tricyclic anti-depressants and
<FONT STYLE="COLOR: #222222; BACKGROUND-COLOR: WHITE">
	N
</FONT>
	-methyl-D-aspartate
	(&ldquo;NMDA&rdquo;) receptor antagonists as topical analgesics for neuralgia. These and other patents cover the combination treatment
	consisting of amitriptyline and ketamine in AmiKet. This technology has been incorporated into AmiKet. Immune has also been granted
	worldwide rights to make, use, develop, sell and market products utilizing the licensed technology in connection with passive dermal
	applications. The Company is obligated to make payments to Dalhousie upon achievement of specified milestones and to pay royalties
	based on annual net sales derived from the products incorporating the licensed technology. The Company is further obligated to
	pay Dalhousie an annual maintenance fee until the license agreement expires or is terminated, or a New Drug Application (&ldquo;NDA&rdquo;)
	for AmiKet is filed with the FDA, or Dalhousie will have the option to terminate the contract. The license agreement with Dalhousie
	terminates upon the expiration of the last to expire licensed patent. In April 2014, the Company entered into a Waiver and Amendment
	to the license agreement pursuant to which Dalhousie agreed to irrevocably waive the Company&rsquo;s obligation to pay the $0.5
	million maintenance fee that was due on August 27, 2012 and August 27, 2013 and in any subsequent year. In addition, the Company
	has agreed to pay Dalhousie royalties of 5% of net sales of licensed technology in countries in which patent coverage is available
	and 3% of net sales in countries in which data protection is available. The parties have also agreed to amend the timing and increase
	the amounts of the milestone payments payable under the license agreement. As of December 31, 2015 and 2014, no amounts were due
	to Dalhousie.&nbsp; Additional milestones payments will become due upon sub licensing and receipt of certain regulatory approvals,
	none of which have yet been met or received.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<B>
<I>
	Endo Pharmaceuticals
	Inc. (&ldquo;Endo&rdquo;)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="COLOR: #222222">
	In
	December 2003, and prior to the consummation of the Merger, EpiCept entered into a license agreement (&ldquo;License Agreement&rdquo;)
	with&nbsp;Endo under, which EpiCept granted&nbsp;Endo&nbsp;(and its affiliates) the exclusive (including as to EpiCept and its
	affiliates) worldwide right to commercialize LidoPAIN BP. EpiCept also granted&nbsp;Endo worldwide rights to use certain of EpiCept&rsquo;s
</FONT>
	patents
<FONT STYLE="COLOR: #222222">
	for the development of certain other non-sterile, topical lidocaine patches, including Lidoderm,&nbsp;Endo&rsquo;s
	non-sterile topical lidocaine-containing patch for the treatment of chronic lower back pain. The Company assumed the license agreement
	at the time of the Merger.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #222222; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #222222">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT; COLOR: #222222">
	Under
	this license agreement the Company shall receive payments of up to $52.5 million upon the achievement of various milestones relating
	to product development, regulatory approval and commercial success for both the Company&rsquo;s LidoPAIN BP product and&nbsp;Endo&rsquo;s
	own back pain product, so long as, in the case of&nbsp;Endo&rsquo;s product candidate, the Company&rsquo;s patents provide protection
	thereof. The Company is also expected to receive royalties from&nbsp;Endo&nbsp;based on the net sales of LidoPAIN BP. These royalties
	are payable until generic equivalents to the LidoPAIN BP product are available or until expiration of&nbsp;the patents covering
	LidoPAIN BP, whichever is sooner. The Company is also eligible to receive milestone payments from&nbsp;Endo&nbsp;of up to $30.0
	million upon the achievement of specified regulatory and net sales milestones of Lidoderm,&nbsp;Endo&rsquo;s chronic lower back
	pain product candidate, so long as the Company&rsquo;s patents provide protection thereof. The license terminates upon the later
	of the conclusion of the royalty term, on a country-by-country basis, and the expiration of the last applicable EpiCept patent
	covering licensed&nbsp;Endo&nbsp;product candidates on a country-by-country basis. Either&nbsp;party may terminate the agreement
	upon an uncured material breach by the other or, subject to the relevant bankruptcy laws, upon a bankruptcy event of the other.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; BACKGROUND-COLOR: WHITE; COLOR: #222222">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; COLOR: #222222">
	In
	July 2015, the Company amended its 2003 Licensing Agreement with Endo. As a result, Immune transferred to Endo its previously licensed
	patents related to the use of topical lidocaine in acute and chronic back pain and Endo granted to Immune a royalty-free, non-exclusive,
	fully transferable license to those patents. Endo will make undisclosed milestone payments to Immune if Endo receives a back pain
	indication for a lidocaine-based product, as per the original 2003 Licensing Agreement. Immune re-gained full exclusive rights
	to develop, commercialize and license LidoPAIN. The Company is assessing strategic alternatives for this non-core asset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Intellectual Property and Exclusivity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company seeks
	to protect its product candidates and its technology through a combination of patents, trade secrets, proprietary know-how, regulatory
	exclusivity and contractual restrictions on disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Patents and Patent Applications
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company owns or
	licenses rights with respect to patents and patent applications relating to bertilimumab, AmiKet, Ceplene, AMB8LK and other product
	candidates. In addition, the Company has licensed rights to several technology platforms for the development of proprietary products
	including rights to: antibody nanoparticle conjugates (NanomAbs); Human Antibody Production Technology; Bispecific Antibody Technology
	and nanoparticles for dermal and systemic delivery of drugs, which are necessary to conduct its business. Patents related to such
	product candidates and technology platforms may provide future competitive advantages by providing exclusivity related to the composition
	of matter, formulation, and methods of use of the applicable product candidate or technology platform. The patent positions for
	the Company&rsquo;s product candidates and platforms are described below and include at least 10 granted U.S. patents, 33 granted
	foreign patents, 4 pending U.S. applications, and 19 pending foreign patent applications that it owns or licenses. These patents
	generally have a term of 20 years from the date of the non-provisional filing unless referring to an earlier filed application.
	Some of the Company&rsquo;s U.S. patents have a term of 17 years from the grant date. Where possible, the Company intends to seek
	patent term extensions in the U.S. for approved products. The length of the patent term extension will vary and is related to the
	length of time the drug is under regulatory review while the patent is in force. The Hatch-Waxman Act may permit a patent term
	extension of up to five years beyond the expiration date set for the patent. The Company&rsquo;s patent positions are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A license to a patent family that covers a composition of matter of bertilimumab and a method of
	using bertilimumab to screen for an antibody or antibody fragment that binds eotaxin-1, including: four registered patents in the
	U.S. and registered patents in Europe (Switzerland, Germany, France, and Ireland), Brazil, Canada, Israel, Australia, Japan, New
	Zealand and Singapore, and one pending patent applications in the U.S. The foreign patents and patents granted with respect to
	pending patent applications in this family will expire, without extension, in March 2021.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to a patent application family that covers a method for treating
	an IBD with an anti-human eotaxin antibody, including bertilimumab in the US, Europe, Australia, Canada, China, Israel, and New
	Zealand. Any patents granted with respect to the pending patent application will expire, without extension, in March 2034.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to the U.S. and European (Germany, Switzerland, Spain, UK,
	Italy, and France) registered patents that cover AMB8LK composition of matter and/or methods of use for targeting of a molecule
	to certain tumors and for localizing a tumor in a subject. The European patent granted with respect to the pending patent applications
	in this family will expire, without extension, in January 2020. The U.S. patent, which benefits from patent term adjustment from
	the United States Patent and Trademark Office (&ldquo;USPTO&rdquo;), will expire in January 2022.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to a registered U.S. patent, a registered European patent
	(Belgium, Switzerland, Germany, Spain, France, UK, Ireland, Italy, and the Netherlands), and two pending patent applications in
	Canada and the U.S. claiming a chimeric AMB8LK. The granted U.S. patent, which benefits from patent term adjustment from the USPTO,
	will expire in July 2030. The European patents and any patents granted with respect to the pending patent applications will expire,
	without extension, in September 2027.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A license to a patent family that covers polymer-based nanoparticles for the dermal or systemic
	delivery of therapeutic compounds. Patent applications for this family are pending in Australia, Canada, China, Europe, Israel,
	India, Japan, South Korea, and the U.S. Any patents granted with respect to this pending patent application will expire, without
	extension, in January 2032.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to a U.S. patent application related to the Human Antibody
	Production Technology Platform. Any patent granted with respect to the pending patent application will expire, without extension,
	in May 2033.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to several families of patents related to the AmiKet product,
	including four granted U.S. patents, as well as granted patents in Australia, Canada, China, Hong Kong, Israel, Mexico, and New
	Zealand. Patent applications for this family are pending in Chile, Japan, Mexico and Venezuela. These granted patents and any patents
	granted with respect to any pending patent applications will expire, without extension, between 2017 and 2023. These patents and
	patent application have claims directed to topical uses of tricyclic antidepressants, such as amitriptyline, and NMDA receptor
	antagonists, such as ketamine, as treatments for relieving pain, including neuropathic pain.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to patents covering the synthesis of histamine dihydrochloride
	(Ceplene) and its use for treating cancer, including three granted U.S. patents, as well as a registered European patent (Austria,
	Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden,
	Switzerland, and UK). The U.S. patents will expire in May 2016 and January 2019, and the other patents will expire in December
	2019.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights, title and interest in and to U.S. Canadian, and Japanese patents and a European patent
	application related to crolibulin, structurally related analogs, and uses thereof. The U.S. patent will expire, without extension,
	in November 2029. The granted Canadian patent and any pending patent applications will expire in July 2027.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company seeks
	to protect its proprietary information by requiring its employees, consultants, contractors, outside partners and other advisers
	to execute, as appropriate, nondisclosure and assignment of invention agreements upon commencement of their employment or engagement.
	Immune also require confidentiality or material transfer agreements from third parties that receive its confidential data or materials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune believes that
	the Company&rsquo;s owned and licensed patents and pending patent applications provide coverage for its product candidates and
	technology platforms and it intends to aggressively enforce its intellectual property rights if necessary to preserve such rights
	and to gain the benefit of its investment. The patent positions of companies like Immune are generally uncertain and involve complex
	legal and factual questions. The Company&rsquo;s ability to maintain and solidify its proprietary position for its product candidates
	and technology platforms will depend on the Company&rsquo;s success in obtaining effective claims and enforcing those claims once
	granted. The Company does not know whether any of its patent applications or those patent applications that it license will result
	in the issuance of any patents. The Company&rsquo;s granted patents and those that it may issue in the future, or those licensed
	to it, may be challenged, narrowed, circumvented or found to be invalid or unenforceable, which could limit the Company&rsquo;s
	ability to stop competitors from marketing related products or the length of term of patent protection that the Company may have
	for its products. Neither Immune nor its licensors can be certain that they were the first to invent the inventions claimed in
	the Company&rsquo;s owned or licensed patents or patent applications. In addition, Immune&rsquo;s competitors may independently
	develop similar technologies or duplicate any technology developed by the Company, and the rights granted under any granted patents
	may not provide Immune with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive
	time required for development, testing and regulatory review of a potential product, it is possible that, before any of the Company&rsquo;s
	products can be commercialized, any related patent may expire or remain in force for only a short period following commercialization,
	thereby reducing any advantage of the patent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s
	commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of its technologies
	and product candidates as well as successfully defending these patents against third-party challenges. The Company has various
	compositions of matter and use patents, which have claims directed to its product candidates or their methods of use. The Company&rsquo;s
	patent policy is to pursue, maintain, defend, retain and secure patents and patent rights, whether developed internally or licensed
	from third parties, for the technology, inventions and improvements related to its core portfolio of product candidates and that
	are or may be commercially important to the development of its business. The Company also relies on trade secrets, technical know-how
	and continuing innovation to develop and maintain its competitive position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The pharmaceutical,
	biotechnology and other life sciences industries are characterized by the existence of a large number of patents and frequent litigation
	based upon allegations of patent infringement. While the Company&rsquo;s product candidates are in clinical trials, and prior to
	commercialization, the Company believes that its current activities fall within the scope of the exemptions provided by 35 U.S.C.
	Section 271(e) in the U.S. and Section 55.2(1) of the Canadian Patent Act, each of which covers activities related to developing
	information for submission to the FDA and its counterpart agency in Canada. As the Company&rsquo;s product candidates&rsquo; progress
	toward commercialization, the possibility of an infringement claim against it increases. While Immune attempts to ensure that its
	product candidates and the methods it employs to manufacture them do not infringe other parties&rsquo; patents and other proprietary
	rights, competitors or other parties may assert that the Company infringed on their proprietary rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Trade Secrets and Proprietary Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition to patents,
	the Company relies on trade secrets and technical know-how to develop and maintain its competitive position. Trade secrets and
	technical know-how can be difficult to protect. The Company seeks to protect its proprietary processes, in part, by confidentiality
	agreements and invention assignment agreements with its employees, consultants, scientific advisors, contractors and commercial
	partners. These agreements are designed to protect its proprietary information. The Company also seeks to preserve the integrity
	and confidentiality of its data, trade secrets and technical know-how by maintaining physical security of its premises and physical
	and electronic security of its information technology systems. While the Company has confidence in these individuals, organizations
	and systems, such agreements or security measures may be breached, and it may not have adequate remedies for any breach. In addition,
	the Company&rsquo;s trade secrets may otherwise become known or be independently discovered by competitors or others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Manufacturing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune does not own
	or operate manufacturing facilities for any of its products, nor does it plan to develop its own manufacturing operations in the
	foreseeable future. The Company currently depends on third party contract manufacture organizations for all of its bulk drug substance
	and drug candidates for its preclinical and clinical trials. The raw materials that the Company requires to manufacture its product
	candidates are readily available commodities commonly used in the pharmaceutical industry. On June&nbsp;27, 2011,&nbsp;Immune signed
	a manufacturing agreement with Lonza, which relates to the Phase II production of bertilimumab using Lonza&rsquo;s proprietary
	cell line technology. Under the agreement, Lonza will produce Phase II clinical trial material at its mammalian development and
	manufacturing facility and prepare documentation required for submission to the FDA, including the applicable clinical trial application.&nbsp;
	To date, two clinical batches have been produced and delivered by Lonza under this agreement. A third batch is currently being
	manufactured to support conducting additional pilot clinical trials.&nbsp;On May&nbsp;2, 2012,&nbsp;Immune entered into a license
	agreement with Lonza with respect to, among other uses, the production, sale and distribution of bertilimumab as manufactured using
	Lonza&rsquo;s system of cell lines, vectors and know-how.&nbsp; See &ldquo;&mdash;License Agreements&mdash;Lonza Sales AG&rdquo;
	above. In addition, the Company relies on certain third parties to perform filling, finishing, labeling, packaging, distribution,
	laboratory testing and other services related to the manufacture of bertilimumab clinical supply.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In 2014, the Company
	entered into an agreement with Probiogen AG to develop a new Chinese Hamster Ovary (&ldquo;CHO&rdquo;) derived cell line with improved
	characteristics, including higher productivity. A new manufacturing process was developed for bertilimumab by STC Biologics Inc.
	The agreements are based on fee for service and does not include any licensing fees. Effective the first quarter of 2016, the Company
	signed a new agreement to transfer the manufacturing of bertilimumab to MassBiologics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Manufacturers of Immune&rsquo;s
	products are required to comply with applicable Good Manufacturing Practices (&ldquo;GMP&rdquo;) regulations. GMP regulations require,
	among other things, quality control and quality assurance, as well as the corresponding maintenance of records and documentation.
	Accordingly, manufacturers must continue to spend time, money, and effort in the area of production and quality control in order
	to maintain GMP regulatory compliance. In addition, changes to the manufacturing process generally require prior Regulatory Health
	Authority approval before being implemented.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company and its
	contract manufacturers must ensure that all of the processes, methods and equipment are compliant with GMP for drugs on an ongoing
	basis, as mandated by the FDA and other regulatory authorities, and conduct extensive audits of vendors, contract laboratories
	and suppliers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Contract Research Organizations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 39.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune outsources
	clinical trial activities to Clinical Research Organizations (&ldquo;CROs&rdquo;). The Company&rsquo;s clinical CROs comply with
	guidelines from the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for
	Human Use, which attempt to harmonize the FDA and the EMA regulations and guidelines. Immune creates and implements the drug development
	plans and manage the CROs according to the specific requirements of the drug candidate under development. To the extent clinical
	research is conducted by the CROs (or the Company in the future), compliance with certain federal regulations, including but not
	limited to 21 C.F.R. parts 50, 54, 56, 58 and 318, which pertain to, among other things, institutional review boards, informed
	consent, financial conflicts of interest by investigators, good laboratory practices and submitting IND applications, may be required.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Marketing, Sales and Commercialization
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 39.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Given the Company&rsquo;s
	stage of development, it does not have any internal sales, marketing or distribution infrastructure or capabilities. In the event
	the Company receives regulatory approval for its product candidates, it intends, where appropriate, to pursue commercialization
	relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are
	equipped to market and/or sell the Company&rsquo;s products, if any, through their well-developed sales, marketing and distribution
	organizations in order to gain access to global markets. In addition, the Company may out-license some or all of its worldwide
	patent rights to more than one party to achieve the fullest development, marketing and distribution of any products it develops.
	Over the longer term, the Company may consider ultimately building an internal marketing, sales and commercial infrastructure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Environmental Matters
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company, its agents
	and its service providers, including its manufacturers, may be subject to various environmental, health and safety laws and regulations,
	including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of
	hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. The Company believes that its
	business, operations and facilities, including, to its knowledge, those of its agents and service providers, are being operated
	in compliance in all material respects with applicable environmental and health and safety laws and regulations. All information
	with respect to any chemical substance is filed and stored as a Material Safety Data Sheet, as required by applicable environmental
	regulations. Based on information currently available to the Company, Immune does not expect environmental costs and contingencies
	to have a material adverse effect on the Company. However, significant expenditures could be required in the future if Immune,
	its agents or its service providers are required to comply with new or more stringent environmental or health and safety laws,
	regulations or requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	United States Government Regulations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	New Drug Application
	(&ldquo;NDA&rdquo;) Approval Processes
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In the U.S., the FDA
	regulates drugs under the Federal Food, Drug, and Cosmetic Act (&ldquo;FFDCA&rdquo;), and implementing regulations. Failure to
	comply with the applicable U.S. requirements at any time during the product development process or approval process, or after approval,
	may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on the Company.
	These sanctions could include refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold,
	warning letters, product seizures, total or partial suspension of production or distribution, or injunctions, fines, disgorgement,
	and civil or criminal penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The process required
	by the FDA before a drug may be marketed in the U.S. generally involves the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	completion of nonclinical laboratory tests, animal studies and formulation studies conducted according
	to Good Laboratory Practices (&ldquo;GLPs&rdquo;), or other applicable regulations;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	performance of adequate and well-controlled human clinical trials according to Good Clinical Practices
	(&ldquo;GCPs&rdquo;), to establish the safety and efficacy of the proposed drug for its intended use;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	submission to the FDA of an NDA;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which
	the product is produced to assess compliance with current Good Manufacturing Practices, (&ldquo;cGMPs&rdquo;), to assure that the
	facilities, methods and controls are adequate to preserve the drug&rsquo;s identity, strength, quality and purity;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	satisfactory completion of FDA inspections of clinical sites and GLP toxicology studies; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	FDA review and approval of the NDA.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The testing and approval process requires
	substantial time, effort and financial resources, and Immune cannot be certain that any approvals for its product candidates will
	be granted on a timely basis, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Once a product candidate
	is identified for development, it enters the preclinical or nonclinical testing stage. Preclinical tests include laboratory evaluations
	of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical
	tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical testing may
	continue after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include
	a clinical trial protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring
	safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically
	becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold.
	In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical
	hold may occur at any time during the life of an IND, due to safety concerns or non-compliance, and may affect one or more specific
	studies or all studies conducted under the IND.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	All clinical trials
	must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. These regulations include
	the requirement that all research subjects provide informed consent. Further, an Institutional Review Board (&ldquo;IRB&rdquo;)
	must review and approve the plan for any clinical trial before it commences at any institution. An IRB considers, among other things,
	whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits.
	The IRB also approves the information regarding the trial and the consent form that must be provided to each trial subject or his
	or her legal representative and must monitor the study until completed. All clinical trials must be conducted under protocols detailing
	the objectives of the trial, dosing procedures, research subject inclusion and exclusion criteria and the safety and effectiveness
	criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and progress reports detailing the status
	of the clinical trials must be submitted to the FDA annually. Sponsors must also report within set timeframes to the FDA serious
	and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that
	listed in the protocol or investigation brochure, or any findings from other studies or animal or in vitro testing that suggest
	a significant risk in humans exposed to the drug.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Human clinical trials
	are typically conducted in three sequential phases that may overlap or be combined:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Phase I.
</I>
	The drug is initially introduced into healthy human subjects and tested for safety,
	dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some products for severe or life-threatening
	diseases, such as cancer, especially when the product may be inherently too toxic to ethically administer to healthy volunteers,
	the initial human testing is often conducted in patients.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Phase II.
</I>
	Clinical trials are performed on a limited patient population intended to identify
	possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases
	and to determine dosage tolerance and optimal dosage.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Phase III.
</I>
	Clinical trials are undertaken to further evaluate dosage, clinical efficacy
	and safety in an expanded patient population at geographically dispersed clinical study sites. Phase III clinical trials are conducted
	to provide sufficient data for the statistically valid evidence of safety and efficacy.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;Human clinical
	trials are inherently uncertain and Phase I, Phase II and Phase III testing may not be successfully completed. The FDA or the sponsor
	may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are
	being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
	if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated
	with unexpected serious harm to patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	During the development
	of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to the submission
	of an IND, at the end of Phase II and before an NDA is submitted. Meetings at other times may be requested. These meetings can
	provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on
	the next phase of development. Sponsors typically use the meeting at the end of Phase II to discuss their Phase II clinical results
	and present their plans for the pivotal Phase III clinical trial that they believe will support the approval of the NDA. If a Phase
	II clinical trial is the subject of discussion at the end of Phase II meeting with the FDA, a sponsor may be able to request a
	Special Protocol Assessment (&ldquo;SPA&rdquo;), the purpose of which is to reach agreement with the FDA on the Phase III clinical
	trial protocol design and analysis that will form the primary basis of an efficacy claim.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	According to published
	guidance on the SPA process, a sponsor, which meets the prerequisites, may make a specific request for a SPA and provide information
	regarding the design and size of the proposed clinical trial. The FDA is supposed to evaluate the protocol within 45 days of the
	request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request for additional
	information. An SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial
	begins. If a written agreement is reached, it will be documented and made part of the record. The agreement will be binding on
	the FDA and may not be changed by the sponsor or the FDA after the trial begins except with the written agreement of the sponsor
	and the FDA or if the FDA determines that a substantial scientific issue essential to determining the safety or efficacy of the
	drug was identified after the testing began. There is no indication that the Company will be able to meet the requirements necessary
	for an SPA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Concurrent with clinical
	trials, sponsors usually complete any remaining animal safety studies and also develop additional information about the chemistry
	and physical characteristics of the drug and finalize a process for manufacturing commercial quantities of the product in accordance
	with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug and the
	manufacturer must develop methods for testing the quality, purity and potency of the drug. Additionally, appropriate packaging
	must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable
	deterioration over its proposed shelf-life.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The results of product
	development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests and
	other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
	approval to market the product. The submission of an NDA is subject to the payment of user fees, but a waiver of such fees may
	be obtained under specified circumstances. The Company expects to seek a waiver of these fees as a small company submitting its
	first marketing application. If the waiver is granted it would not extend to establishment or product fees. The FDA reviews all
	NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request
	additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information.
	The resubmitted application also is subject to review before the FDA accepts it for filing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, under
	the Pediatric Research Equity Act (&ldquo;PREA&rdquo;), an NDA or supplement to an NDA must contain data to assess the safety and
	effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration
	for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or
	full or partial waivers. Submission of a pediatric assessment is not required for an application to market a product for an orphan-designated
	indication, and waivers are not needed at this time. However, if only one indication for a product has orphan designation, a pediatric
	assessment may still be required for any applications to market that same product for the non-orphan indication(s).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Once the submission
	is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug representing
	a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. The FDA may refuse to approve
	an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data. Even if such data
	are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA reviews an NDA to
	determine, among other things, whether a product is safe and effective for its intended use and whether its&rsquo; manufacturing
	is cGMP-compliant. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application
	should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally
	follows such recommendations. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured
	and tested. The FDA will also inspect selected clinical sites that participated in the clinical studies and may inspect the testing
	facilities that performed the GLP toxicology studies cited in the NDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Expedited Review
	and Approval
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	NDAs receive either
	standard or priority review. A drug representing a significant improvement in treatment, prevention or diagnosis of disease may
	receive priority review. The FDA has various specific programs, including Fast Track, Breakthrough Therapy, Accelerated Approval
	and Priority Review, which are each intended to expedite the process for reviewing drugs, and in certain cases involving Accelerated
	Review, permit approval of a drug on the basis of a surrogate endpoint. Even if a drug qualifies for one or more of these programs,
	the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review
	or approval will be shortened. Generally, drugs that are eligible for these programs are those for serious or life-threatening
	conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments.
	For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or
	life-threatening diseases or conditions and fill unmet medical needs, and Breakthrough Therapy designation is designed to expedite
	the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates
	that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). Priority
	review is designed to give drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists
	an initial review within six months as compared to a standard review time of ten months. Although Fast Track, Breakthrough Therapy
	designation and Priority Review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent
	meetings with a sponsor of a Fast Track or Breakthrough Therapy designated drug and expedite review of the application for a drug
	designated for Priority Review. The FDA will also provide Breakthrough Therapy designated drugs intensive guidance on an efficient
	drug development program and provide these drug developers with an organizational commitment from the FDA involving senior managers.
	Since sponsors can design clinical trials in a number of ways, in providing its guidance for drugs designated as breakthrough therapies,
	the FDA will seek to ensure that the sponsor of the product designated as a breakthrough therapy receives timely advice and interactive
	communications in order to help the sponsor design and conduct a development program as efficiently as possible. During these interactions,
	the FDA may suggest, or a sponsor can propose, alternative clinical trial designs (e.g., adaptive designs, an enrichment strategy,
	use of historical controls) that may result in smaller trials or more efficient trials that require less time to complete. Such
	trial designs could also help minimize the number of patients exposed to a potentially less efficacious treatment (i.e., the control
	group treated with available therapy). Accelerated Approval, which is described in 21 C.F.R. &sect; 314.500 et seq., provides for
	an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills
	an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a laboratory measurement or physical sign used as
	an indirect or substitute measurement representing a clinically meaningful outcome. As a condition of approval, the FDA may require
	that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Priority
	Review and Accelerated Approval do not change the standards for approval, but may expedite the approval process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	If a product receives
	regulatory approval, the approval may be significantly limited to specific diseases, subpopulations, and dosages or the indications
	for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a
	company to conduct Phase IV testing, which involves clinical trials designed to further assess a drug&rsquo;s safety and effectiveness
	after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been
	commercialized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Patent Term
	Restoration and Marketing Exclusivity
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Depending upon the
	timing, duration and specifics of FDA approval of the use of product candidates, U.S. patents may be eligible for limited patent
	term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation
	for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot
	extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration
	period is generally one-half the time between the effective date of an IND, and the submission date of an NDA, plus the time between
	the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible
	for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation
	with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, the Company intends
	to apply for restorations of patent term for some of its currently owned patents to add patent life beyond their current expiration
	date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Market exclusivity
	provisions under the Federal Food, Drug and Cosmetic Act (&ldquo;FDCA&rdquo;) also can delay the submission or the approval of
	certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the
	first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously
	approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug
	substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&ldquo;ANDA&rdquo;),
	or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal
	right of reference to all the data required for approval. However, an application may be submitted after four years if it contains
	a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA,
	505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted
	or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications,
	dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical
	investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five year and
	three year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would
	be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
	trials necessary to demonstrate safety and effectiveness.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Post-approval
	Requirements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Once an approval is
	granted, the FDA, European authorities and other regulatory authorities may withdraw the approval if compliance with regulatory
	requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown
	problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After
	approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling
	claims, are subject to further regulatory authority review and approval. Some of these modifications, especially adding indications,
	would likely require additional clinical studies. In addition, the FDA may require testing and surveillance programs to monitor
	the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing
	of a product based on the results of these post-marketing programs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Any drug product manufactured
	or distributed by the Company pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other
	things record-keeping requirements; reporting of adverse experiences with the drug; providing the FDA with updated safety and efficacy
	information; drug sampling and distribution requirements; notifying the FDA and gaining its approval of specified manufacturing
	or labeling changes; and complying with FDA promotion and advertising requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Drug manufacturers
	and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
	with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies
	for compliance with cGMP and other laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company expects
	to rely on third parties for the production of clinical and commercial quantities of its products. Future FDA and state inspections
	may identify compliance issues at the facilities of its contract manufacturers that may disrupt production or distribution, or
	require substantial resources to correct.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	From time to time,
	legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the
	approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised
	or reinterpreted by the agency in ways that may significantly affect the Company&rsquo;s business and its products. It is impossible
	to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact
	of such changes, if any, may be.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 19.8PT">
<B>
<I>
	International
	Regulations
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Whether or not Immune
	obtains FDA approval for a product, the Company must obtain approval of a product by the comparable regulatory authorities of foreign
	countries before it can commence clinical trials or marketing of the product in those countries. The approval process varies from
	country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct
	of clinical trials, product licensing, pricing and reimbursement also vary greatly from country to country. Although governed by
	the applicable country, clinical trials conducted outside of the U.S. typically are administered with the three-phase sequential
	process that was discussed above under &ldquo;Government Regulation&mdash;U.S.&rdquo; However, the foreign equivalent of an IND
	is not a prerequisite to performing pilot studies or Phase I clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Under European Union
	regulatory systems, the Company may submit marketing authorization applications either under a centralized or decentralized procedure.
	The centralized procedure, which is required for oncology products and is available for medicines produced by biotechnology or
	which are highly innovative, provides for the grant of a single marketing authorization that is valid for all member states. This
	authorization is a marketing authorization application. The decentralized procedure provides for mutual recognition of national
	approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining
	member states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize
	approval. This procedure is referred to as the mutual recognition procedure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, regulatory
	approval of prices is required in most countries other than the U.S. Immune faces the risk that the resulting prices would be insufficient
	to generate an acceptable return to the Company, its shareholders or its collaborators.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Research and Development
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Since the Company&rsquo;s
	inception, it has made substantial investments in research and development. The Company incurred research and development expenses
	of $5.9 million and $5.6 million during the fiscal years ended December 31, 2015 and 2014, respectively. The Company will require
	additional investments in research and development to bring its product candidates to market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune operates in
	highly competitive segments of the biotechnology and biopharmaceutical markets. The Company faces competition from many different
	sources, including commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and private
	and public research institutions. Many of the Company&rsquo;s competitors have significantly greater financial, product development,
	manufacturing and marketing resources than the Company. Large pharmaceutical companies have extensive experience in clinical testing
	and obtaining regulatory approval for drugs. As a result, these companies may obtain marketing approval more rapidly than Immune
	may be able to and may be more effective in selling and marketing their products. Smaller or early stage companies may also prove
	to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition,
	many universities and private and public research institutes are active in cancer research, some in direct competition with the
	Company. Adequate protection of intellectual property, successful product development, adequate funding and retention of skilled,
	experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune&rsquo;s competitors
	may succeed in developing, acquiring or licensing on an exclusive basis technologies and drug products that are more effective
	or less costly than the products that the Company is currently developing or that it may develop, which could render Immune&rsquo;s
	products obsolete and noncompetitive. Immune expects any products that it develops and commercializes to compete on the basis of,
	among other things, efficacy, safety, convenience of administration and delivery, price and the availability of reimbursement from
	government and other third-party payers. The Company also expects to face competition in its efforts to identify appropriate collaborators
	or partners to help commercialize its product candidates in its target commercial markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	As of March 24, 2016,
	the Company&rsquo;s workforce consisted of eight U.S. and four Israeli employees, all of whom are full-time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Corporate and Available Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune Pharmaceuticals
	Inc. (formerly EpiCept) was incorporated in Delaware in March 1993. Immune Ltd., incorporated in Israel in July 2010, entered into
	a definitive merger agreement with Immune in November 2012, which was completed on August 25, 2013. Immune&rsquo;s principal executive
	offices are located at 430 East 29th Street, Suite 940, New York, NY 10016, and the Company&rsquo;s telephone number is (646) 440-9310,
	and its website address is&nbsp;www.immunepharmaceuticals.com. The information contained in, or accessible through, the Company&rsquo;s
	website does not constitute a part this Annual Report on Form 10-K. The Company&rsquo;s Annual Reports on Form 10-K, Quarterly
	Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports, are available to you free of charge through
	the &ldquo;Investors &mdash; SEC Filings&rdquo; section of its website as soon as reasonably practicable after such materials have
	been electronically filed with, or furnished to, the Securities and Exchange Commission. The Company&rsquo;s shares of common stock
	are listed on The NASDAQ Capital Market and NASDAQ OMX, First North Premier, Stockholm under the symbol &ldquo;IMNP.&rdquo;
</P>
</EFX_BUSINESS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_003">
</A>
	ITEM 1A. RISK FACTORS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Our operations
	and financial results are subject to various risks and uncertainties, including those described below, which could adversely affect
	our business, financial condition, results of operations, cash flows, and the trading price of our common stock. Additional risks
	and uncertainties not presently known to us or that we currently deem immaterial also may materially affect our business operations.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 12.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risks Relating to our Financial Position
	and Need for Additional Capital
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We are an early
	stage corporation. Our limited operating history makes it difficult to evaluate our current business and future prospects, and
	our profitability in the future is uncertain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We commenced operations
	in 2010 and are a new, early stage company. We face the problems, expenses, difficulties, complications and delays, many of which
	are beyond our control, associated with any business in its early stages and has no operating history on which an evaluation of
	our prospects can be made. Such prospects should be considered in light of the risks, expenses and difficulties frequently encountered
	in the establishment of a business in a new industry, characterized by a number of market entrants and intense competition, and
	in the shift from development to commercialization of new products based on innovative technologies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We expect to experience
	significant growth in the number of our employees and the scope of our operations. To manage our anticipated future growth, we
	must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to
	recruit and train additional qualified personnel. Due to our limited resources, we may not be able to effectively manage the expansion
	of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant
	costs and may divert our management and business development resources. Any inability on the part of our management to manage growth
	could delay the execution of our business plans or disrupt our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Factors that may inhibit our efforts to
	commercialize our products without strategic partners or licensees include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 49.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the inability of sales personnel to obtain access to or persuade adequate numbers of physicians
	to prescribe our products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the lack of complementary products to be offered by our sales personnel, which may put us at a
	competitive disadvantage against companies with broader product lines;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	unforeseen costs associated with expanding our own sales and marketing team for new products or
	with entering into a partnering agreement with an independent sales and marketing organization; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	efforts by our competitors to commercialize competitive products.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Moreover, we may incur
	significant operating losses over the next several years. Our ability to achieve profitable operations in the future will depend
	in large part upon successful in-licensing of products approved by the FDA, selling and manufacturing these products, completing
	development of our products, obtaining regulatory approvals for these products, and bringing these products to market. The likelihood
	of the long-term success of our company must be considered in light of the expenses, difficulties and delays frequently encountered
	in the development and commercialization of new drug products, competitive factors in the marketplace, as well as the regulatory
	environment in which we operate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, as a new
	business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
<B>
<I>
	Our management
	has identified internal control deficiencies, which our management believes constitute material weaknesses. Any future material
	weaknesses or deficiencies in our internal control over financial reporting could harm stockholder and business confidence in our
	financial reporting, our ability to obtain financing and other aspects of our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In connection with the preparation of our
	audited financial statements for the year ended December 31, 2015 we concluded that a material weakness existed in internal control
	over financial reporting. As of December 31, 2015, we carried out an assessment of the effectiveness of our internal control over
	financial reporting based on the framework in Internal Control-Integrated Framework (2013), updated and reissued by the Committee
	of Sponsoring Organizations (2013) (&ldquo;COSO Framework&rdquo;). &nbsp;Based on our evaluation under the COSO Framework, our
	management concluded that our internal control over financial reporting was not effective as of December 31, 2015.&nbsp; In connection
	with the above assessment, Immune management identified a material weakness in the control environment relating to segregation
	of duties due to lack of sufficient accounting and finance personnel and lack of a sufficient technology infrastructure to support
	the financial reporting function.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	A material weakness is a significant deficiency,
	or combination of significant deficiencies, that results in there being more than a remote likelihood that a material misstatement
	of the annual or interim financial statements will not be prevented or detected on a timely basis by management or employees in
	the normal course of performing their assigned functions. Although the Company has attempted to address the identified material
	weaknesses by hiring a new controller and is in process of implementing a new general ledger system, management concluded that
	the Company's internal controls over financial reporting were not effective at December 31, 2015. Management is in the process
	of taking the steps as outlined in Item 9A to remediate the December 31, 2015 material weaknesses. Therefore, we cannot be certain
	that, in the future, additional material weaknesses or significant deficiencies will not exist or otherwise be discovered. If our
	efforts to address the weakness identified are not successful, or if other deficiencies occur, these weaknesses or deficiencies
	could result in misstatements of our results of operations, restatements of our financial statements, a decline in our stock price
	and investor confidence or other material effects on our business, reputation, financial condition or liquidity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Our auditors
	have expressed doubt about our ability to continue as a going concern. We have a limited operating history, expect to continue
	to incur substantial operating losses and may be unable to obtain additional financing, causing substantial doubt about our ability
	to continue as a going concern.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Independent Registered
	Public Accounting Firm&rsquo;s Reports issued in connection with our audited financial statements for the year ended December 31,
	2015 stated that there is &ldquo;substantial doubt about the Company&rsquo;s ability to continue as a going concern&rdquo;. Because
	we have been issued an opinion by our auditors that substantial doubt exists as to whether it can continue as a going concern,
	it may be more difficult to attract investors. If we are not able to continue our business as a going concern, we may have to liquidate
	our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely
	that investors will lose part or all of their investment. Our ability to continue as a going concern is dependent on a combination
	of several of the following factors: our ability to generate revenues and raise capital, the &ldquo;cash&rdquo; exercise of warrants
	by holders and access to an established credit line. We have limited capital resources and our operations, since inception, have
	been funded by the proceeds of equity and debt financings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We have incurred
	operating losses since our inception. We expect to incur operating losses for the foreseeable future and may never achieve or maintain
	profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We believe that our
	available cash and short-term investments as of the date of this filing may not be sufficient to fund our anticipated level of
	operations for at least the next 12 months. Management believes the Company&rsquo;s ability to continue its operations depends
	on its ability to generate and grow revenue, results of operations and its ability to access capital markets when necessary to
	accomplish its strategic objectives. Management believes that we will continue to incur losses for the immediate future. The Company
	expects to finance its cash needs from additional equity or debt financing, or need to enter into strategic alliances on products
	in development to sustain our operations until we can achieve profitability and positive cash flows from operating activities,
	if ever.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	At December 31, 2015,
	we had working capital deficit of $1.4 million. Our accumulated deficit amounted to $63.0 million and $45.8 million, at December
	31, 2015 and December 2014, respectively. Our net loss for the years ended December 31, 2015 and 2014 was $17.2 million and $23.6
	million, respectively. Net cash used in operating activities for both the years ended December 31, 2015 and 2014 was $13.9 million.
	Operations since inception have been funded primarily with the proceeds from equity and debt financings. As of December 31, 2015,
	we had cash, and cash equivalents of $4.5 million. We will continue to fund operations from cash on hand, and through the similar
	sources of capital previously described. We can give no assurance that such capital will be available to us on favorable terms
	or at all. If we are unable to raise additional funds in the future on acceptable terms, or at all, we may be forced to curtail
	our development activities. In addition we could be forced to delay or discontinue product development, and forego attractive business
	opportunities. Any additional sources of financing will likely involve the sale of our equity securities, which will have a dilutive
	effect on existing stockholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company expects
	that a large percentage of its future research and development expenses to be incurred in support of current and future preclinical
	and clinical development programs. These expenditures are subject to numerous uncertainties in timing and cost to completion. The
	Company tests its product candidates in numerous preclinical studies for toxicology, safety and efficacy. The Company then conducts
	early stage clinical trials for each drug candidate. As the Company obtains results from clinical trials, it may elect to discontinue
	or delay clinical trials for certain product candidates or programs in order to focus resources on more promising product candidates
	or programs. Completion of clinical trials may take several years but the length of time generally varies according to the type,
	complexity, novelty and intended use of a drug candidate. The cost of clinical trials may vary significantly over the life of a
	project as a result of differences arising during clinical development, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the number of sites included in the trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the length of time required to enroll suitable patients;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the number of patients that participate in and complete the trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the number of doses that patients receive;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the duration of follow-up with the patient;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the product candidate&rsquo;s phase of development; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the efficacy and safety profile of the product.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Expenses
	related to clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with multiple
	research institutions and clinical research organizations that conduct clinical trials on the Company&rsquo;s behalf. The financial
	terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows.
	If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, estimates
	of expenses are modified accordingly on a prospective basis
</FONT>
<FONT STYLE="FONT-SIZE: 12PT">
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	None of the Company&rsquo;s drug candidates
	has received FDA or foreign regulatory marketing approval. In order to grant marketing approval, the FDA or foreign regulatory
	agencies must conclude that its clinical data and that of its collaborators establish the safety and efficacy of the Company&rsquo;s
	drug candidates. Furthermore, the Company&rsquo;s strategy includes entering into collaborations with third parties to participate
	in the development and commercialization of its products. In the event that third parties have control over the preclinical development
	or clinical trial process for a product candidate, the estimated completion date would largely be under control of that third party
	rather than under the Company&rsquo;s control. The Company cannot forecast with any degree of certainty which of its drug candidates
	will be subject to future collaborations or how such arrangements would affect its development plan or capital requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	To become and remain
	profitable, we must succeed in developing and commercializing drugs with significant market potential. This will require us to
	be successful in a range of challenging activities, including the discovery of product candidates, successful completion of preclinical
	testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing,
	marketing and selling those products for which we may obtain regulatory approval. We are only in the preliminary stages of these
	activities. We may not be successful enough in these activities to generate revenues that are substantial enough to achieve profitability.
	Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
	failure to become or remain profitable could depress the market price of our common stock and could impair our ability to raise
	capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our
	common stock may also cause a loss of a part or all of your investment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We have limited
	liquidity and, as a result, may not be able to meet our obligations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We have incurred significant
	losses since our inception. We expect to incur additional losses for the foreseeable future and may never achieve or maintain profitability.
	Since our inception on July 11, 2010 (&ldquo;Inception&rdquo;), we have incurred significant losses and expect to continue to operate
	at a net loss in the foreseeable future. For the fiscal year ended December 31, 2015, we incurred net losses of $17.2 million and
	a total accumulated deficit of $63.0 million. To date, we have financed our operations primarily through private placements of
	common stock and preferred stock, public offering, convertible debt securities and borrowings under secured loans. Our revenue
	to date has consisted of royalties on licensed patents. We have devoted substantially all of our financial resources and efforts
	to developing bertilimumab, our Phase II drug for the treatment of inflammatory diseases and NanomAbs, our platform for the targeted
	delivery of cancer drugs, manufacturing bertilimumab under cGMPs, conducting preclinical studies and clinical trials. We are still
	in the early stages of development of our product candidates, and we have not completed development of bertilimumab, NanomAbs or
	other drugs. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses
	may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially
	as we continue the research and development of our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	To become and remain
	profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will
	require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials
	of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates
	and manufacturing, marketing and selling any products for which we may obtain regulatory approval, and establishing and managing
	our collaborations at various stages of each candidate&rsquo;s development. We are only in the preliminary stages of most of these
	activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough
	to achieve profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Because of the numerous
	risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount
	of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA or EMA to perform
	studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development
	of any of our product candidates, our expenses could increase and revenue could be further delayed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Even if we do achieve
	profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and
	remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain
	our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of
	our company could also cause you to lose part or all of your investment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We will require
	substantial additional funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary
	additional capital, we may be unable to complete the development and commercialization of our product candidates, or continue our
	development programs.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;Our operations
	have consumed substantial amounts of cash since Inception. We will require additional capital for the further development and commercialization
	of our product candidates, as well as to fund our other operating expenses and capital expenditures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We cannot be certain
	that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient
	amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue the development or commercialization
	of one or more of our product candidates. We may also seek collaborators for one or more of our current or future product candidates
	at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. Any
	of these events could significantly harm our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In order to carry
	out our business plan and implement our strategy, we anticipate that we will need to obtain additional financing from time to time
	and may choose to raise additional funds through strategic collaborations, licensing arrangements, public or private equity or
	debt financing, bank lines of credit, asset sales, government grants, or other arrangements. We cannot be sure that any additional
	funding, if needed, will be available on terms favorable to us, or at all. Furthermore, any additional equity or equity-related
	financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants
	and significant interest costs. If we obtain funding through a strategic collaboration or licensing arrangement, we may be required
	to relinquish our rights to certain of our product candidates or marketing territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, certain
	investors, including institutional investors, may be unwilling to invest in our securities if we are unable to maintain the listing
	of our common stock on a U.S. national securities exchange. Our inability to raise capital when needed would harm our business,
	financial condition and results of operations, and could cause our stock price to decline or require that we wind down our operations
	altogether.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	The terms of
	our loan and security agreement place restrictions on our operating and financial flexibility. If we raise additional capital through
	this facility, the terms of any new debt could further restrict our ability to operate our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	As of March 24, 2016,
	the outstanding principal balance of our loan and security agreement with Hercules Capital was $4.5 million, with the option to
	borrow an additional $5.0 million in the event we meet certain milestones prior to June 15, 2016. The loan and security agreement
	contains customary affirmative and negative covenants and events of default applicable to us and our subsidiaries. The negative
	covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers
	or acquisitions, paying dividends or making other distributions, making certain investments, incurring liens and selling certain
	assets in each case subject to certain exceptions. If we default under the facility, the lender may accelerate all of our repayment
	obligations and take control of our pledged assets, potentially requiring us to renegotiate our agreement on terms less favorable
	to us or to immediately cease operations. Further, if we are liquidated, the lenders right to repayment would be senior to the
	rights of the holders of our common stock to receive any proceeds from the liquidation. Any declaration by the lender of an event
	of default could significantly harm our business and prospects and could cause the price of our common stock to decline. If we
	raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We may be unable
	to license our product candidate AmiKet on terms that reflect the current carrying value of the asset, or at all, which would negatively
	affect our business, financial condition and results of operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We periodically perform
	an analysis to determine whether an impairment of our assets has occurred.&nbsp;As of December 31, 2015 and 2014, $27.5 million
	was allocated to acquired, in-process, research and development related to the AmiKet license agreement. Our most recent impairment
	analysis determined that no change in the carrying value of AmiKet was required. However, there is no assurance that future analysis
	would not result in the impairment of the fair value attributable to AmiKet. In addition, if the assumptions we used in connection
	with the merger to value our in-process research and development directly related to the AmiKet license agreement turn out to be
	incorrect, the carrying value of AmiKet may ultimately be impaired which would negatively affect our business, financial condition
	and results of operations. Furthermore, if we are unable to license AmiKet or to license AmiKet on terms materially less favorable
	than the assumptions used to value the asset in the merger, the carrying value of the assets would be impaired, which could materially
	adversely affect our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	AmiKet
<SUP>
	&rsquo;
</SUP>
	s
	successful partnering and commercialization may be affected by regulations on orphan drug status, patent restoration and data exclusivity.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	AmiKet primary patents
	are expiring in 2021 and are essentially limited to the U.S.. We are is assuming that a marketing exclusivity of up to five years
	will be available under the Patent Term Restoration in the United States and under other forms in Europe and Japan to compensate
	for the extended development time. This marketing exclusivity may not be deemed to be applicable to AmiKet or may be reduced to
	less than five years in one or multiple jurisdiction. AmiKet has been granted orphan drug status for Post Herpetic Neuralgia (&ldquo;PHN&rdquo;),
	which confers a seven-year marketing exclusivity in the U.S. for that indication. Orphan drug exclusivity may be reduced or eliminated
	by regulators before AmiKet enjoys all or part of this protection.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	The use of FDA-approved
	therapeutics in AmiKet could require us to conduct additional preclinical studies and clinical trials, which could increase development
	costs and lengthen the regulatory approval process.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	AmiKet utilizes proprietary
	formulations and topical delivery technologies to administer FDA-approved pain management therapeutics. We may still be required
	to conduct preclinical trials and clinical trials to determine if our product candidates are safe and effective. In addition, we
	may also be required to conduct additional preclinical trials and Phase I clinical trials to establish the safety of the topical
	delivery of these therapeutics and the level of absorption of the therapeutics into the bloodstream. The FDA may also require us
	to conduct clinical trials to establish that our delivery mechanisms are safer or more effective than the existing methods for
	delivering these therapeutics. As a result, we may be required to conduct complex clinical trials, which could be expensive and
	time-consuming and lengthen the anticipated regulatory approval process. In addition, the cost of clinical trials may vary significantly
	over the life of a project as a result of differences in the design of the clinical trials arising during clinical development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We may be exposed
	to market risk and interest rate risk that may adversely impact our financial position, results of operations or cash flows.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We may be exposed
	to market risk, i.e
<I>
	.
</I>
	the risk of loss related to changes in market prices, including foreign exchange rates, of financial
	instruments that may adversely impact our financial position, results of operations or cash flows. In addition, our investments
	may be exposed to market risk due to fluctuation in interest rates, which may affect its interest income and the fair market value
	of investments, if any. At present, our investments consist primarily of cash and cash equivalents. We may invest in investment-grade
	marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government
	debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we
	receive from our investments without significantly increasing risk of loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We are exposed
	to fluctuations in currency exchange rates, which could have a material adverse effect on us.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our foreign currency
	exposures gives rise to market risk associated with exchange rate movements of the U.S. dollar, our functional and reporting currency,
	mainly against the New Israeli Shekel, (&ldquo;NIS&rdquo;), the Euro and the British pound sterling. A significant portion of our
	expenses are denominated in U.S. dollars (with certain expenses payable to Lonza, if any, in the British pound sterling and to
	Israeli personnel, including sub-contractors and consultants, in the NIS). Our U.S. dollar expenses consist principally of payments
	made to personnel in the U.S., including sub-contractors and consultants for preclinical studies, clinical trials and other research
	and development activities. We anticipate that the bulk of our expenses will continue to be denominated in U.S. dollars, the NIS
	or the British pound sterling. If the U.S. dollar fluctuates significantly against the NIS or the British pound sterling (to the
	extent we must make payments to Lonza) it may have a negative impact on our results of operations. In addition, non-U.S. dollar
	linked balance sheet items may create foreign exchange gains or losses, depending upon the relative dollar values of the non-U.S.
	currencies at the beginning and end of the reporting period, affecting our net income and earnings per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	To date, we have not
	engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial
	exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately
	protect us from the material adverse effects of such fluctuations. Exchange rate fluctuations resulting in a devaluation of the
	NIS or the British pound sterling compared with the U.S. dollar could have a material adverse impact on our results of operations
	and share price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to
	Regulatory Development, Approval and other Legal Compliance
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	If we are not
	able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to develop and then commercialize
	our product candidates or will not be able to do so as soon as anticipated, and our ability to generate revenue will be materially
	impaired.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our product candidates
	and the activities associated with their development, applications for regulatory approval, and commercialization, including their
	design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution,
	are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar
	regulatory authorities outside the U.S. and Europe. Failure to obtain approval of clinical trial applications, CTAs, in EU countries
	may delay or prevent us from developing our drugs in one or more jurisdictions. Similarly, failure to obtain marketing approval
	for a product candidate (NDA, BLA, or MAA) will prevent us from commercializing our product candidate. While our executives have
	experience with the IND, NDA, BLA, CTA and MAA processes, we expect to rely on third parties to assist us in this process. Securing
	marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory
	authorities for each therapeutic indication to establish the product candidate&rsquo;s safety and efficacy. Securing development
	and later marketing approval also requires the submission of information about the product manufacturing process to, and inspection
	of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately
	effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our
	obtaining marketing approval or prevent or limit commercial use. For example, new drugs frequently are indicated only for patient
	populations that have not responded to an existing therapy or have relapsed. If any of our product candidates with such an indication
	receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales
	of the product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The process of obtaining
	marketing approvals, both in the United States and abroad, is expensive and may take many years. If additional clinical trials
	are required for certain jurisdictions, these trials can vary substantially based upon a variety of factors, including the type,
	complexity and novelty of the product candidates involved, and may ultimately be unsuccessful. Changes in marketing approval policies
	during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review
	process for each submitted product application, may cause delays in the review and approval of an application. Regulatory authorities
	have substantial discretion in the approval process and may reject a marketing application as deficient or may decide that our
	data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations
	of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a product
	candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that
	render the approved product not commercially viable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Although we have already
	met with the FDA regarding the development of bertilimumab, it is possible that the FDA may change its requirements or require
	us to conduct additional preclinical studies and/or clinical trials that may delay the development and approval of this drug. Unfavorable
	data from our clinical trials may restrict the potential development and commercialization of bertilimumab or lead to the termination
	of its development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Ceplene is approved
	by the EMA and registered in over 30 countries in Europe and Israel. It also has Orphan Drug status in both the EU and US for AML.
	The FDA however, refused to file the Ceplene NDA submission due to the lack of an Overall Survival primary endpoint in the study
	and the lack of an IL-2 treatment alone control arm. Based on new biologic and clinical findings that have been studied and analyzed
	since the last communication with the FDA, we are planning further formal discussions with the FDA regarding a path forward for
	registration in the U.S., including the reaching an agreement with the agency on a Special Protocol Assessment (SPA).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Azixa and crolibulin
	are still in early-mid-stage clinical development and the next steps are being considered. Once those are determined, discussions
	will ensue with the FDA regarding the developmental pathways for these drugs. Azixa has Orphan Drug status in the US for glioblastoma
	multiforme (GBM).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	AmiKet has received
	Fast Track designation from the FDA for the treatment of chemotherapy-induced peripheral neuropathy (&ldquo;CIPN&rdquo;), which
	allows for guidance, rolling submission of NDA components and a shorter review cycle than with standard applications. However there
	is no guarantee that the FDA will not change its requirements or that the studies reviewed by FDA will be adequate for marketing
	approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	NanomAbs are novel
	nano-therapeutics. Although the FDA and other regulatory authorities have approved nano-therapeutics in the past, the agency is
	monitoring whether nanotechnology-based therapeutics pose any specific health and human safety risks. While they have not issued
	any regulations to date, it is possible that the FDA and other regulatory authorities could issue regulations or establish policy
	positions in the future regarding nano-therapeutics that could adversely affect our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	With the recent approval
	of Blincyto (blinatumomab), a novel constructed bispecific T-cell engager monoclonal antibodies (BiTEs), the clinical and regulatory
	pathway for bispecifics drugs is now validated. However, as with all therapeutic antibodies, issues such as immunogenicity and
	possible inhibition of critical non-redundant biologic pathways must be considered regulatory risks.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	If we experience
	delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product
	candidates may be harmed and our ability to generate revenues will be materially impaired.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We and other
	drug development companies have suffered setbacks in late-stage clinical trials even after achieving promising results in early
	stage development. Accordingly, the results from completed preclinical studies and early stage clinical trials may not be predictive
	of results in later stage trials and may not be predictive of the likelihood of regulatory approval.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Clinical trial designs
	that were discussed with regulatory authorities prior to their commencement may subsequently be considered insufficient for approval
	at the time of application for regulatory approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We or our partners
	discuss with and obtain guidance from regulatory authorities on clinical trial protocols. Over the course of conducting clinical
	trials, circumstances may change, such as standards of safety, efficacy or medical practice, which could affect regulatory authorities&rsquo;
	perception of the adequacy of any of our clinical trial designs or the data we develop from our clinical trials. Changes in circumstances
	could affect our ability to conduct clinical trials as planned. Even with successful clinical safety and efficacy data, we may
	be required to conduct additional, expensive trials to obtain regulatory approval. Any failure or significant delay in completing
	clinical trials for our product candidates, or in receiving regulatory approval for the commercialization of our product candidates,
	may severely harm our business and delay or prevent us from being able to generate revenue and our stock price will likely decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	If we receive
	regulatory approval, our marketed products will also be subject to ongoing FDA and/or foreign regulatory agency obligations and
	continued regulatory review, and if we fail to comply with these regulations, we could lose approvals to market any products, and
	our business would be seriously harmed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Following initial
	regulatory approval of any of our product candidates, we will be subject to continuing regulatory review, including review of adverse
	experiences and clinical results that are reported after our products become commercially available. This would include results
	from any post-marketing tests or vigilance required as a condition of approval. The manufacturer and manufacturing facilities we
	use to make any of our product candidates will also be subject to periodic review and inspection by the FDA or foreign regulatory
	agencies. If a previously unknown problem or problems with a product, manufacturing or laboratory facility used by us is discovered,
	the FDA or foreign regulatory agency may impose restrictions on that product or on the manufacturing facility, including requiring
	us to withdraw the product from the market. Any changes to an approved product, including the way it is manufactured or promoted,
	often require FDA approval before the product, as modified, can be marketed. Our manufacturers and we will be subject to ongoing
	FDA requirements for submission of safety and other post-market information. If we or our manufacturers fail to comply with applicable
	regulatory requirements, a regulatory agency may:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	issue warning letters;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	impose civil or criminal penalties;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	suspend or withdraw regulatory approval;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	suspend any ongoing clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	refuse to approve pending applications or supplements to approved applications;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	impose restrictions on operations;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	close the facilities of manufacturers; or
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	seize or detain products or require a product recall.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, the policies of
	the FDA or other applicable regulatory agencies may change and additional government regulations may be enacted that could prevent
	or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of adverse government
	regulation that may arise from future legislation or administrative action, either in the U.S. or abroad.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Any regulatory
	approval we receive for our product candidates will be limited to those indications and conditions for which we are able to show
	clinical safety and efficacy.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Any regulatory approval
	that we may receive for our current or future product candidates will be limited to those diseases and indications for which such
	product candidates are clinically demonstrated to be safe and effective. For example, in addition to the FDA approval required
	for new formulations, any new indication to an approved product also requires FDA approval. If we are not able to obtain regulatory
	approval for a broad range of indications for our product candidates, our ability to effectively market and sell our product candidates
	may be greatly reduced and may harm our ability to generate revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	While physicians may
	choose to prescribe drugs for uses that are not described in the product&rsquo;s labeling and for uses that differ from those tested
	in clinical studies and approved by regulatory authorities, our regulatory approvals will be limited to those indications that
	are specifically submitted to the regulatory agency for review. These &ldquo;off-label&rdquo; uses are common across medical specialties
	and may constitute the best treatment for many patients in varied circumstances. Regulatory authorities in the U.S. generally do
	not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications
	by pharmaceutical companies on the subject of off-label use. If our promotional activities fail to comply with these regulations
	or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow
	regulatory rules and guidelines relating to promotion and advertising may cause the regulatory agency to delay its approval or
	refuse to approve a product, the suspension or withdrawal of an approved product from the market, recalls, fines, disgorgement
	of money, operating restrictions, injunctions or criminal prosecutions, any of which could harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	The results
	of our clinical trials are uncertain, which could substantially delay or prevent us from bringing our product candidates to market.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Before we can obtain
	regulatory approval for a product candidate, we must undertake extensive clinical testing in humans to demonstrate safety and efficacy
	to the satisfaction of the FDA or other regulatory agencies. Clinical trials are very expensive and difficult to design and implement.
	The clinical trial process is also time consuming. The commencement and completion of our clinical trials could be delayed or prevented
	by several factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	delays in obtaining regulatory approvals to commence or continue a study;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	delays in reaching agreement on acceptable clinical trial parameters;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	slower than expected rates of patient recruitment and enrollment;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability to demonstrate effectiveness or statistically significant results in our clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	unforeseen safety issues;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	uncertain dosing issues;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability to monitor patients adequately during or after treatment; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability or unwillingness of medical investigators to follow our clinical protocols.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We cannot assure you
	that our planned clinical trials will begin or be completed on time or at all, or that they will not need to be restructured prior
	to completion. Significant delays in clinical testing will impede our ability to commercialize our product candidates and generate
	revenue from product sales and could materially increase our development costs. Completion of clinical trials may take several
	years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product
	candidate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	In some instances,
	we rely on third parties, over which we have little or no control, to conduct clinical trials for our product candidates and their
	failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product
	candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The nature of clinical
	trials and our business strategy requires us to rely on clinical research centers and other third parties to assist us with clinical
	testing and certain research and development activities, such as the agreement we had with Myrexis, Inc. related to the MX90745
	series of apoptosis-inducer anti-cancer compounds. As a result, our success is dependent upon the success of these third parties
	in performing their responsibilities. We cannot directly control the adequacy and timeliness of the resources and expertise applied
	to these activities by such third parties. If such contractors do not perform their activities in an adequate or timely manner,
	the development and commercialization of our product candidates could be delayed. We may enter into agreements, similar to the
	agreement we had with Myrexis, Inc., from time to time with additional third parties for our other product candidates whereby these
	third parties undertake significant responsibility for research, clinical trials or other aspects of obtaining FDA approval. As
	a result, we may face delays if these additional third parties do not conduct clinical studies and trials, or prepare or file regulatory
	related documents, in a timely or competent fashion. The conduct of the clinical studies by, and the regulatory strategies of,
	these additional third parties, over which we have limited or no control, may delay or prevent regulatory approval of our product
	candidates, which would delay or limit our ability to generate revenue from product sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Our therapeutic
	product candidates for which we intend to seek approval are primarily biological products and may face competition sooner than
	expected. This is particularly relevant for our lead product candidate, bertilimumab.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	With the enactment
	of the Biologics Price Competition and Innovation Act of 2009 (&ldquo;BPCIA&rdquo;) as part of the Health Care Reform Law, an abbreviated
	pathway for the approval of bio-similar and interchangeable biological products was created. The new abbreviated regulatory pathway
	establishes legal authority for the FDA to review and approve bio-similar biologics, including the possible designation of a bio-similar
	as &ldquo;interchangeable.&rdquo; The FDA defines an interchangeable bio-similar as a product that, in terms of safety or diminished
	efficacy, presents no greater risk when switching between the bio-similar and its reference product than the risk of using the
	reference product alone. Under the BPCIA, an application for a bio-similar product cannot be submitted to the FDA until four years,
	or approved by the FDA until 12 years, after the original brand product identified as the reference product was approved under
	a BLA. The new law is complex and is only beginning to be interpreted by the FDA. As a result, its ultimate impact, implementation
	and meaning are subject to uncertainty. While it is uncertain when any such processes may be fully adopted by the FDA, any such
	processes could have a material adverse effect on the future commercial prospects for our biological products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We believe that if
	any of our product candidates were to be approved as biological products under a BLA, such approved products should qualify for
	the 12-year period of exclusivity. However, there is a risk that the U.S. Congress could amend the BPCIA to significantly shorten
	this exclusivity period as proposed by President Obama, potentially creating the opportunity for generic competition sooner than
	anticipated. Moreover, the extent to which a bio-similar, once approved, will be substituted for any one of our reference products
	in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a
	number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the bio-similar
	route and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to
	which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We may not be
	able to obtain orphan drug exclusivity for our product candidates, particularly for bertilimumab in bullous pemphigoid or for NanomAbs
	in certain less frequent cancer indications.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Regulatory authorities
	in some jurisdictions, including the U.S. and Europe, may designate drugs for relatively small patient populations as orphan drugs.
	Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or
	condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States.
	One of our strategic assumptions is that we can obtain Orphan Drug Designation for bertilimumab in bullous pemphigoid, a disease
	with a patient population of less than 15,000 individuals in the U.S. and for certain formulations of NanomAbs in various cancer
	indications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Generally, if a product
	with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation,
	the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing
	application for the same drug for that time period. The applicable period is seven years in the U.S. and ten years in Europe. The
	European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if
	the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the
	FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
	quantity of the drug to meet the needs of patients with the rare disease or condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Even if we obtain
	orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different
	drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same
	drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more
	effective or makes a major contribution to patient care.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to
	Our Dependence on Third Parties
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Any collaborations
	that we enter into could be important to our business. If we are unable to maintain any of these collaborations, or if these collaborations
	are not successful, our business could be adversely affected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We intend to enter
	into collaborations with other biopharmaceutical companies to develop NanomAbs based on therapeutic payloads and/ or ligands or
	antibodies from their product pipelines. We also intend to partner AmiKet for Phase III development and commercialization and bertilimumab
	after we achieve Phase II Proof of Concept although we currently have no agreement with any commercial partner and may never secure
	a commercial partner. If entered into, these collaborations are expected to generate funding for our research programs and may
	pose a number of risks, including the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may have significant discretion in determining the efforts and resources that they
	will apply to these collaborations;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may not perform their obligations as expected;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may not pursue development and commercialization of any product candidates that achieve
	regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results,
	changes in the collaborators&rsquo; strategic focus or available funding, or external factors, such as an acquisition, that divert
	resources or create competing priorities;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may delay clinical trials, provide insufficient funding for a clinical trial program,
	stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product
	candidate for clinical testing;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators could independently develop, or develop with third parties, products that compete
	directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more
	likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours, which
	may cause collaborators to cease to devote resources to the commercialization of our product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a collaborator with marketing and distribution rights to one or more of our product candidates
	that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	disagreements with collaborators, including disagreements over proprietary rights, contract interpretation
	or the preferred course of development, might cause delays or termination of the research, development or commercialization of
	product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation
	or arbitration, any of which would be time-consuming and expensive;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may not properly maintain or defend our intellectual property rights or may use our
	proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or
	proprietary information or expose us to potential litigation;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may infringe the intellectual property rights of third parties, which may expose
	us to litigation and potential liability;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborations may be terminated for the convenience of the collaborator and, if terminated, we
	would potentially lose the right to pursue further development or commercialization of the applicable product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	collaborators may learn about our technology and use this knowledge to compete with us in the future;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	results of collaborators&rsquo; preclinical or clinical trials could produce results that harm
	or impair other products using our technology;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	there may be conflicts between different collaborators that could negatively affect those collaborations
	and potentially others; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the number and type of our collaborations could adversely affect our attractiveness to future collaborators
	or acquirers.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	If any collaborations we enter
	into do not result in the successful development and commercialization of our products or if one of our collaborators terminates
	its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under the
	collaboration. If we do not receive the funding we expect under these agreements, our continued development of our product candidates
	could be delayed and we may need additional resources to develop additional product candidates. All of the risks relating to our
	product development, regulatory approval and commercialization also apply to the activities of our collaborators and there can
	be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Additionally, subject
	to its contractual obligations to us, if a collaborator of ours is involved in a business combination or otherwise changes its
	business priorities, the collaborator might deemphasize or terminate the development or commercialization of any product candidate
	licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new
	collaborators and our perception in the business and financial communities and our stock price could be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We may in the future
	determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization
	of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive
	agreement for collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise,
	the terms and conditions of the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors.
	If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may not
	be able to access therapeutic payloads that would be suitable to development with our platform, have to curtail the development
	of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential
	commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development
	or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
	on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms
	or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
	and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue
	to develop our product platform and our business may be materially and adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We rely, and
	expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily,
	including failing to meet deadlines for the completion of such trials.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We currently rely
	on third-party CROs to conduct our ongoing Phase II clinical trials of bertilimumab and do not plan to independently conduct clinical
	trials of our other product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management
	organizations, medical institutions and clinical investigators, to conduct and manage our clinical trials. These agreements might
	terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements,
	that would delay our product development activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our reliance on these
	third parties for research and development activities will reduce our control over these activities but will not relieve us of
	our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance
	with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards,
	commonly referred to as good clinical practices (&ldquo;GCPs&rdquo;), for conducting, recording and reporting the results of clinical
	trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of
	trial participants are protected. Other countries&rsquo; regulatory agencies also have requirements for clinical trials with which
	we must comply. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a
	government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity
	and civil and criminal sanctions. Furthermore, these third parties may also have relationships with other entities, some of which
	may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines
	or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain,
	or may be delayed in obtaining marketing approvals for our product candidates and will not be able to, or may be delayed in our
	efforts to, successfully commercialize our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We also expect to
	rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part
	of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our
	products, producing additional losses and depriving us of potential product revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We contract
	with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to
	do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities
	of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development
	or commercialization efforts.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We do not have any
	manufacturing facilities that meet the FDA&rsquo;s current cGMP requirements for the production of any product candidates used
	in humans. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical
	and clinical testing, as well as for the commercial manufacture if any of our product candidates once they receive marketing approval.
	This reliance on third parties increases the risk that we may not have sufficient quantities of our product candidates on a timely
	basis or at all or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development
	or commercialization efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We may be unable to
	establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements
	with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	failure of third-party manufacturers to comply with regulatory requirements and maintain quality
	assurance;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	breach of the manufacturing agreement by the third party;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	failure to manufacture our product according to our specifications;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	failure to manufacture our product according to our schedule or at all;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	misappropriation of our proprietary information, including our trade secrets and know-how; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient
	for us.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Third-party manufacturers
	may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S.. Our failure, or the failure
	of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including
	clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures
	or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly
	and adversely affect supplies of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our product candidates
	and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities.
	There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for
	us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Any performance failure
	on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently
	have arrangements in place for redundant supply or a second source for required raw materials used in the manufacture of our product
	candidates, including our lead product candidate bertilimumab. If our current contract manufacturer, Lonza, cannot perform as agreed,
	we may be required to replace such manufacturer and we may be unable to replace them on a timely basis or at all. Our contract
	with Lonza imposes restrictions, including additional payments if we elect to work with another contract manufacturer. Additionally,
	we have not yet secured cGMP manufacturers for NanomAbs, which may delay regulatory development toward an IND authorization and
	initial of clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our current and anticipated
	future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit
	margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to Our
	Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Our ability to protect
	our intellectual property rights will be critically important to the success of our business, and we may not be able to protect
	or enforce these rights in the U.S. or abroad.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We own or hold licenses
	to a number of issued U.S. patents and U.S. pending patent applications, as well as foreign patents and patent applications. Our
	success depends in part on our ability to obtain patent protection both in the U.S. and in other countries for our product candidates,
	as well as the methods for treating patients in the product indications using these product candidates. Our ability to protect
	our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain
	and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability
	of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain, maintain
	and enforce patents is uncertain and involves complex legal and factual questions. Even if our product candidates, as well as methods
	for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and
	have claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a
	limited amount of time. Accordingly, rights under any issued patents may not provide us with sufficient protection for our product
	candidates or provide sufficient protection to afford us a commercial advantage against competitive products or processes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, we cannot
	guarantee that any patents issued from any pending or future patent applications owned by or licensed to us. Even if patents have
	issued or will issue, we cannot guarantee that the claims of these patents are or will be valid or enforceable or will provide
	us with any significant protection against competitive products or otherwise be commercially valuable to us. The laws of some foreign
	jurisdictions do not protect intellectual property rights to the same extent as in the U.S. and many companies have encountered
	significant difficulties in protecting and defending such rights in foreign jurisdictions. Furthermore, different countries have
	different procedures for obtaining patents, and patents issued in different countries offer different degrees of protection against
	use of the patented invention by others. If we encounter such difficulties in protecting or are otherwise precluded from effectively
	protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The patent positions of
	biotechnology companies, including our patent position, involve complex legal and factual questions, and, therefore, validity and
	enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated, or circumvented.
	Our patents can be challenged by our competitors who can argue that our patents are invalid, unenforceable, lack utility, or sufficient
	written description or enablement, or that the claims of the issued patents should be limited or narrowly construed. Patents also
	will not protect our product candidates if competitors devise ways of making or using these product candidates without legally
	infringing our patents. The Federal Food, Drug, and Cosmetic Act and FDA regulations and policies create a regulatory environment
	that encourages companies to challenge branded drug patents or to create non-infringing versions of a patented product in order
	to facilitate the approval of abbreviated new drug applications for generic substitutes. These same types of incentives encourage
	competitors to submit new drug applications that rely on literature and clinical data not prepared for or by the drug sponsor,
	providing a less burdensome pathway to approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The degree of future protection
	afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
	protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Others may be able to make compounds that are similar to our
	product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	We or our licensors or strategic partners might not have been
	the first to make the inventions covered by the issued patent or pending patent application that we own or have
	exclusively licensed.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	We or our licensors or strategic partners might not have
	been the first to file patent applications covering certain of our inventions.
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Others may independently develop similar or alternative
	technologies or duplicate any of our technologies without infringing on our intellectual property rights.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	It is possible that our pending patent applications will not lead to issued patents.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Issued patents that we own or have exclusively licensed may
	not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges
	by our competitors.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Our competitors might conduct research and development
	activities in countries where we do not have patent rights and then use the information learned from such activities to develop
	competitive products for sale in our major commercial markets.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	We may not develop additional proprietary technologies that are patentable.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The patents of others may have an adverse effect on our business.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Should any of these events
	occur, they could significantly harm our business, results of operations and prospects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We will be able to protect
	our proprietary rights from unauthorized use by third parties only to the extent that our technologies, product candidates, and
	any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets and we have the
	funds to enforce our rights, if necessary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The expiration of our
	owned or licensed patents before completing the research and development of our product candidates and receiving all required approvals
	in order to sell and distribute the products on a commercial scale can adversely affect our business and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, the laws
	of certain foreign countries do not protect our intellectual property rights to the same extent as do the laws of the U.S.. If
	we fail to apply for intellectual property protection or if we cannot adequately protect our intellectual property rights in these
	foreign countries, our competitors may be able to compete more effectively against us, which could adversely affect our competitive
	position, as well as our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Filing, prosecuting and
	defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors may use our
	technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export
	otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in
	the U.S.. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent
	claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Litigation regarding
	patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved in such litigation,
	it could cause delays in bringing product candidates to market and harm our ability to operate.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our success will depend
	in part on our ability to operate without infringing the proprietary rights of third parties. The pharmaceutical industry is characterized
	by extensive litigation regarding patents and other intellectual property rights. Other parties may obtain patents in the future
	and allege that the use of our technologies infringes these patent claims or that we are employing their proprietary technology
	without authorization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Litigation relating to
	the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated
	by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending
	against claims that our technology infringes or misappropriates third party intellectual property rights. However, we may seek
	to use various post- grant administrative proceedings, including new procedures created under the America Invents Act, to invalidate
	potentially overly-broad third party rights. Even if we are able to defend our position, the cost of doing so may adversely affect
	our ability to grow, generate revenue or become profitable. Although we have not yet experienced any patent litigation, we may
	in the future be subject to such litigation and may not be able to protect our intellectual property at a reasonable cost, or at
	all, if such litigation is initiated. The outcome of litigation is always uncertain, and in some cases could include judgments
	against us that require us to pay damages, enjoin us from certain activities or otherwise affect our legal or contractual rights,
	which could have a significant adverse effect on our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition, third parties
	may challenge or infringe upon our existing or future patents. Proceedings involving our patents or patent applications or those
	of others could result in adverse decisions regarding:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the patentability of our inventions relating to our product candidates; and/or
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the enforceability, validity or scope of protection offered by our patents relating to our product candidates.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Even if we are successful
	in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which
	could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required
	to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly
	and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we
	do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have
	infringed patents declared invalid, we may:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	incur substantial monetary damages;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	encounter significant delays in bringing our product candidates to market; and/or
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	be precluded from participating in the manufacture, use
	or sale of our product candidates or methods of treatment requiring licenses.
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our commercial success
	depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount
	of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including
	Patent Office administrative proceedings, such as inter-party reviews, and reexamination proceedings before the USPTO or oppositions
	and revocations and other comparable proceedings in foreign jurisdictions. Numerous United States and foreign issued patents and
	pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates.
	As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates
	may give rise to claims of infringement of the patent rights of others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Despite safe harbor provisions,
	third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents,
	of which we are currently unaware, with claims to materials, formulations, methods of doing research or library screening, methods
	of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications
	can take many years to issue, there may be published patent applications, which may later result in issued patents that our product
	candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes
	upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process
	of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders
	of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the
	applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly,
	if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture
	or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block
	our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our use, or until such
	patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available
	to us on commercially reasonable terms or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Parties making claims
	against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize
	one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
	expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
	against us, we may have to pay substantial damages, including treble damages and attorneys&rsquo; fees for willful infringement,
	obtain one or more licenses from third parties, limit our use, pay royalties or redesign our infringing product candidates, which
	may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available
	at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may
	need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may
	fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable
	to further develop and commercialize one or more of our product candidates, which could harm our business significantly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Many companies have encountered
	significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
	countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
	particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents
	or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in
	foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Third-party claims
	of intellectual property infringement may prevent or delay our drug discovery and development efforts.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Confidentiality
	agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary
	information and may not adequately protect our intellectual property, which could limit our ability to compete. Because we
	operate in a highly technical field of research and development of small molecule drugs, we rely in part on trade secret
	protection in order to protect our proprietary trade secrets and unpatented know-how. However, trade secrets are difficult to
	protect, and we cannot be certain that others will not develop the same or similar technologies on their own. We have taken
	steps, including entering into confidentiality agreements with our employees, consultants, outside scientific collaborators,
	sponsored researchers and other advisors, to protect our trade secrets and unpatented know-how. These agreements generally
	require that the other party keep confidential and not disclose to third parties all confidential information developed by
	the party or made known to the party by us during the course of the party&rsquo;s relationship with us. We also typically
	obtain agreements from these parties which provide that inventions conceived by the party in the course of rendering services
	to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign
	intellectual property rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets or
	know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the U.S.
	may be less willing to protect trade secrets or know-how. The failure to obtain or maintain trade secret protection could
	adversely affect our competitive position
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We license patent rights from
	third-party owners. Such licenses may be subject to early termination if we fail to comply with our obligations in our licenses
	with third parties, which could result in the loss of rights or technology that are material to our business.
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We are a party to licenses
	that give us rights to third-party intellectual property that is necessary or useful for our business, and we may enter into additional
	licenses in the future. Under these license agreements we are obligated to pay the licensor fees, which may include annual license
	fees, milestone payments, royalties, a percentage of revenues associated with the licensed technology and a percentage of sublicensing
	revenue. In addition, under certain of such agreements, we are required to diligently pursue the development of products using
	the licensed technology. If we fail to comply with these obligations and fail to cure our breach within a specified period of time,
	the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology
	that are material to our business. If the licensor retains control of prosecution of the patents and patent applications licensed
	to us, we may have limited or no control over the manner in which the licensor chooses to prosecute or maintain its patents and
	patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor
	elects to abandon. The loss of any such rights provided under our license agreements could materially harm our financial condition
	and operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We may be unable
	to adequately prevent disclosure of trade secrets and other proprietary information.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We rely on trade secrets
	to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However,
	trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside
	scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and other proprietary information.
	These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the
	event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets
	and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our
	proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	If we are unable
	to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements under which we license
	rights to patents or other intellectual property from third parties, we could lose licensing rights that are important to our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	If we are unable to maintain
	and/or obtain licenses needed for the development of our product candidates in the future, we may have to develop alternatives
	to avoid infringing on the patents of others, potentially causing increased costs and delays in drug development and introduction
	or precluding the development, manufacture, or sale of planned products. Some of our licenses provide for limited periods of exclusivity
	that require minimum license fees and payments and/or may be extended only with the consent of the licensor. We can provide no
	assurance that we will be able to meet these minimum license fees in the future or that these third parties will grant extensions
	on any or all such licenses. This same restriction may be contained in licenses obtained in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Additionally, we can provide
	no assurance that the patents underlying any licenses will be valid and enforceable. To the extent any products developed by us
	are based on licensed technology, royalty payments on the licenses will reduce our gross profit from such product sales and may
	render the sales of such products uneconomical. In addition, the loss of any current or future licenses or the exclusivity rights
	provided therein could materially harm our business financial condition and our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	If any of our trade
	secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary
	rights would be significantly impaired and our business and competitive position would suffer.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our success also depends
	upon the skills, knowledge and experience of our scientific and technical personnel and our consultants and advisors, as well as
	our licensors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to
	obtain, we rely on trade secret protection and confidentiality agreements. Unlike some of our competitors, we maintain our proprietary
	libraries for ourselves as we believe they have proven to be superior in obtaining strong binder product candidates. To this end,
	we require all of our employees, consultants, advisors and contractors to enter into agreements, which prohibit the disclosure
	of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries
	and inventions important to our business. These agreements may not provide adequate protection for our trade secrets, know-how
	or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such
	information. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets,
	know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	From time to time
	we may need to license patents, intellectual property and proprietary technologies from third parties, which may be difficult or
	expensive to obtain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We may need to obtain
	licenses to patents and other proprietary rights held by third parties to successfully develop, manufacture and market our drug
	products. As an example, it may be necessary to use a third party&rsquo;s proprietary technology to reformulate one of our drug
	products in order to improve upon the capabilities of the drug product. If we are unable to timely obtain these licenses on reasonable
	terms, our ability to commercially exploit such drug products may be inhibited or prevented.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to Our
	Business and Industry
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We have a limited
	operating history and are heavily dependent on the success of our technologies and product candidates, and we cannot give any assurance
	that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	To date, we have invested
	a significant portion of our efforts and financial resources in the acquisition and development of our product candidates. We have
	not demonstrated our ability to perform the functions necessary for the successful acquisition, development or commercialization
	of the technologies we are seeking to develop. Because we only recently commenced operations, we have a limited operating history
	upon which you can evaluate our business and prospects. Also, as an early stage company, we have limited experience and have not
	yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in
	new and rapidly evolving fields, particularly in the biopharmaceutical area. Our future success is substantially dependent on our
	ability to successfully develop, obtain regulatory approval for, and then successfully commercialize such product candidates. Our
	product candidates are currently in preclinical development or in clinical trials. Our business depends entirely on the successful
	development and commercialization of our product candidates, which may never occur. We currently generate no revenues from the
	sale of any drugs, and we may never be able to develop or commercialize a marketable drug.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The successful development,
	and any commercialization, of our technologies and any product candidates would require us to successfully perform a variety of
	functions, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	developing our technology platform;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	identifying, developing, manufacturing and commercializing product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	entering into successful licensing and other arrangements with product development partners;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	participating in regulatory approval processes;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	formulating and manufacturing products; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	conducting sales and marketing activities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our operations have been
	limited to organizing our company, acquiring, developing and securing our proprietary technology and identifying and obtaining
	early preclinical data or clinical data for various product candidates. These operations provide a limited basis for you to assess
	our ability to continue to develop our technology, identify product candidates, develop and commercialize any product candidates
	we are able to identify and enter into successful collaborative arrangements with other companies, as well as for you to assess
	the advisability of investing in our securities. Each of these requirements will require substantial time, effort and financial
	resources.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Each of our product candidates
	will require additional preclinical or clinical development, management of preclinical, clinical and manufacturing activities,
	regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, and significant
	marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our product
	candidates before we receive regulatory approval from the FDA, or comparable foreign regulatory authorities, and we may never receive
	such regulatory approval for any of our product candidates. In addition, our product development programs contemplate the development
	of companion diagnostics by our third-party collaborators. Companion diagnostics are subject to regulation as medical devices and
	must themselves be cleared or approved for marketing by the FDA or certain other foreign regulatory agencies before we may commercialize
	our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Clinical drug development
	involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive
	of future trial results.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Clinical testing is expensive
	and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical
	trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of
	the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired
	safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon
	for companies in the biopharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy
	or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	This product candidate
	development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product
	candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it
	is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered
	along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize
	the product candidates for late stage clinical trials, approval and commercialization, such changes do carry the risk that they
	will not achieve these intended objectives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We have not previously
	initiated or completed a corporate-sponsored clinical trial. Consequently, we may not have the necessary capabilities, including
	adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate, in a way that leads
	to our obtaining marketing approval for our product candidates in a timely manner, or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In the event we are able
	to conduct a pivotal clinical trial of a product candidate, the results of such trial may not be adequate to support marketing
	approval. Because our product candidates are intended for use in life- threatening diseases, in some cases we ultimately intend
	to seek marketing approval for each product candidate based on the results of a single pivotal clinical trial. As a result, these
	trials may receive enhanced scrutiny from the FDA. For any such pivotal trial, if the FDA disagrees with our choice of primary
	endpoint or the results for the primary endpoint are not robust or significant relative to control, are subject to confounding
	factors, or are not adequately supported by other study endpoints, including possibly overall survival or complete response rate,
	the FDA may refuse to approve a BLA or an NDA based on such pivotal trial. The FDA may require additional clinical trials as a
	condition for approving our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Delays in clinical
	testing could result in increased costs to us and delay our ability to generate revenue.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Although we are planning
	for certain clinical trials relating to bertilimumab and AmiKet, we may experience delays in our clinical trials and we do not
	know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule,
	if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms
	of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtaining IRB, approval at each site;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	recruiting suitable patients to participate in a trial;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	clinical sites deviating from trial protocol or dropping out of a trial;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	having patients complete a trial or return for post-treatment follow-up;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	developing and validating companion diagnostics on a timely basis, if required;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	adding new clinical trial sites;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	manufacturing sufficient quantities of product candidate for use in clinical trials; or
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Patient enrollment, a significant factor in the timing of clinical trials, is affected by many
	factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria
	for the trial, the design of the clinical trial, competing clinical trials and clinicians&rsquo; and patients&rsquo; perceptions
	as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that
	may be approved for the indications we are investigating.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Furthermore, we intend
	to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we intend to have agreements
	governing their committed activities, for which we will have limited influence over their actual performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We could encounter delays
	if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted,
	by the Data Safety Monitoring Board (&ldquo;DSMB&rdquo;), for such trial or by the FDA or other regulatory authorities. Such authorities
	may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance
	with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or
	other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
	failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
	funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of
	our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product
	revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase
	our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales
	and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition,
	many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead
	to the denial of regulatory approval of our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We may expand our
	business through the acquisition of companies or businesses or by entering into collaborations or in-licensing product candidates
	that could disrupt our business and harm our financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We may in the future seek to expand our pipeline
	and capabilities by acquiring one or more companies or businesses, entering into collaborations or in-licensing one or more product
	candidates. Acquisitions, collaborations and in-licenses involve numerous risks, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potentially dilutive issuance of equity securities;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	substantial cash expenditures;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	difficulties in assimilating the operations and technology of the acquired companies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential disputes regarding contingent consideration;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the assumption of unknown liabilities of the acquired businesses;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	diverting our management&rsquo;s attention away from other business concerns;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	entering markets in which we have limited or no direct experience; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential loss of our key employees or key employees of the acquired companies or businesses.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our experience in making acquisitions,
	entering collaborations and in-licensing product candidates is limited. We cannot assure you that any acquisition, collaboration
	or in-license will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
	company or business or in-licensed product candidate. In addition, our future success would depend in part on our ability to manage
	the rapid growth associated with some of these acquisitions, collaborations and in-licenses. We cannot assure you that we would
	be able to successfully combine our business with that of acquired businesses, manage a collaboration or integrate in-licensed
	product candidates or that such efforts would be successful. Furthermore, the development or expansion of our business or any acquired
	business or company or any collaboration or in-licensed product candidate may require a substantial capital investment by us. We
	may use our securities as payment for all or a portion of the purchase price or acquisitions. If we issue significant amounts of
	our equity securities for such acquisitions, this would result in substantial dilution of the equity interests of our stockholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Competition for
	patients in conducting clinical trials may prevent or delay product development and strain our limited financial resources.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Many pharmaceutical companies
	are conducting clinical trials in patients with the disease indications that our potential drug products target. As a result, we
	must compete with them for clinical sites, physicians and the limited number of patients who fulfill the stringent requirements
	for participation in clinical trials. Also, due to the confidential nature of clinical trials, we do not know how many of the eligible
	patients may be enrolled in competing studies and who are consequently not available to us for our clinical trials. Our clinical
	trials may be delayed or terminated due to the inability to enroll enough patients. Patient enrollment depends on many factors,
	including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites and
	the eligibility criteria for the study. The delay or inability to meet planned patient enrollment may result in increased costs
	and delays or termination of the trial, which could have a harmful effect on our ability to develop products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	The regulatory review
	and approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable,
	and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The time required to obtain
	approval from the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement
	of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition,
	review and approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during
	the course of a product candidate&rsquo;s clinical development and may vary among jurisdictions. We have not obtained regulatory
	approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we
	may seek to develop in the future will ever obtain regulatory approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our product candidates
	could fail to receive regulatory approval for many reasons, including the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may disagree with the design or implementation
	of our clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
	authorities that a product candidate is safe and effective for its proposed indication;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the results of clinical trials may not meet the level of statistical significance required by the
	FDA or comparable foreign regulatory authorities for approval;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data
	from preclinical studies or clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the data collected from clinical trials of our product candidates may not be sufficient to support
	the submission of an NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes
	or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics
	we contemplate developing with partners; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the approval policies or regulations of the FDA or comparable foreign regulatory authorities may
	significantly change in a manner rendering our clinical data insufficient for approval. This lengthy approval process as well as
	the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product
	candidates, which would significantly harm our business, results of operations and prospects.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;In addition, even if we were to obtain
	approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request,
	may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing
	clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable
	for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial
	prospects for our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We have not previously
	submitted a BLA or an NDA to the FDA or similar drug approval filings to comparable foreign authorities for any product candidate,
	and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval.
	Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not
	receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully
	obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon our
	collaborators&rsquo; ability to obtain regulatory approval of the companion diagnostics to be used with our product candidates,
	as well as the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the
	markets for patients that we are targeting for our product candidates are not as significant as we estimate, we may not generate
	significant revenues from sales of such products, if approved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We plan to seek regulatory
	approval to commercialize our product candidates both in the United States, the European Union and in additional foreign countries.
	While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries
	we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing,
	among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict
	success in these jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Our most rapid and
	cost effective access to market approval for NanomAbs depends on meeting the conditions for approval under Section 505(b)(2) of
	the Federal Food, Drug and Cosmetic Act, (&ldquo;FFDCA&rdquo;).
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We will be seeking approval
	for NanomAbs under Section 505(b)(2) of the FFDCA, enacted as part of the Drug Price Competition and Patent Restoration Act of
	1984, otherwise known as the Hatch-Waxman Act, which permits applicants to rely in part on preclinical and clinical data generated
	by third parties. For instance, FDA currently does not know which data will be sufficient to support various cancer indications.
	Sufficiency of the data for approval will be a review issue after an NDA filing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Healthcare reform
	measures could hinder or prevent our product candidates&rsquo; commercial success.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In both the U.S. and certain
	foreign jurisdictions, there have been and we expect there will continue to be a number of legislative and regulatory changes to
	the health care system that could impact our ability to sell our products profitably. The U.S. government and other governments
	have shown significant interest in pursuing healthcare reform. In particular, the Medicare Modernization Act of 2003 revised the
	payment methodology for many products under the Medicare program in the United States. This has resulted in lower rates of reimbursement.
	In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively,
	the Healthcare Reform Law, was enacted. The Healthcare Reform Law substantially changes the way healthcare is financed by both
	governmental and private insurers. Such government-adopted reform measures may adversely impact the pricing of healthcare products
	and services in the U.S. or internationally and the amount of reimbursement available from governmental agencies or other third-party
	payors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	There have been, and likely
	will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability
	of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future.
	The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services
	to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory
	approval, as well as our ability to set satisfactory prices for our products, to generate revenues, and to achieve and maintain
	profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to the
	Commercialization of Our Product Candidates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Even if any of our
	product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients,
	third-party payors and others in the medical community necessary for commercial success.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	If any of our product
	candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party
	payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are
	well established in the medical community, and physicians may continue to rely on these treatments. In addition, many new drugs
	have been recently approved and many more are in the pipeline for the same diseases for which we are developing our product candidates.
	If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and
	we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will
	depend on a number of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	their efficacy, safety and other potential advantages compared to alternative treatments;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to offer them for sale at competitive prices;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	their convenience and ease of administration compared to alternative treatments;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the willingness of the target patient population to try new therapies and of physicians to prescribe
	these therapies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the strength of marketing and distribution support;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the availability of third-party coverage and adequate reimbursement for our product candidates
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the prevalence and severity of their side effects;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any restrictions on the use of our products together with other medications;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	interactions of our products with other medicines patients are taking; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability of certain types of patients to take our product.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	If we are unable to establish effective
	sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities, we may not be
	successful in commercializing our product candidates if and when they are approved.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We do not have a sales
	or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve
	commercial success for any product for which we obtain marketing approval, we will need to establish a sales and marketing organization
	or make arrangements with third parties to perform sales and marketing functions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In the future, we expect
	to build a focused specialty sales and marketing infrastructure to market or co-promote some of our product candidates in the U.S.
	and potentially elsewhere, if and when they are approved. There are risks involved with establishing our own sales, marketing and
	distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any
	product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities
	is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses.
	This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Factors that may inhibit
	our efforts to commercialize our products on our own include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the inability of sales personnel to obtain access to or educate physicians on the benefits of our
	products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the lack of complementary products to be offered by sales personnel, which may put us at a competitive
	disadvantage relative to companies with more extensive product lines;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	unforeseen costs and expenses associated with creating an independent sales and marketing organization;
	and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability to obtain sufficient coverage and reimbursement from third-party payors and governmental
	agencies.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;Outside the U.S., we expect
	to rely on third parties to sell, market and distribute our product candidates. We may not be successful in entering into arrangements
	with such third parties or may be unable to do so on terms that are favorable to us. In addition, our product revenues and our
	profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute
	any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to
	devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing
	and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful
	in commercializing our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We face substantial
	competition, which may result in others discovering, developing or commercializing competing products before or more successfully
	than we do.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The development and commercialization
	of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition
	with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies,
	specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology
	companies that currently market and sell products or are pursuing the development of products for the treatment of the disease
	indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific
	approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors
	also include academic institutions, government agencies and other public and private research organizations that conduct research,
	seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Many of the companies against which we are
	competing or against which we may compete in the future have significantly greater financial resources, established presence in
	the market and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining
	regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology
	industries may result in even more resources being concentrated among a smaller number of our competitors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Smaller and other early
	stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
	companies. These third parties compete with us in recruiting and retaining qualified scientific, sales and marketing and management
	personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
	complementary to, or necessary for, our programs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our commercial opportunity
	could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less
	severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may
	obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result
	in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete
	may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. Major competing
	products to our lead drug, bertilimumab, such as Remicade and Humira are expected to become available on a generic basis over the
	coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium
	over competitive generic products. Multiple other new drugs will be launched prior to bertilimumab in its various target indications
	but may limit its potential market acceptance. NanomAbs are competing with other Ligand Nanoparticle Conjugates developed by well-funded
	companies such as BIND Therapeutics and Merrimack. They are also competing with other types of Bio-Conjugates including Antibody
	Drug Conjugates developed by Seattle Genetics and Immunogen. Insufficient funding or inability to secure timely corporate partnerships
	will prevent Immune Pharmaceuticals from successfully developing the commercial opportunity with NanomAbs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Even if we are able
	to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement
	practices or healthcare reform initiatives, which would harm our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The regulations that govern
	marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and
	future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays
	in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries,
	the pricing review period begins after marketing or product-licensing approval is granted. In some foreign markets, prescription
	pharmaceutical pricing remains subject to continuing governmental control, including possible price reductions, even after initial
	approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject
	to price regulations that delay our commercial launch of the product, possibly for lengthy period of time, and negatively impact
	the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability
	to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our ability to commercialize
	any product candidates successfully also will depend in part on the extent to which coverage and reimbursement for these products
	and related treatments will be available from government health administration authorities, private health insurers and other organizations.
	Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which
	medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere
	is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the
	amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide
	them with predetermined discounts from list prices and are challenging the prices charged for drugs. Coverage and reimbursement
	may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not
	be sufficient to generate a profit. Reimbursement may affect the demand for, or the price of, any product candidate for which we
	obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required
	to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other
	therapies. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be
	able to successfully commercialize any product candidate for which we obtain marketing approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	There may be significant
	delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug
	is approved for by the FDA or similar regulatory authorities outside the U.S.. Moreover, eligibility for reimbursement does not
	imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
	sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs
	and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which
	it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments
	for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs
	or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be
	sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations
	in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both
	government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating
	results, our ability to raise capital needed to commercialize products and our overall financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Product liability
	lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may
	develop.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We face an inherent risk
	of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater
	risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our
	product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome,
	liability claims may result in:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	decreased demand for any product candidates or products that we may develop;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	injury to our reputation and significant negative media attention;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	withdrawal of clinical trial participants;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	significant costs to defend the related litigation;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	substantial monetary awards to trial participants or patients;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	loss of revenue;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reduced resources of our management to pursue our business strategy; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the inability to commercialize any products that we may develop.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We currently hold $3.0
	million in clinical trial liability insurance coverage in the aggregate and per incident, which may not be adequate to cover all
	liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence
	commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance
	coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to Our
	Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	In the event that
	we elect to pay dividends or conversion premiums related to our outstanding Series D convertible preferred stock in the form of
	common stock instead of cash, our existing stockholders could be diluted.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Although the $12.0 million
	Series D convertible Preferred Stock represents the issuance of 4.8 million shares of common stock at a $2.50 fixed conversion
	price, we may decide to pay the dividends or conversion premiums in the form of common stock instead of cash.&nbsp; To the extent
	we issue shares of common stock in payment of the conversion premiums, or elect to pay dividends on the Series D Preferred Stock
	in the form of our common stock rather than cash, such issuances would significantly dilute the ownership interests of existing
	stockholders. During the year ended December 31, 2015, Discover converted 300 shares of Series D Preferred Stock for a total of
	1.2 million common shares and an additional 3.3 million common shares were issued as payment of dividends and conversion premium.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	The price of our
	common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our shareholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our stock price is likely
	to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced
	extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our
	common stock may be influenced by many factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the success of competitive products or technologies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	results of clinical trials of our product candidates or those of our competitors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	developments related to our existing or any future collaboration;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	regulatory or legal developments in the U.S. and other countries;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	developments or disputes concerning patent applications, issued patents or other proprietary rights;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the recruitment or departure of key personnel;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the level of expenses related to any of our product candidates or clinical development programs;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
	analysts;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	variations in our financial results or those of companies that are perceived to be similar to us;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in the structure of healthcare payment systems;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	market conditions in the pharmaceutical and biotechnology sectors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	general economic, industry and market conditions; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the other factors described in this &ldquo;Risk Factors&rdquo; section.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	If securities or industry analysts do
	not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our
	stock price and trading volume could decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The trading market for
	our common stock will be influenced by the research and reports that industry or securities analysts publish about our business
	or us. Three analysts in the U.S. and one in Sweden currently cover our stock. If any of the analysts who cover us issue an adverse
	or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target animal
	studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of
	these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets,
	which in turn could cause our stock price or trading volume to decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Provisions in our
	restated certificate of incorporation and amended and restated by-laws and under Delaware law could make an acquisition of our
	company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or
	remove our current management.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Provisions in our certificate
	of incorporation and our amended and restated by-laws may discourage, delay or prevent a merger, acquisition or other change in
	control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a
	premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares
	of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible
	for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to
	replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors.
	Among other things, these provisions include those establishing:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a classified board of directors with three-year staggered terms, which may delay the ability of
	stockholders to change the membership of a majority of our Board of Directors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	no cumulative voting in the election of directors, which limits the ability of minority stockholders
	to elect director candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the exclusive right of our Board of Directors to elect a director to fill a vacancy created by
	the expansion of the Board of Directors or the resignation, death or removal of a director, which prevents stockholders from filling
	vacancies on our Board of Directors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the ability of our Board of Directors to authorize the issuance of shares of preferred stock and
	to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used
	to significantly dilute the ownership of a hostile acquirer;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the ability of our Board of Directors to alter our bylaws without obtaining stockholder approval;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the required approval of the holders of at least three-quarters (75%) of the shares entitled to
	vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our certificate of incorporation
	regarding the election and removal of directors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a prohibition on stockholder action by written consent, which forces stockholder action to be taken
	at an annual or special meeting of our stockholders;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the requirement that a special meeting of stockholders may be called only by the Chairman of the
	Board of Directors, the chief executive officer, the president or the Board of Directors, which may delay the ability of our stockholders
	to force consideration of a proposal or to take action, including the removal of directors; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	advance notice procedures that stockholders must comply with in order to nominate candidates to
	our Board of Directors or to propose matters to be acted upon at a stockholders&rsquo; meeting, which may discourage or deter a
	potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise
	attempting to obtain control of us.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Moreover, because we are
	incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware,
	which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period
	of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock,
	unless the merger or combination is approved in a prescribed manner.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Because we do not
	anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your
	sole source of gain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We have never declared
	or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth
	and development of our business. In addition, our credit facility currently prohibits us from paying dividends on our equity securities,
	and any future debt agreements may likewise preclude us from paying dividends. As a result, capital appreciation, if any, of our
	common stock will be your sole source of gain for the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Series D Preferred
	Stock bears an accrued annual dividend rate of 8.0% per annum, based on the stated value of $10,000 per share, which may range
	from 0% to 15% payable in cash or, at our option and subject to the satisfaction of certain conditions, in shares of common stock,
	based on certain adjustments and conditions, including changes in the volume weighted average price of the Company&rsquo;s common
	stock. Upon conversion, we shall pay the holders of the Series D Preferred Stock being converted a conversion premium equal to
	the amount of dividends that such shares would have otherwise issued if they had been held through the 6 and one half-year maturity
	date of the Series D Agreement. Dividends on the Preferred Stock will accrue from the date of issuance until maturity and be paid
	on the date of conversion thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We could be subject
	to securities class action litigation.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In the past, securities
	class action litigation has often been brought against a company following a decline in the market price of its securities. This
	risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent
	years. If we face such litigation, it could result in substantial costs and a diversion of management&rsquo;s attention and resources,
	which could harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	If we fail to comply
	with the continued listing requirements of the NASDAQ Capital Market LLC (&ldquo;NASDAQ&rdquo;), our common stock may be delisted
	and the price of our common stock and our ability to access the capital markets could be negatively impacted.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Our common stock is listed
	for trading on the NASDAQ. We must satisfy NASDAQ&rsquo;s continued listing requirements, including, among other things, a minimum
	closing bid price requirement of $1.00 per share for 30 consecutive business days. If a company&rsquo;s common stock trades for
	30 consecutive business days below the $1.00 minimum closing bid price requirement, NASDAQ will send a deficiency notice to the
	company, advising that it has been afforded a &quot;compliance period&quot; of 180 calendar days to regain compliance with the
	applicable requirements. Thereafter, if such a company does not regain compliance with the bid price requirement, a second 180-day
	compliance period may be available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	A delisting of our common
	stock from NASDAQ could materially reduce the liquidity of our common stock and result in a corresponding material reduction in
	the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources
	on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business
	development opportunities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On January 5, 2016, we
	received a notification letter from NASDAQ informing us that for the last 30 consecutive business days, the bid price of our securities
	had closed below $1.00 per share. This notice has no immediate effect on our NASDAQ listing and we have 180 calendar days, or until
	July&nbsp;5, 2016, to regain compliance. To regain compliance, the closing bid price of our securities must be at least $1.00 per
	share for a minimum of ten consecutive business days. If we do not regain compliance&nbsp;by July&nbsp;5, 2016, we may be eligible
	for additional time to regain compliance or if we are otherwise not eligible, we may request a hearing before a hearings panel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Risks Related to Employee
	Matters and Managing Growth and Other Risks Related to Our Business
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Our future success
	depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We are highly dependent
	on Dr. Daniel G. Teper, our Chief Executive Officer, as well as the other principal members of our management, scientific and clinical
	team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their
	employment with us at any time. We do not maintain &ldquo;key person&rdquo; insurance for any of our executives or other employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Recruiting and retaining
	qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss
	of the services of our executive officers or other key employees could impede the achievement of our research, development and
	commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing
	executive officers and key employees may be difficult and may take an extended period of time because of the limited number of
	individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval
	of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain
	or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies
	for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and
	research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist
	us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by
	employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their
	availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth
	strategy will be limited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	We expect to expand
	our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
	result, we may encounter difficulties in managing our growth, which could disrupt our operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We expect to experience
	significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development,
	regulatory affairs, manufacturing and, if any of our product candidates receives marketing approval, sales, marketing and distribution.
	To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems,
	expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources
	and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively
	manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may
	lead to significant costs and may divert our management and business development resources. Any inability to manage growth could
	delay the execution of our business plans or disrupt our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	A variety of risks
	associated with operating internationally could materially adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In addition to our U.S.
	operations, we have operations in Israel through our wholly owned subsidiary, Immune Pharmaceuticals Ltd., and may have other such
	international operations in the future. We face risks associated with our operations in Israel, including possible unfavorable
	regulatory, pricing and reimbursement, legal, political, tax and labor conditions, which could harm our business. We are also conducting
	and in the future plan to continue to conduct clinical trials of product candidates in Israel. We are subject to numerous risks
	associated with international business activities in Israel and elsewhere, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	compliance with differing or unexpected regulatory requirements for our products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	compliance with Israeli laws with respect to our wholly owned subsidiary, Immune Ltd.;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	difficulties in staffing and managing foreign operations;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	foreign government taxes, regulations and permit requirements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	U.S. and foreign government tariffs, trade restrictions, price and exchange controls and other
	regulatory requirements;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	economic weakness, including inflation, natural disasters, war, events of terrorism or political
	instability in particular foreign countries;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	fluctuations in currency exchange rates, which could result in increased operating expenses and
	reduced revenues;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	compliance with tax, employment, immigration and labor laws, regulations and restrictions for employees
	living or traveling abroad;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in diplomatic and trade relationships; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	challenges in enforcing our contractual and intellectual property rights, especially in those foreign
	countries that do not respect and protect intellectual property rights to the same extent as the United States.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	These and other risks
	associated with our international operations in Israel and elsewhere may materially adversely affect our business, financial condition
	and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Our business and
	operations would suffer in the event of system failures.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Despite the implementation
	of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable
	to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
	While we are not aware of any such material system failure, accident or security breach to date, if such an event were to occur
	and cause interruptions in our operations, it could result in a material disruption of our development programs and our business
	operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our
	regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties
	to manufacture our product candidates and conduct clinical trials, and similar events relating to their computer systems could
	also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss
	of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
	liability and the further development and commercialization of our product candidates could be delayed.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_004">
</A>
	ITEM 1B. UNRESOLVED STAFF COMMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_005">
</A>
	ITEM 2. PROPERTIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In February 2015, the Company&rsquo;s corporate
	headquarters was relocated to New York, NY under a lease agreement with Alexandria Real Estate, which expires in 2020. On August
	13, 2015, the Company signed an amendment to the New York, NY lease agreement with Alexandria Real Estate for lab space and offices
	for an additional 1,674 square feet commencing on September 1, 2015 and ending in 2020. The total base rent for offices and lab
	space, as amended, is $30,000 per month, subject to annual rent escalations. On January 15, 2016, Immune Ltd. signed a one year
	lease agreement with a renewal option for an additional year for new office space in Israel For the years ended December 31, 2015
	and, 2014, the Company recorded rent expense of $0.4 million and $0.2 million, respectively.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_006">
</A>
	ITEM 3. LEGAL PROCEEDINGS&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune Pharmaceuticals Inc. was the defendant
	in litigation involving a dispute with the plaintiffs Kenton L. Cowley and John A. Flores. The complaint alleges breach of contract,
	breach of covenant of good faith and fair dealing, fraud and rescission of contract with respect to the development of a topical
	cream containing ketamine and butamben, known as EpiCept NP-2. A summary judgment in Immune&rsquo;s favor was granted in January
	2012 and the plaintiffs filed an appeal in the United States Court of Appeals for the Ninth Circuit in September 2012. A hearing
	on the motion occurred in November 2013. In May 2014, the court scheduled the trial in November 2014 and a mandatory settlement
	conference in July 2014. In July 2014, the parties failed to reach a settlement at the mandatory settlement conference. The case
	was tried by a jury, which rendered a decision on March 23, 2015, in favor of the Company on all causes of action. During the year
	ended December 31, 2015, in connection with the trial, the Company incurred approximately $0.5 million of legal costs, $0.2 million
	which were settled in cash, and 116,594 shares of stock, with a fair value of $0.2 million which is included in general and administrative
	expenses in the consolidated statements of operations. The Company issued an additional 40,000 shares on April 1, 2015 with a fair
	value of $70,000 to settle current outstanding legal costs. In April 2015, the plaintiffs filed a motion for a new trial, which
	was heard by the Court on June 8, 2015. In October 2015, the court denied the plaintiff&rsquo;s motion for a new trial and on October
	9, 2015; the plaintiffs filed a notice of appeal to the court. No ruling has been made by the court on plaintiff&rsquo;s motion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In October 2014, the Company received a written
	demand from a former lender (&ldquo;Lender&rdquo;), for $9.1 million which was based on an agreement with Immune Ltd., from 2011,
	relating to a loan of $0.3 million, which was repaid in full in 2011. The Lender demands to receive certain warrants to purchase
	shares of the Company&rsquo;s common stock, to participate in a future public offering or merger of the Company, with certain discounted
	terms and cash damages. The Company currently estimates that its future loss would range between $0.3 million (as accrued for)
	to $1.0 million, which if determined to be payable to Lender, the Company believes would be likely settled in common stock. The
	Company intends to vigorously defend itself against those demands, if and when official legal proceedings relating to this matter
	is initiated.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_007">
</A>
	ITEM 4. MINE SAFETY DISCLOSURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<A NAME="V434974_10K_HTM_A_008">
</A>
<B>
	PART&nbsp;II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<A NAME="V434974_10K_HTM_A_009">
</A>
	ITEM 5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED
	STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Market Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s common
	stock has been listed on The NASDAQ Capital Market under the symbol &ldquo;IMNP&rdquo; since August 21, 2014. Prior to August 21,
	2014, the Company&rsquo;s common stock was quoted on the OTCQX under the symbol &ldquo;IMNP.&rdquo; The last reported sale price
	for the Company&rsquo;s common stock on March 24, 2016 was $0.46 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The table below sets forth
	closing information on the range of high and low sales prices for the Company&rsquo;s common stock as reported by The NASDAQ Capital
	Market since August 21, 2014 and the high and low bid prices for the Company&rsquo;s common stock as reported on the OTCQX prior
	to August 21, 2014, during the periods indicated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT">
	First Quarter
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2.32
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1.50
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Second Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.69
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.02
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	First Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Second Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
	Stockholders
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.65PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	As of March 24, 2016,
	there were approximately 89 stockholders of record of the Company&rsquo;s 35,985,761 outstanding shares of common stock. This does
	not reflect persons or entities that hold their stock in nominee or &ldquo;street&rdquo; name through various brokerage firms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Dividends
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company has never
	declared or paid dividends on its common stock and does not anticipate paying any cash dividends on the Company&rsquo;s capital
	stock in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of the Company&rsquo;s
	Board of Directors and will depend on applicable law and then-existing conditions, including the Company&rsquo;s financial condition,
	operating results, contractual restrictions, capital requirements, business prospects and other factors the Company&rsquo;s Board
	of Directors may deem relevant. In addition, the Company&rsquo;s ability to pay cash dividends is currently prohibited by the terms
	of its credit facility with Hercules Capital. The Company currently intends to retain all available funds and any future earnings
	to fund the development and growth of its business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;However, the Company&rsquo;s
	Series D Preferred Stock bears an accrued annual dividend rate of 8.0% per annum, based on the stated value of $10,000 per share,
	which may range from 0% to 15%, based on certain adjustments and conditions, including changes in the volume weighted average price
	of the Company&rsquo;s common stock. Dividends on the Preferred Stock will accrue from the date of issuance until maturity and
	will be paid on the date of conversion thereof. As of December 31, 2015, the dividend rate of the Series D Preferred Stock was
	15%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
	Issuer Purchases of Equity Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
	Unregistered Sales of Equity Securities&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	On November 24, 2015, the Company issued to
	a consultant 117,647 shares of common stock for services performed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The issuance of the foregoing
	securities were exempt from registration under the Securities Act of 1933, as amended, under Section 4(a)(2) thereof as transactions
	by an issuer not involving any public offering inasmuch as the Company believes the acquirer is an accredited investor that acquired
	the securities for investment purposes and such securities were issued without any form of general solicitation or general advertising.
</P>
</EFX_MARKET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; BACKGROUND-COLOR: WHITE">
	&nbsp;&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_010">
</A>
	ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp; SELECTED
	FINANCIAL DATA
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_011">
</A>
	ITEM 7. MANAGEMENT&rsquo;S DISCUSSION AND
	ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	The following discussion
	and analysis of the Company&rsquo;s financial condition and results of operations should be read in conjunction with, and is qualified
	in its entirety by, the Company&rsquo;s consolidated financial statements (including notes to the consolidated financial statements)
	and the other consolidated financial information appearing elsewhere in this Annual Report on Form 10-K. In addition to historical
	financial information, the following discussion contains forward-looking statements that reflect the Company&rsquo;s plans, estimates
	and beliefs. Some of the information contained in this discussion and analysis, including information with respect to the Company&rsquo;s
	plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many
	factors,&nbsp;including those set forth under the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this report, actual
	results may differ materially from those described in or implied by the forward-looking statements contained in the following discussion
	and analysis.&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9.9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune
	Pharmaceuticals Inc., together with its subsidiaries (&ldquo;Immune&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;
	or the &ldquo;Company&rdquo;), is a clinical stage biopharmaceutical company specializing in the development and commercialization
	of novel targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company focuses on a precision medicine
	approach to treatment of diseases by incorporating methods for better patient selection in its clinical trials and
</FONT>
<FONT STYLE="FONT-SIZE: 12PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the potential for development of
</FONT>
<FONT STYLE="FONT-SIZE: 12PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	companion
	diagnostics. The Company&rsquo;s Immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully
	human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products
	and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s current
	product portfolio is summarized in the table below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="WIDTH: 28%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Product(s)/
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Product Candidate(s)
</B>
</P>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 33%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Primary Indication(s)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Status
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 21%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 1.45PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Commercialization Rights
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	BERTILIMUMAB
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Bullous Pemphigoid
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	IBD (Crohn's and ulcerative colitis)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Atopic Dermatitis
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase I/II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	NASH
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase I/II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NANOCYCLO (cyclosporin-A)
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Atopic Dermatitis, Psoriasis
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Preclinical
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	IMMUNO-ONCOLOGY
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Crolibulin
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Solid Tumors
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Azixa
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Glioblastoma multiforme
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NanomAbs
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Solid Tumors
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Preclinical
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Bispecific Antibodies
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Oncology
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Preclinical
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Ceplene
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Acute Myeloid Leukemia (in combination witj IL-2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase III/ (marketed in the EU by Meda AB)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Americas, Israel), Meda (EU, RoW)
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	OTHER/ PAIN
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AmiKet
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Neuropathic Pain
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase III (Ready)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	LidoPAIN
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Pain
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Phase II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 1.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immune (Worldwide)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The
	Company&rsquo;s immuno-oncology pipeline includes Ceplene, a first-in-class small molecule targeting the Histamine-2 Receptor
	to overcome immunosuppression in Acute Myeloid Leukemia (&ldquo;AML&rdquo;) and potentially other malignancies. Ceplene has
	completed Phase III clinical trials and is approved by the European Medicines Agency and in Israel and is marketed by Meda
	AB. Azixa and crolibulin are Phase II clinical stage vascular disrupting agents. NanomAbs, is a technology platform that
	allows the targeted delivery of chemotherapeutics into cancer cells; and a novel technology platform for the construction of
	bispecific antibodies for immunotherapies. The Company continues to review opportunities relating to the Company&rsquo;s
	non-core assets for the treatment of neuropathic pain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Strategy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune&rsquo;s goal is
	to be a leading biotechnology company focused on the discovery, development and commercialization of novel immunotherapies for
	the treatment of diseases that currently lack effective therapies. The Company&rsquo;s work targets are primarily in severe inflammatory
	diseases in dermatology and gastro-enterology and cancer. The Company plans to achieve this by;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	unlocking the value of its pipeline
	by allowing financing of specific asset groups such as but not limited to Immuno-Oncology through the establishment of
	independently funded asset-centric subsidiaries;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Securing scientific expert collaborative partnerships with academia to develop its products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	accelerating clinical development of its products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	expanding its product portfolio through targeted acquisitions and through the development of new drug candidates utilizing
	the Company&rsquo;s proprietary nanoparticle and bispecific technologies; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	securing collaborative partnerships with other companies to co-develop and commercialize its products.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Business and Recent Developments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On March 22, 2016, the
	Company announced the publication of preclinical data in support of its bispecific antibody platform in the Journal of Immunology
	by Dr. Jean Kadouche, scientific co-founder of Immune, and other collaborators from a consortium of academic centers. The authors
	described the design and validation of a novel platform for the production of tetravalent&nbsp;IgG1-like bispecific antibodies,
	including final in-vivo proof-of-concept data for the benchmark molecule targeting human leukocyte antigen class II histocompatibility
	antigen and cluster of differentiation 5 (&ldquo;HLA-DR/CD5&rdquo;) protein. This work has been funded in part by a European grant
	to the collaborative European consortium.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On March 17, 2016 the
	Company announced that new clinical pharmacology and outcomes data will be presented by Prof. Kristoffer Hellstrand, Dr. Anna Martner
	and their scientific colleagues from the University of Gothenburg, Sweden and Universit&agrave; di Roma, Italy, at the upcoming
	American Association of Cancer Research annual conference to be held April 16-20 in New Orleans. Results of a post-marketing clinical
	study using Ceplene in patients with AML will be presented at the conference. The study showed that immunotherapy with Ceplene
	and low-dose IL-2 led to a re-distribution of cytotoxic T-cell subsets in blood towards a tumor-killing phenotype. These immunological
	properties of Ceplene/IL-2 therapy significantly predicted clinical outcomes such as relapse and survival. The results illustrate
	the potential for the use of T-cell biomarkers to accurately predict the efficacy of Ceplene/IL-2 in patients with AML, and to
	focus treatment on those patients most likely to benefit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	On February 24, 2016, Immune announced publication
	of new data on the role of eotaxin-1 in Ulcerative Colitis and Crohn's Disease. The article, published in Digestive Disease Science,
	presented results of an observational clinical study intended to characterize serum and intestinal wall eotaxin-1 levels in inflammatory
	bowel disease (&ldquo;IBD&rdquo;) patients, and explored the effect of targeting eotaxin-1 by specific antibodies in an animal
	IBD model. These studies were conducted under the oversight of Professor Eran Goldin, Chairman of the Digestive Diseases Institute
	at Shaare Zedek Medical Center of the Hebrew University School of Medicine in Jerusalem, and supported in part by an unrestricted
	grant from the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On February 10, 2016 the
	Company announced that it had filed a patent application directed to the treatment of AML and other cancers. The new invention
	provides methods of treating cancer by administration of Ceplene (histamine dihydrochloride) in combination with immune checkpoint
	inhibitors. The new invention also provides methods of predicting the efficacy of Ceplene and IL-2 therapy in patients with AML.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On January 1, 2016, Immune
	Pharmaceuticals Inc., through its wholly owned subsidiary, Immune Pharmaceuticals Ltd. (&ldquo;Immune Ltd.&rdquo;) entered into
	a definitive research and license agreement with BioNanoSim Ltd., (&ldquo;BNS&rdquo;). The license was entered into pursuant to
	an existing binding MOU, dated June 10, 2015, by and between the Company and Yissum. Under the license, the Company obtained from
	BNS an exclusive, worldwide sublicense, with a right to further sublicense, for the development, manufacturing and commercialization
	of certain inventions and research results regarding Yissum&rsquo;s patents in connection with nanoparticles for topical delivery
	of cyclosporine-A (Nanocyclo), for all topical skin indications. In consideration for the License, the Company will pay BNS the
	following payments throughout the term of the License:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual maintenance fee of $30,000, commencing on January 1, 2021, which maintenance fee shall
	increase by 30% each year, up to a maximum annual maintenance fee of $0.1 million and may be credited against royalties or milestone
	payments payable in the same calendar year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a license fee in the amount of $0.5 million, to be paid in four equal installments to be made between
	January 4, 2016 and October 1, 2016; and
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	royalties on net sales of products (as such term is defined in the License) by the Company in the amount of up to 5%, subject
	to certain possible reductions in certain jurisdictions.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Sublicense fees in the amount of
	18% of any non-sales related consideration received by the Company from a sublicense or an option to receive a sublicense for
	the products and/or the licensed technology (as such terms are defined in the license); and milestones payments of up to
	approximately $4.5 million and 250,000 shares of the Company&rsquo;s common stock upon the achievement of certain regulatory,
	clinical development and commercialization milestones, though in the event that the Company receives consideration from a
	sublicensee for any such milestones, the Company will pay to BNS the higher of either (a) the amount of the particular
	milestone payment or (b) the amount of the sublicense fees that are due for such sublicensee consideration paid to the
	Company. In addition, the Company shall reimburse BNS within 60 days for expenses relating to patent fees and will sponsor a
	12-month research program to prepare the program for investigational new drug (&ldquo;IND&rdquo;) submission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	On December 28, 2015, the Company entered into
	an exclusive license with Atlante Biotech SAS (&ldquo;Atlante&rdquo;) to the patents and know-how for a new format of bispecific
	antibodies. The research and development (&ldquo;R&amp;D&rdquo;) work on the bispecific antibodies will be performed in Immune's
	recently established Immunology R&amp;D unit at the Alexandria Center for Life Sciences in New York City, NY, under the leadership
	of Dr. Boris Shor, Executive Director of R&amp;D, who joined the Company from Pfizer Oncology. In recently presented data, the
	platform prototype bispecific antibody was shown to retain effector functions and mediate redirect killing of target cells by cytokine
	induced killer T cells. The bispecific antibody demonstrated direct anti-cancer effects in vitro, as well as in vivo anti-tumor
	activity and improved survival in a mouse xenograft model of disseminated leukemia. A collaborative European consortium led by
	Dr. Jean Kadouche from Atlante, and funded by a European grant developed the novel platform for production of tetravalent IgG1-like
	bispecific antibodies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	On November
	19, 2015, the Company announced two new additions to its leadership team with the appointment of Miri Ben-Ami, M.D.,
	President of Immune Pharmaceuticals Ltd and Executive Vice President (EVP), Oncology; and Monica E. Luchi, M.D., FACR, MBA to
	EVP Global Drug Development, Chief Medical Officer. On December 7, 2015 the Company announced that it has appointed G. John
	Mohr as Senior Vice President of Business Development and a member of the Immune Executive Committee. In this role, Mr. Mohr
	will be responsible for overseeing alliance and business development activities for the Company. In January 2016 Mark Levitt,
	MD, PhD joined the Company as Senior Vice President, Clinical Affairs, Oncology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On November 9, 2015, the
	Company announced that the FDA had cleared an IND application in the U.S. to allow the Company to begin recruiting for its Phase
	II clinical trial with bertilimumab, for the treatment of bullous pemphigoid (&ldquo;BP&rdquo;), a rare autoimmune skin disease
	known to have increased eotaxin-1 levels in serum and blister fluids. On November 17, 2015, the Company announced that the first
	patient has been enrolled into the Phase II clinical trial evaluating the safety and efficacy of its first-in-class fully human
	monoclonal antibody, bertilimumab in UC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	In September 2015, the Company announced that
	Boris Shor, Ph.D. joined the Company as Executive Director, R&amp;D and Scientific Partnerships and Dr. Shor will be establishing
	and directing a new immunology research laboratory at the Alexandria Center for Life Science in New York City for Immune, at the
	Company's headquarters. &nbsp;He will lead translational research efforts to support the development of the company's lead clinical
	stage candidate, bertilimumab, as well as the discovery and development of&nbsp;pipeline drugs utilizing NanomAbs&reg;, antibody
	nano-conjugates for the targeted delivery of cancer drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On August 7, 2015, Melini
	Capital Corp (&ldquo;Melini&rdquo;) agreed to extend the revolving line of credit to the Company until September 30, 2015. On October
	14, 2015, Melini agreed to extend the revolving line of credit until November 30, 2016. In October 2015, the Company paid a fee
	of $0.3 million to Melini as reimbursement for direct financial and administrative expenses accrued for the maintenance of the
	line of credit from April 2014 to March 2016. To date, no amounts have been drawn under the revolving line of credit. Any amounts
	borrowed under the revolving line of credit are required to be repaid by the November 30, 2016 maturity date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On July 29, 2015,
	the Company announced that it had secured financings (&ldquo;July 2015 Financing&rdquo;) of up to $21.5 million through two
	financing agreements. The first, with Hercules Capital (&quot;Hercules&quot;), was for a term loan of $4.5 million
	(&ldquo;Hercules Loan&rdquo;) with the option to draw down additional capital of up to $5.0 million prior to June 15, 2016,
	subject to certain clinical milestones and other conditions. The second agreement, with mutual fund Discover Growth Fund
	(&ldquo;Discover&rdquo;), for the sale to Discover of newly created Series D Redeemable Convertible Preferred Stock
	(&ldquo;Series D Preferred Stock&rdquo;) was for up to $12.0 million in gross proceeds to the Company. On July 29, 2015, the
	Company received $13.5 million in gross proceeds: $9.0 million from Discover through the issuance and sale of 947 shares of
	its Series D Preferred Stock and $4.5 million from Hercules, following the execution of the two agreements. On September 29,
	2015, pursuant to the Stock Purchase Agreement with Discover and upon the satisfaction of the closing conditions included
	therein, the Company issued and sold 316 shares of its Series D Preferred Stock for total gross proceeds of $3.0 million,
	which the Company received on September 29, 2015. The Company repaid the MidCap Financial Trust (&ldquo;MidCap&rdquo;) $2.1
	million senior secured term loan from the proceeds of the financings plus prepayment fees of $0.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On July 16, 2015, the
	Company entered into Securities Exchange Agreements (the &ldquo;Exchange Agreements&rdquo;) with certain holders (the &ldquo;Holders&rdquo;)
	of all of their shares of Series C 8% Convertible Preferred Stock, (the &ldquo;Series C Preferred Stock&rdquo;), pursuant to which
	the Company agreed to issue the Holders an aggregate of 2.25 million shares of the Company&rsquo;s common stock and five-year warrants
	to purchase an aggregate of up to 431,457 shares of Common Stock, at an exercise price of $3.00 per share and exercisable commencing
	six months following the date of issuance. In exchange, the Holders&rsquo; agreed to exchange an aggregate of 2,286 shares of Series
	C Preferred Stock, originally issued by the Company on March 14, 2014, including any accrued but unpaid dividends payable thereon
	(the &ldquo;Exchange&rdquo;), pro rata to each Holder&rsquo;s Preferred Stock ownership. The shares of common stock were issued
	in reliance on the exemption from the registration contained in Section 3(a)(9) of the Securities Act for securities exchanged
	by the issuer and an existing security holder where no commission or other remuneration is paid or given directly or indirectly
	by the issuer for soliciting such exchange. In addition, in July 2015, Daniel G. Teper, the Company&rsquo;s Chief Executive Officer,
	and Daniel Kazado, the Chairman of Immune&rsquo;s Board of Directors converted an aggregate of 32 Series C Preferred Stock into
	an aggregate of 23,561 shares of Immune&rsquo;s common stock pursuant to the original terms of the Series C Preferred Stock. As
	of December 31, 2015, no shares of the Company&rsquo;s Series C Preferred Stock remained outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On June 25, 2015, the
	Company entered into a definitive research and license agreement with Yissum Research Development Company of The Hebrew University
	of Jerusalem, Ltd. (&ldquo;Yissum). Under the license, the Company has obtained an exclusive, worldwide license from Yissum, with
	certain sublicensing rights, to make commercial use of certain of Yissum&rsquo;s patents and know-how in connection with a topical
	nano-formulated delivery of AmiKet for the development, manufacturing, marketing, distribution and commercialization of products
	based on the technology. In consideration for the license, the Company will pay Yissum the following payments throughout the term
	of the license:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual maintenance fee of $30,000 commencing on June 25, 2020, which maintenance fee shall increase
	by 30% each year, up to a maximum annual maintenance fee of $0.1 million and may be credited against royalties or milestone payments
	payable in the same calendar year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	royalties on net sales of products (as such term is defined in the license) by the Company in the
	amount of up to 3%, subject to certain possible reductions in certain jurisdictions;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	milestones payments of up to approximately $4.5 million upon the achievement of certain regulatory,
	clinical development and commercialization milestone; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reimbursement of related patent fees.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Furthermore, the Company
	will fund an annual research program in the amount of approximately $0.4 million annually, plus VAT and any applicable taxes, commencing
	on October 1, 2015 (or such other time as mutually agreed between the parties). The results of the research, including any patents
	or patent applications shall automatically be licensed to the Company. During the year ended December 31, 2015, the Company accrued
	the first installment of the annual research fee of $0.2 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s Management believes that
	Immune will continue to incur losses for the immediate future. Therefore the Company may either need additional equity or debt
	financing, or need to enter into strategic alliances on products in development to sustain its operations until it can achieve
	profitability and positive cash flows from operating activities, if ever. The Company&rsquo;s future depends on the costs, timing,
	and outcome of regulatory reviews of its product candidates and the costs of commercialization activities, including product marketing,
	sales and distribution. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
	The Company&rsquo;s consolidated financial statements do not include any adjustments relating to the recovery of assets or the
	classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Year ended December 31, 2015 compared
	to the year ended December 31, 2014
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Revenues ($ in thousands)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 87%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years&nbsp;ended&nbsp;December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company recorded no revenue during the
	year ended December 31, 2015. Revenue for the year ended December 31, 2014 was $2,000, which was primarily derived from royalties
	on licensed patents. The Company has devoted substantially all of its financial resources and efforts to developing bertilimumab,
	the Company&rsquo;s Phase II drug candidate, for the treatment of inflammatory diseases and NanomAbs, the Company&rsquo;s platform
	for the targeted delivery of cancer drugs, manufacturing bertilimumab under cGMPs, conducting preclinical studies and clinical
	trials. The Company is still in the early stages of development of its product candidates, and it has not completed the development
	of bertilimumab, NanomAbs or other drug candidates. The Company expects to continue to incur significant expenses and operating
	losses for the foreseeable future. The Company&rsquo;s net losses may fluctuate significantly from quarter to quarter and year
	to year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Research and development expense ($ in
	thousands)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 87%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years&nbsp;ended&nbsp;December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,935
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,640
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	295
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	R&amp;D expenses increased by $0.3 million
	or 5% during the year ended December 31, 2015 to $5.9 million compared with $5.6 million during the year ended December 31, 2014.
	The increase was mainly due to an increase in outsourced consulting services, related to the Phase II clinical trials of bertilimumab.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	General and administrative expense ($
	in thousands)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 87%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years&nbsp;ended&nbsp;December&nbsp;31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,789
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,725
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(936
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	General and administrative expense decreased
	by approximately $0.9 million or 9% during the year ended December 31, 2015 to $9.8 million, compared with $10.7 million during
	year ended December 31, 2014. The decrease was primarily due to a reduction in stock compensation expense of $2.6 million due to
	the vesting of shares issued to consultants in 2014. These reductions were partially offset by increased salaries due to the moving
	of the Company&rsquo;s headquarters to New York in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Non-operating expense ($ in thousands)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 87%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years&nbsp;ended&nbsp;December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-operating expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,433
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,187
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,754
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 25.3PT">
<B>
	&nbsp;
</B>
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Non-operating expense amounted to $1.4 million
	during year ended December 31, 2015 compared with non-operating expense of $7.2 million during year ended December 31, 2014, a
	decrease of $5.7 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Non-operating expense for the year ended December
	31, 2015 consisted of interest expense of $0.8 million primarily relating to cash interest paid and amortization of the debt discount
	for the Company&rsquo;s loan and security agreement with Hercules and the senior secured term loan with Midcap, loss on the change
	in fair value of derivative liability instrument of $0.1 million and loss on extinguishment of debt of $0.5 million. The loss on
	the change in fair value of derivative liability instrument of $0.1 million for the year ended December 31, 2015 represents the
	change in fair value of the Hercules warrants issued in conjunction with the Hercules loan and security agreement and the change
	in fair value of the derivative liability associated with the Discover Series D Preferred Stock. In conjunction with the repayment
	of the MidCap senior secured term loan during 2015, the Company recorded a loss on extinguishment of debt of $0.5 million, which
	primarily represented early termination fees related to the repayment of the MidCap loan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Non-operating expense for the year ended December
	31, 2014 consisted of interest expense of $3.4 million primarily due to a $2.2 million charge for the accelerated vesting of restricted
	stock recorded as debt issuance costs and $0.7 million of debt discount expensed due to the conversion of the November 2014 convertible
	promissory note. Non-operating expense also included $3.1 million in warrant amendment expense in conjunction with the amendment
	of the March 2014 Warrants. In addition, non-operating expense included a $0.6 million loss on the change in the fair value of
	derivative liability instrument. The change in the derivative liability was mainly influenced by changes in the price of the Company&rsquo;s
	common stock price during the period. On August 13, 2014, pursuant to an amendment agreement, the Company and all of the holders
	of March 2014 Warrants agreed to amend and restate the March 2014 warrants to remove all anti-dilution provisions. As a result
	of the removal of the anti-dilution provision, the Company was no longer required to fair value and mark to market the March 2014
	warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Deemed Dividend
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company recorded approximately $7.0 million
	in deemed dividend for the year ended December 31, 2015. The Series D Preferred Stock accrues dividend and contains a conversion
	premium that may be settled in cash or stock. For the year ended December 31, 2015, the Company recorded approximately $5.4 million
	in deemed dividend primarily related to the conversion of its Series D Preferred Stock. In addition the Company recorded approximately
	$1.6 million in deemed dividend also primarily related to the conversion of its Series C Preferred Stock for the year ended December
	31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In 2014, the Company accounted for the amendment
	of its Preferred C Stock, classified as mezzanine equity prior to such amendment, as a modification of terms, as the additional
	fair value granted to investors for such modification was less than 10% of pre-amendment value of Preferred C Stock. As such, on
	June 23, 2014, the Company recognized the value of June 2014 Warrants, in the total amount of $0.4 million as a deemed dividend.
	In addition, an accrued dividend liability for investors of Preferred C Stock of $20.3 million for the year ended December 31,
	2014 was recorded as a deemed dividend. Furthermore, in September 2014, the Company&rsquo;s Board of Directors agreed to extend
	the expiration date of 235,333 warrants, at an exercise price of between $3.36 and $4.20 until December 31, 2015. As a result,
	the Company recorded the incremental value of $0.2 million as a deemed dividend.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Liquidity and Capital Resources
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The following table summarizes select balance
	sheet and working capital amounts as at December 31, 2015 and December 31, 2014 ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	As&nbsp;of
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	As&nbsp;of
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December&nbsp;31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December&nbsp;31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,543
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6,767
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(2,224
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Working capital deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,370
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(840
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes and loans payable, current portion
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,011
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company believes that its available
	cash as of the date of this filing may not be sufficient to fund its anticipated level of operations for at least the next
	12 months. The Company&rsquo;s ability to continue as a &ldquo;going concern&rdquo; is dependent on a combination of several
	of the following factors: the Company&rsquo;s ability to raise capital, the potential exercise for cash of warrants and
	options, the Company&rsquo;s ability to monetize assets, the receipt of grants and access to an established credit line. The
	Company has limited capital resources and its operations have been funded by the proceeds of equity and debt
	offerings.&nbsp;&nbsp;The Company has devoted substantially all of its cash resources to R&amp;D programs and incurred
	significant general and administrative expenses to enable it to finance and grow its business and operations. To date, the
	Company has not generated any significant revenues and may not generate any such revenue for a number of years, if at all. If
	the Company is unable to raise additional funds in the future on acceptable terms, or at all, it may be forced to curtail its
	development activities. In addition the Company could be forced to delay or discontinue certain or all product developments,
	and forego attractive business opportunities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	At December 31, 2015, the Company had working
	capital deficit of approximately $1.4 million. Accumulated deficit amounted to $63.0 million and $45.8 million at December 31,
	2015 and December 31, 2014, respectively. Net loss for the years ended December 31, 2015 and 2014 was $17.2 million and $23.6 million,
	respectively. Net cash used in operating activities was $13.9 million for both years ended December 31, 2015 and 2014. Operations
	since inception have been funded primarily with the proceeds from equity and debt offerings. As of December 31, 2015, the Company
	had cash and cash equivalents of $4.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company has
	historically funded its operations primarily through debt, the sale of its securities, including sales of common stock,
	convertible notes, preferred stock and warrants. During 2015, the Company raised a total of up to $21.5 million through two
	financing agreements. The first, on July 29, 2015 with Hercules, was for a term loan of $4.5 million with the option to draw
	down additional capital of up to $5.0 million prior to June 15, 2016, subject to certain clinical milestones and other
	conditions, for which no additional capital has been drawn as of December 31, 2015. The second on July 28, 2015, was with
	Discover through the issuance and sale of 947 shares of the Company&rsquo;s Series D Preferred Stock for gross proceeds of
	$9.0 million. On September 29, 2015, pursuant to the Stock Purchase Agreement the Company issued and sold an additional 316
	shares of its Series D Preferred Stock, for a total gross proceeds of $3.0 million. The Company repaid the MidCap $2.1
	million senior secured term loan and an early termination fee of $0.5 million from the proceeds of the July 2015
	financings. &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company will require additional financing
	in fiscal 2016 in order to continue at its expected level of operations. If the Company fails to obtain the needed capital, it
	will be forced to delay, scale back, partner out or eliminate some or all of its R&amp;D programs, which could result in an impairment
	of the Company&rsquo;s intangible assets and have a material adverse impact on its financial condition and results of operation.
	There is no assurance that the Company will be successful in any capital-raising efforts that it may undertake to fund operations
	during 2016. The Company anticipate that it will continue to issue equity and/or debt securities as a source of liquidity, when
	needed, until its able to generate positive cash flow to support its operations. The Company cannot give any assurance that the
	necessary capital will be raised or that, if funds are raised, it will be on favorable terms. Any future sales of securities to
	finance the Company will dilute existing stockholders' ownership. The Company cannot guarantee when or if it will ever generate
	positive cash flow. In addition, the Company may partner or license the Company&rsquo;s assets, which may allow for additional
	non-dilutive financing in the future. The Company has previously received grants in Israel and may receive additional grant funding
	in 2016. The Independent Registered Public Accounting Firms&rsquo; Reports issued in connection with the Company&rsquo;s audited
	consolidated financial statements for the year ended December 31, 2015 stated that there is &ldquo;substantial doubt about the
	Company&rsquo;s ability to continue as a going concern.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Funding Requirements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s future financing requirements
	will depend on many factors, some of which are beyond the Company&rsquo;s control. Factors affecting the Company&rsquo;s financing
	requirements include, but are not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the rate of progress and cost of the Company&rsquo;s clinical trials, preclinical studies and other discovery and research and development activities;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the timing of, and costs involved in, seeking and obtaining marketing approvals for the Company&rsquo;s products, and in maintaining quality systems standards for the Company&rsquo;s products;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Company&rsquo;s ability to manufacture sufficient quantities of its future products to meet expected demand;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the costs of preparing, filing, prosecuting, maintaining and enforcing any patent claims and other intellectual property rights, litigation costs and the results of litigation;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Company&rsquo;s ability to enter into collaboration, licensing or distribution arrangements and the terms and timing of these arrangements;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the potential need to expand the Company&rsquo;s business, resulting in additional payroll and other overhead expenses;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the potential need to acquire, by acquisition or in-licensing, other products or technologies; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the emergence of competing technologies or other adverse market or technological developments.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Future
	capital requirements will also depend on the extent to which the Company acquires or invests in additional complementary
	businesses, products and technologies. The Company&rsquo;s strategy to fund its operations is to monetize its multiple asset
	groups, raise capital, and the potential exercise for cash of warrants and options. The Company&rsquo;s strategy to fund
	its operations is to monetize its multiple asset groups either through partnerships, asset-centric subsidiaries or
	joint ventures, raise capital, and the potential exercise for cash of warrants and options. On March 30, 2016, the Company
	executed a binding term sheet with Regatta Select Healthcare LLC (&ldquo;Regatta&rdquo;) whereby Regatta
	shall purchase up to 3.5 million shares of the Company&rsquo;s common stock over a twelve-month term at the discretion of the
	Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Cash Flow Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The following table summarizes the Company&rsquo;s
	cash flows for the periods set forth below ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For&nbsp;the&nbsp;year&nbsp;ended&nbsp;December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Net cash used in operating activities
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(13,906
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(13,864
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(42
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net cash (used in) provided by investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(177
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(294
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net cash provided by financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,859
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,465
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,606
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Operating Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Net cash used
	in operating activities for the year ended December 31, 2015 was unchanged at $13.9 million compared with net cash used in operating
	activities of $13.9 million used in the year ended December 31, 2014. The Company&rsquo;s increased operating cash outflows was
	driven by continued R&amp;D spending on its lead drug candidate bertilimumab, and general and administrative spending resulting
	from relocation of corporate headquarters to New York, NY and related staffing needs. It also reflected lower accrued expenses
	for the year ended December 31, 2015.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Net cash used in operating activities for the year ended
	December 31, 2014 was also $13.9 million. The Company&rsquo;s increased operating cash outflows was primarily due to the settlement
	of liabilities assumed as part of the Merger, as well as repayment of accrued payments to vendors and related parties delayed up
	until the closing of the March 2014 Financing.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s net cash used in operating
	activities could increase if it engages in future business development activities. As the Company expects to move towards revenue
	generation in the future, the Company expects that these amounts will be offset over time by the collection of revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Investing Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	During the year ended
	December 31, 2015, the Company&rsquo;s net cash used in investing activities was $0.2 million, primarily driven by the acquisitions
	of office and laboratory equipment. During the year ended December 31, 2014, the Company&rsquo;s net cash provided by investing
	activities amounted to $0.1 million and included the acquisitions of office equipment offset by a decrease in restricted cash.
	The Company expects that net cash used in investing activities will increase should it acquire additional intellectual property,
	assets and invest surplus cash, according to the Company&rsquo;s investment policy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Financing Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	For the year ended December 31, 2015, the Company&rsquo;s
	net cash provided by financing activities was $11.9 million. This was primarily comprised of proceeds from the Company&rsquo;s
	July 2015 Financing, which included proceeds from the issuance of the Series D Preferred Stock of $12.0 million and proceeds from
	the loan and security agreement with Hercules of $4.5 million. This was partially offset by the repayment of the Midcap senior
	secured term loan in the amount of $3.2 million and the payment of $1.6 million in financing costs related to the July 2015 financing.&nbsp;For
	the year ended December 31, 2014, net cash provided by financing activities included cash provided by the March 2014 Financing,
	the private placements in August and September of 2014, the November 2014 underwritten public offering, the November 2014 convertible
	promissory note, and the exercise of options and warrants totaling of $22.5 million, and repayment of loans of $1.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company has historically funded its operations
	primarily through the sale of its debt and equity securities. The Company anticipates issuing equity and/or debt as a source of
	liquidity, when needed, until it starts generating positive cash flow to support its operations. The Company cannot give any assurance
	that the necessary capital will be raised or that, if funds are raised, it will be on favorable terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Critical Accounting Policies and Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune's discussion and
	analysis of the financial condition and results of operations are based upon the consolidated financial statements, which have
	been prepared in accordance with U.S.&nbsp;GAAP. The preparation of these financial statements and related disclosures in compliance
	with U.S.&nbsp;GAAP requires the application of appropriate technical accounting rules and guidance as well as the use of estimates
	and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent
	assets and liabilities. The application of these policies involves judgments regarding future events, including the likelihood
	of success of particular product candidates, regulatory challenges, and the fair value of certain assets and liabilities. These
	judgments, in and of themselves, could materially affect the financial statements and disclosures based on varying assumptions,
	which may be appropriate to use. In addition, the financial and operating environment may also have a significant effect, not only
	on the operation of the business, but on the results reported through the application of accounting measures used in preparing
	the financial statements and related disclosures, even if the nature of the accounting policies have not changed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	On an ongoing basis, the
	Company evaluates these estimates, utilizing historic experience, consultation with experts and other methods the Company considers
	reasonable. In any event, actual results may differ substantially from the Company's estimates. Any effects on the Company's business,
	financial position or results of operations resulting from revisions to these estimates are recorded in the period in which the
	information that gives rise to the revision becomes known.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune's significant accounting
	policies are summarized in Item&nbsp;15&nbsp;&mdash;&nbsp;Note 3,
<I>
	Summary of Significant Accounting Policies,
</I>
	Note 4,
<I>
	Derivative
	Financial Instruments
</I>
	and Note 5,
<I>
	Fair Value Measurements
</I>
	to the Consolidated Financial Statements. The Company identifies
	its most critical accounting policies as those that are the most pervasive and important to the portrayal of the Company's financial
	position and results of operations, and that require the most difficult, subjective and/or complex judgments by management regarding
	estimates about matters that are inherently uncertain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Accounting Policy
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 68%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Judgments/Uncertainties Affecting Application
</B>
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Derivative Instruments
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Assumptions used in valuation techniques
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Assumptions used in forecasting borrowings
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Market maturity and economic conditions
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Contract interpretation
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Income Taxes and Valuation Allowance for Deferred Tax Assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Ability to be sustained upon audit examination of taxing authorities
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Interpret existing tax statute and regulations upon application to transactions
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Ability to utilize tax benefits through carry backs to prior periods and carry forwards to future periods
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Impairment of Long Lived Assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Recoverability of investment through future operations
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Regulatory and political environments and requirements
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimated useful lives of assets
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimates of future cash flows
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimates of fair value
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Judgment about triggering events indicating impairment
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Intangible Assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimated useful lives for intangible assets
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Judgment about impairment triggering events
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimates of fair value
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Fair value estimate of intangible assets acquired in business combinations
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Contingencies
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Estimated financial impact of event(s)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Judgment about likelihood of event(s) occurring
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Regulatory and political environments and requirements
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Recent Accounting
	Pronouncements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	See Item 15 &mdash; Note 3,
<I>
	Summary of
</I>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Significant
	Accounting Policies,
</I>
</FONT>
	to the Consolidated Financial Statements for a discussion of recent accounting developments.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 25.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	As of December 31, 2015, the Company had no
	off-balance sheet arrangements. Immune has no guarantees or obligations other than those, which arise, out of the Company&rsquo;s
	ordinary business operations.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_012">
</A>
	ITEM 7A. QUALITATIVE AND QUANTITATIVE DISCLOSURES
	ABOUT MARKET RISKS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Not applicable
<B>
	.
</B>
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_013">
</A>
	ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
	DATA
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	See the Company&rsquo;s
	consolidated financial statements filed with this Annual Report on Form 10-K under Item 15 below.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_014">
</A>
	ITEM 9. CHANGES IN AND DISAGREEMENTS WITH
	ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTING_CHANGES>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_015">
</A>
	ITEM 9A. CONTROLS AND
	PROCEDURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 0.5IN; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 0.5IN; TEXT-INDENT: 0; PADDING: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(a)
</I>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Evaluation of Disclosure Controls and Procedures
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune&rsquo;s management,
	with the participation and supervision of its Chief Executive Officer and Principal Financial Officer, are responsible for the
	Company&rsquo;s disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
	of 1934, as amended, or the Exchange Act. Disclosure controls and procedures are controls and other procedures that are designed
	to ensure that information required to be disclosed in the Company&rsquo;s reports filed or submitted under the Exchange Act is
	recorded, processed, summarized and reported, within the time periods specified under the Securities and Exchange Commission&rsquo;s
	rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required
	to be disclosed in the Company&rsquo;s reports filed under the Exchange Act is accumulated and communicated to its principal executive
	officer and its principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune&rsquo;s management,
	including its Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of the Company&rsquo;s
	disclosure controls and procedures as of December 31, 2015. Based on this evaluation, Immune&rsquo;s management concluded that
	as of December 31, 2015, the Company&rsquo;s disclosure controls and procedures were not effective at a reasonable assurance level
	due to the material weaknesses identified in the Company&rsquo;s internal control over financial reporting as of December 31, 2015
	(discussed in paragraph (b) to this Item 9A), which the Immune&rsquo;s management views as an integral part of the Company&rsquo;s
	disclosure controls and procedures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(b)
</I>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Management&rsquo;s Annual Report on Internal Control over Financial Reporting
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Immune&rsquo;s management
	is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial
	reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended, as a process designed
	by, or under the supervision of, the Company&rsquo;s Chief Executive Officer and Principal Financial Officer and effected by the
	Company&rsquo;s Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of
	financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
	principles. The Company&rsquo;s internal control over financial reporting includes those policies and procedures that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
	the transactions and dispositions of the assets of the Company;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	provide reasonable assurance that transactions are recorded as necessary to permit preparation
	of financial statements in accordance with generally accepted
	accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations
	of management and directors of the Company; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
	use or disposition of the company&rsquo;s assets that
	could have a material effect on the financial statements.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Because of its inherent
	limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of
	effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or
	that the degree of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	A material weakness is
	a significant deficiency, or combination of significant deficiencies, that results in there being more than a remote likelihood
	that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis
	by management or employees in the normal course of performing their assigned functions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s management
	assessed the effectiveness of the Company&rsquo;s internal control over financial reporting as of December 31, 2015. Management&rsquo;s
	assessment identified the following material weaknesses in the Company&rsquo;s internal control over financial reporting: segregation
	of duties issues due to lack of sufficient accounting and finance personnel and lack of a sufficient technology infrastructure
	to support the financial reporting function.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In making this assessment,
	management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal
	Control-Integrated Framework (2013). Because of the material weaknesses described above, management believes that, as of December
	31, 2015, the Company&rsquo;s internal control over financial reporting was not effective based on those criteria.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	During the year ended December
	31, 2015, the Company&rsquo;s management undertook the following actions that materially affect, or are reasonably likely to materially
	affect, the Company&rsquo;s internal control over financial reporting and to remediate the material weaknesses in the Company&rsquo;s
	2015 Annual Report on Form 10-K. Remediation efforts will continue through the next several financial close cycles until such time
	as management is able to conclude that its remediation efforts are operating and effective:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company hired a senior level VP of Finance, Controller, Chief Accounting Officer with expertise
	in applying complex accounting and financial reporting and disclosure rules required under U.S. GAAP and SEC reporting regulations.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company moved its accounting and financial reporting from Israel to the U.S.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In October 2015, the Company purchased the license to a new accounting general ledger system, which
	will be implemented in first quarter of fiscal 2016.&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company has hired consultants during the year ended December 31, 2015 to help document the
	Company&rsquo;s internal control environment.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 0.5IN; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 0.5IN; TEXT-INDENT: 0; PADDING: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(c)
</I>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Changes in Internal Controls
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 19.8PT; TEXT-INDENT: 0.25IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Except for the remediation
	measures described above, there were no changes in the Company&rsquo;s internal control over financial reporting, identified in
	connection with the evaluation of such internal control that occurred during the fourth quarter of the Company&rsquo;s last fiscal
	year that have materially affected, or are reasonably likely to materially affect, the Company&rsquo;s internal control over financial
	reporting.&nbsp;
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_016">
</A>
	ITEM 9B. OTHER INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	None.
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V434974_10K_HTM_A_017">
</A>
<B>
	PART&nbsp;III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 39.65PT">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_018">
</A>
	ITEM&nbsp;10. DIRECTORS, EXECUTIVE OFFICERS
	AND CORPORATE GOVERNANCE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Information called for
	by this Item may be found in the Immune&rsquo;s definitive Proxy Statement in connection with the Company&rsquo;s 2015 Annual Meeting
	of Stockholders to be filed with the SEC under the captions &ldquo;Management and Corporate Governance Matters,&rdquo; &ldquo;Section
	16(a) Beneficial Ownership Reporting Compliance,&rdquo; and &ldquo;Code of Conduct and Ethics&rdquo; is incorporated by reference
	in this Item 10.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_019">
</A>
	ITEM&nbsp;11. EXECUTIVE COMPENSATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Information called for
	by this Item may be found in Immune&rsquo;s definitive Proxy Statement in connection with the Company&rsquo;s 2015 Annual Meeting
	of Stockholders to be filed with the SEC under the captions &ldquo;Executive Officer and Director Compensation&rdquo; and &ldquo;Management
	and Corporate Governance&rdquo; and is incorporated by reference in this Item 11.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_020">
</A>
	ITEM&nbsp;12. SECURITY OWNERSHIP OF CERTAIN
	BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Information called for
	by this Item may be found in Immune&rsquo;s definitive Proxy Statement in connection with the Company&rsquo;s 2015 Annual Meeting
	of Stockholders to be filed with the SEC under the captions &ldquo;Security Ownership of Certain Beneficial Owners and Management&rdquo;
	and &ldquo;Equity Compensation Plan Information&rdquo; and is incorporated by reference in this Item 12.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<A NAME="V434974_10K_HTM_A_021">
</A>
	ITEM&nbsp;13. CERTAIN RELATIONSHIPS AND
	RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Information called for
	by this Item may be found in Immune&rsquo;s definitive Proxy Statement in connection with the Company&rsquo;s 2015 Annual Meeting
	of Stockholders to be filed with the SEC under the captions &ldquo;Certain Relationships and Related Person Transactions&rdquo;
	and &ldquo;Management and Corporate Governance&rdquo; and is incorporated by reference in this Item 13.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<A NAME="V434974_10K_HTM_A_022">
</A>
	ITEM&nbsp;14. PRINCIPAL ACCOUNTING FEES AND SERVICES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	Information called for
	by this Item may be found in Immune&rsquo;s definitive Proxy Statement in connection with the Company&rsquo;s 2015 Annual Meeting
	of Stockholders to be filed with the SEC under the caption &ldquo;Independent Registered Public Accounting Firm&rdquo; and is incorporated
	by reference in this Item 14.
</P>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0IN">
<B>
<A NAME="V434974_10K_HTM_A_023">
</A>
	ITEM 15. EXHIBITS AND FINANCIAL STATEMENT
	SCHEDULES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(a)(1)
<I>
	Financial Statements.
</I>
	For the financial statements
	included in this annual report, see &ldquo;Index to the Financial Statements&rdquo; on page F-1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(a)(2)
<I>
	Financial Statement Schedules.
</I>
	All schedules are omitted
	because they are not applicable or because the required information is included in the financial statements or notes thereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(a)(3)
<I>
	Exhibits.
</I>
	The list of exhibits filed as a part of
	this annual report is set forth on the Exhibit Index immediately preceding such exhibits and is incorporated by reference in this
	Item 15(a)(3).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	(b)
<I>
	Exhibits.
</I>
	See Exhibit Index.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	(c)
<I>
	Separate Financial Statements and Schedules
</I>
	. None.
</P>
</EFX_EXHIBITS>
</EFX_PART_IV>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT INDEX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.7PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibit
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Number
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 91%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Merger Agreement and Plan of Reorganization,
	dated as of November 7, 2012, by and among EpiCept Corporation, EpiCept Israel Ltd. and Immune Pharmaceuticals Ltd.; Amendment
	to Merger Agreement and Plan of Reorganization, dated as of November 27, 2012; Amendment No. 2 to Merger Agreement and Plan of
	Reorganization, dated as of February 11, 2013; Amendment No. 3 to Merger Agreement and Plan of Reorganization, dated as of March
	14, 2013; and Amendment No. 4 to Merger Agreement and Plan of Reorganization, dated as of June 17, 2013; (incorporated by reference
	to the Company&rsquo;s Definitive Proxy Statement on Form DEF 14A filed with the SEC on June 18, 2013).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	2.2
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Agreement and Plan of Merger, dated as of September 6,
	2005, among EpiCept Corporation, Magazine Acquisition Corp. and Maxim Pharmaceuticals, Inc. (incorporated by reference to Exhibit
	2.1 to Maxim Pharmaceuticals Inc.&rsquo;s Current Report on Form 8-K filed with the SEC on September 6, 2005).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Third Amended and Restated Certificate of
	Incorporation (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC
	on May 21, 2008).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Amendment to the Third Amended and Restated Certificate of
	Incorporation (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the
	SEC on July 9, 2009).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.3
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on January14,&nbsp;2010).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.4
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August&nbsp;21,&nbsp;2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Certificate of Designation of Preferences, Rights and
	Limitations of Series C 8% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s
	Current Report on Form 8-K filed with the SEC on March 11, 2014).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Certificate of Amendment to Certificate of Designation of
	Preferences, Rights and Limitations of Series C 8% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1
	to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 23, 2014).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.7
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Designations of Preferences, Rights and Limitations of Series D Redeemable Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 29, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	3.8
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on February 18, 2010).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Common Stock Purchase Warrant, dated August 23, 2013
	(incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 29,
	2013).&nbsp;&nbsp;&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company&rsquo;s Current Report on Form 8-K filed March 11, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 23, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Restated Series A Warrant and Restated Series B Warrant (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 14, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.8
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 20, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.9
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant (July 16, 2015) (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 17, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	4.10
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant to be issued to Hercules Capital (July 2015) (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 29, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Loan and Security Agreement, dated May 27, 2011, by and among MidCap Funding III, LLC, EpiCept Corporation, Maxim Pharmaceuticals, Inc. and Cytovia, Inc. (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 31, 2011.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.2
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Consent Agreement, dated June 18, 2012, by and among MidCap Funding III, LLC, EpiCept Corporation, Maxim Pharmaceuticals, Inc. and Cytovia, Inc. (incorporated by reference to Exhibit 10.4 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 21, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.3
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	First Amendment to Loan and Security Agreement dated August 27, 2012, by and among MidCap Funding III, LLC, EpiCept Corporation, Maxim Pharmaceuticals, Inc. and Cytovia, Inc. (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 31, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.4
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Second Amendment to Loan and Security Agreement with Midcap Funding III, LLC, dated July 31, 2013 (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 1, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Third Amendment to Loan and Security Agreement with Midcap Funding III, LLC, dated August 23, 2013 (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 29, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Fourth Amendment, Consent and Waiver to Loan and Security Agreement by and among Immune Pharmaceutical Inc., Maxim Pharmaceuticals Inc., Cytovia, Inc. and MidCap Funding III, LLC (incorporated by reference to Exhibit 4.3 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 11, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.7&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated 2005 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 30, 2007).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.8&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune Pharmaceuticals Inc. 2013 Stock Ownership and Option Plan (incorporated by reference to Exhibit 99.2 to the Company&rsquo;s Registration Statement on Form S-8 filed with the SEC on September 2, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.9&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of incentive stock option granted under Amended and Restated 2005 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Company&rsquo;s Registration Statement on Form S-8 filed with the SEC on September 2, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.10&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of 102 capital gains stock option award agreement, granted in Israel, under Amended and Restated 2005 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to the Company&rsquo;s Registration Statement on Form S-8 filed with the SEC on September 2, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.11&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Immune Pharmaceuticals Inc. 2015 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company&rsquo;s Registration Statement on Form S-8 filed with the SEC on December 24, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.12&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Stock Option Award Agreement under the Registrant&rsquo;s 2015 Equity Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company&rsquo;s Registration Statement on Form S-8 filed with the SEC on December 24, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.13&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement dated June 4, 2014, by and between Immune Pharmaceuticals Inc. and Daniel G. Teper (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 6, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.14&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement dated as of September 1, 2011, between Immune Pharmaceuticals Ltd. and Daniel G. Teper (incorporated by reference to Exhibit 10.11 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.15&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment to Employment Agreement dated June 23, 2014, by and between Immune Pharmaceuticals Ltd. and Daniel G. Teper (incorporated by reference to Exhibit 10.4 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.17
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Securities Purchase Agreement dated March 10, 2014, by and among the Company and the Purchasers part thereto (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 11, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.18
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Services Agreement, dated as of August 6, 2013, by and between Immune Pharmaceuticals Ltd. and Melini Capital Corp (incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 19, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Option Agreement, dated as of August 10, 2013, by and between Immune Pharmaceuticals Ltd. and Melini Capital Corp (incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 19, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Consulting Services Agreement, dated as of August 10, 2013, by and between Immune Pharmaceuticals Ltd. and Jean Kadouche (incorporated by reference to Exhibit 10.4 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 19, 2013) (incorporated by reference to Exhibit 10.27 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.22
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Research and License Agreement, dated as of April 6, 2011, by and between Immune Pharmaceuticals Ltd. and Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. (incorporated by reference to Exhibit 10.28 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.23
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	First Amendment to the Research and License Agreement dated September 26, 2011, between Immune Pharmaceuticals Ltd. and Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. (incorporated by reference to Exhibit 10.29 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Research and License Agreement, dated as of June 25, 2015, by and between Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. and Immune Pharmaceuticals Inc.&nbsp;(incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 29, 2015).
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.24&plusmn;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Product Sublicense Agreement dated as of December 7, 2010, by and between Immune Pharmaceuticals Ltd., Immune Pharmaceuticals Corporation and iCo Therapeutics Incorporated (incorporated by reference to Exhibit 10.30 to the Company&rsquo;s Amendment No. 2 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on October 3, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.25
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Assignment Agreement, dated as of March 28, 2012, by and between Immune Pharmaceuticals Ltd. and Mablife S.A.S. (f/k/a Monoclonal Antibodies Therapeutics M.A.P.) (incorporated by reference to Exhibit 10.31 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.26
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Assignment Agreement Amendment, dated as of February 8, 2014, by and between Immune Pharmaceuticals Ltd. and Mablife S.A.S. (f/k/a Monoclonal Antibodies Therapeutics M.A.P.) (incorporated by reference to Exhibit 10.32 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.27
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Sublicense Agreement, dated as of August 27, 1999, between Epitome Pharmaceuticals Limited (Dalhousie University) and American Pharmed Labs, Inc. (incorporated by reference to Exhibit 10.11 to the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on May 3, 2005).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.28
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement, dated as of March 1, 2004, by and between Shire Biochem Inc., Maxim Pharmaceuticals, Inc. and Cytovia, Inc., as amended (incorporated by reference to Exhibit 10.1 to each of Maxim Pharmaceuticals, Inc.&rsquo;s Quarterly Reports on Form 10-Q filed with the SEC on May 7, 2004 and May 5, 2005, respectively).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.29
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Waiver and Amendment to License Agreement, dated as of April 3, 2014, by and between Immune Pharmaceuticals Inc. and Dalhousie University (incorporated by reference to Exhibit 10.35 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 9, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.30
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Revolving Line of Credit, dated as of April 17, 2014, by and between Immune Pharmaceuticals Inc. and Melini Capital Corp. (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 11, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.31
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Amendment Agreement (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 14, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.32
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Lease Agreement, dated as of December 30, 2014, by and between Immune Pharmaceuticals Inc. and ARE-East River Science Park, LLC (incorporated by reference to Exhibit 10.38 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 15, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.33
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Second Amendment to Lease Agreement, dated as of August 31, 2015, by and between Immune Pharmaceuticals Inc. and ARE-East River Science Park, LLC (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 16, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.34&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Letter Agreement dated January 21, 2015, by and between Immune Pharmaceuticals Inc. and Gad Berdugo (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report Form 8-K filed with the SEC on January 21, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.35
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement, dated as of December 18, 2003, by and between Endo Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.9 to the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on May 3, 2005).&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.36
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment, by and between Immune Pharmaceuticals Inc. and Endo Pharmaceuticals Inc., dated July 7, 2015 (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on with the SEC on July 8, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.37&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	First Amendment to Employment
	Agreement, dated February 28, 2015, by and between Immune Pharmaceuticals Inc. and Daniel G. Teper (incorporated by reference
	to Exhibit 10.41 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 15, 2015).
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.38&dagger;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Termination Agreement and General Release, dated February 28, 2015, by and between Immune Pharmaceuticals, Ltd. and Daniel G. Teper (incorporated by reference to Exhibit 10.42 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on April 15, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.39
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Securities Exchange Agreement (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July17, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.40
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Loan and Security Agreement, dated July 29, 2015, by and among Immune Pharmaceuticals Inc. and Immune Pharmaceuticals USA Corp., Immune Pharmaceuticals Ltd., as guarantor, and Hercules Capital, as agent for itself and lender (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 29, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.41
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Stock Purchase Agreement, dated as of July 28, 2015, by and between Immune Pharmaceuticals Inc. and the investor named therein (registered direct offering) (incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 29, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	10.42
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Stock Purchase Agreement, dated as of July 28, 2015, by and between Immune Pharmaceuticals Inc. and the investor named therein (private placement) (incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 29, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	10.43
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Voting Agreement (incorporated by reference to Exhibit 10.4 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 29, 2015).&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.44&dagger;*
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 91%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement dated November 1, 2015, by and between Immune Pharmaceuticals Ltd. and Miri Ben-Ami.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.45&dagger;*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement dated November 18, 2015 , by and between Immune Pharmaceuticals Inc. and Monica E. Luchi.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.46&dagger;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement, dated as of December 31, 2015, by and between Immune Pharmaceuticals Inc. and John Militello (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on December 31, 2015).&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.47&dagger;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Release and Consulting Agreement, dated as of December 28, 2015, by and between Immune Pharmaceuticals Inc. and Gad Berdugo (incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on December 31, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.48
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research and License Agreement, dated as of January 1, 2016, by and between BioNanoSim Ltd. and Immune Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 7, 2016).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21.1*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	List of Subsidiaries of Immune Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23.1*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consent of BDO USA, LLP.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23.2*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consent of EisnerAmper LLP.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.1*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a- 14(a) and 15(d)-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.2*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a- 14(a) and 15(d)-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.1**
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.2**
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.INS*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBLR Instance Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.SCH*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBLR Taxonomy Extension Schema Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.CAL*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBLR Taxonomy Extension Calculation Linkbase Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.DEF*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBLR Taxonomy Extension Definition Linkbase Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.LAB*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBLR Taxonomy Extension Label Linkbase Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.PRE*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBLR Taxonomy Extension Presentation Linkbase Document
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 17.6PT; TEXT-INDENT: -17.6PT">
	* Filed herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 17.6PT; TEXT-INDENT: -17.6PT">
	** Furnished herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&dagger; Management contract or compensatory plan or arrangement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&plusmn; Confidential treatment has been granted with respect to
	certain portions of this exhibit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBIT_INDEX>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.5PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<B>
<A NAME="V434974_10K_HTM_A_024">
</A>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	Pursuant to the requirements of Section&nbsp;13
	or 15(d)&nbsp;of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the
	undersigned, thereunto duly authorized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
	IMMUNE PHARMACEUTICALS INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Dr. Daniel G. Teper
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Daniel G. Teper
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Chief Executive Officer
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	Pursuant to the requirements of the Securities
	Exchange Act of 1934, this report has been signed by the following persons in the capacities indicated and on the dates indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 28%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Signature
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 54%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Title
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 16%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Date
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/Dr. Daniel G. Teper
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Executive Officer&nbsp;(Principal Executive Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Daniel G. Teper
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ John Militello
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	VP Finance, Controller and Chief Accounting Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	John Militello
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Financial Officer and Principal Accounting Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Daniel Kazado
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Daniel Kazado
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Dr. Cameron Durrant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Cameron Durrant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Elliot M. Maza
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Elliot M. Maza
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 28%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ John A. Neczesny
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 54%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 16%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	John A. Neczesny
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
</TR>
<TR>
<TD COLSPAN="5" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 28%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Dr. Jeffrey Paley
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 54%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 16%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;March 30, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Jeffrey Paley
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	INDEX TO FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	IMMUNE PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V434974_10K_HTM_FIN_001">
<FONT STYLE="FONT-SIZE: 10PT">
	Reports of Independent Registered Public Accounting Firms
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	61
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V434974_10K_HTM_FIN_002">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Balance Sheets as of December&nbsp;31, 2015 and 2014
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	63
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V434974_10K_HTM_FIN_003">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December&nbsp;31, 2015 and 2014
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	64
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V434974_10K_HTM_FIN_004">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Stockholders&rsquo; Equity for the Years Ended December&nbsp;31, 2015 and 2014
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	65
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V434974_10K_HTM_FIN_005">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Cash Flows for the Years Ended December&nbsp;31, 2015 and 2014
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	66
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V434974_10K_HTM_FIN_006">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	67
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V434974_10K_HTM_FIN_001">
</A>
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Board of Directors
	and Shareholders
<BR>
	Immune Pharmaceuticals Inc.
<BR>
	New York, New York
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We have audited the
	accompanying balance sheet of Immune Pharmaceuticals Inc. as of December 31, 2015 and the related statements of operations and
	comprehensive loss, stockholders&rsquo; equity and cash flows for the year then ended. These financial statements are the responsibility
	of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 20.05PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We conducted our audit
	in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
	we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
	The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting.
	Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are
	appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
	control over financial reporting. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
	in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as
	evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 20.05PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	In our opinion, the
	financial statements referred to above present fairly, in all material respects, the financial position of Immune Pharmaceuticals
	Inc. as of December 31, 2015, and the results of its operations and its cash flows for the year then ended, in conformity with
	accounting principles generally accepted in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 20.05PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	The accompanying financial
	statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial
	statements, the Company has negative working capital, an accumulated deficit, recurring losses from operations and expects continuing
	future losses that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these
	matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome
	of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 20.05PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ BDO USA, LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	New York, New York
<BR>
	March 30, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	REPORT OF INDEPENDENT
	REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors and Stockholders
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Immune Pharmaceuticals Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated
	balance sheet of Immune Pharmaceuticals, Inc. and Subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2014, and the related
	consolidated statements of operations and comprehensive loss, stockholders&rsquo; equity, and cash flows for the year then ended.
	The financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion
	on these financial statements based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audit in accordance with
	the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
	the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company
	is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit
	included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
	in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control
	over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting
	the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant
	estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides
	a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the financial statements
	referred to above present fairly, in all material respects, the consolidated financial position of Immune Pharmaceuticals Inc.
	and Subsidiaries as of December 31, 2014, and the consolidated results of their operations and their cash flows for the year then
	ended, in conformity with accounting principles generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ EisnerAmper LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Iselin, New Jersey
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	April 15, 2015
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V434974_10K_HTM_FIN_002">
</A>
<B>
	Immune Pharmaceuticals Inc. and Subsidiaries
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Consolidated Balance Sheets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	($ in thousands, except share and per
	share amounts)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,543
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,767
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Restricted cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other current assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	258
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	99
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total current assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,832
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,887
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property and equipment, at cost, net of accumulated depreciation of $77 and $51
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	371
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	In-process research and development acquired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Intangible assets, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,415
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	370
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,184
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,864
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,439
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,243
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,660
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,133
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Due to related parties
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Derivative financial instruments, warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes and loans payable, current portion, net of debt discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,011
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Obligations under capital lease, current portion
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total current liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,286
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,417
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Grants payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	469
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes and loans payable, net of current portion
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,564
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Obligations under capital lease, net of current portion and debt discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	91
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series D Preferred Stock derivative liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,529
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Deferred tax liability
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,870
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,870
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,662
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,320
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Series D Preferred Stock, net of discount, par value $0.0001, 12,000 shares authorized, 1,263 shares issued and 963 shares outstanding as of December 31, 2015 and 0 shares issued and outstanding as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,659
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Commitments and contingencies
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Stockholders&rsquo; Equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Series C Preferred Stock, par value $0.0001; 15,000 shares authorized, 2,832 shares issued and 0 shares outstanding as of December 31, 2015, and 2,832 shares issued and outstanding, as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	821
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common stock, $0.0001 par value; authorized 225,000,000 shares; 32,434,942 and 23,975,358 shares issued and outstanding at December 31, 2015 and December&nbsp;31, 2014, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	70,846
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62,550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(62,986
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(45,829
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total stockholders&rsquo; equity
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,863
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17,544
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total liabilities and stockholders&rsquo; equity
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,184
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,864
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	The accompanying notes are an integral
	part of the consolidated financial statements.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V434974_10K_HTM_FIN_003">
</A>
	Immune Pharmaceuticals Inc. and Subsidiaries
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Consolidated Statements of Operations
	and Comprehensive Loss
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	($ in thousands, except share and per
	share amounts)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For The Years Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Costs and expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,935
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,640
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,789
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,725
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total costs and expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,724
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,365
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loss from operations
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(15,724
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(16,363
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Non-operating expense:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(827
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Derivative liability instrument expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(558
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrant amendment expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,145
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss on extinguishment of debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(463
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other expense, net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(80
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total non-operating expense:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,433
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,187
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net loss before income taxes
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,157
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(23,550
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,157
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(23,550
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deemed dividend
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,959
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(616
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Series C Preferred Stock dividend
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(256
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loss attributable to common stockholders
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(24,116
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(24,422
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Basic and diluted loss per common share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.90
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1.46
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted average common shares outstanding - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,741,392
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,742,550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Comprehensive loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,157
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(23,550
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	The accompanying notes are an integral
	part of the consolidated financial statements.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V434974_10K_HTM_FIN_004">
</A>
	Consolidated Statement of Stockholders&rsquo;
	Equity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	For the Years Ended December 31, 2015
	and 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	($ in thousands, except share amounts)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Series
	C Preferred Stock
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Common
	Stock
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Additional
<BR>
	Paid-In
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Accumulated
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Amount
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Amount
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Capital
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Deficit
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Total
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 30%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance at December 31, 2013
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,276,037
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	27,761
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(22,279
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	$
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	5,483
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Reclassification of warrants from liability to equity
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,202
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,202
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of shares of common stock as part of March 2014 Warrant amendment
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	224,127
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	825
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	825
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Exercise of options and warrants
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	97,292
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	251
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	251
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of shares and warrants, net of issuance costs of $1,136
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	4,505,697
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	11,028
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	11,029
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Settlement of derivative liability
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	300,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	750
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	750
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Conversion of convertible promissory note
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	400,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,000
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Conversion of Series C Preferred Stock reclassified from mezzanine
	to equity
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,209
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,209
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Reclassification of Series C Preferred Stock from mezzanine
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	6,512
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,887
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,887
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Conversion of Series C Preferred Stock
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(3,680
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(1,066
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,975,319
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,066
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Accrued dividend for Series C Preferred Stock
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(256
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(256
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Acceleration of stock awards in connection with November 2014 convertible
	promissory note
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	866,666
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,217
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,217
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock-based compensation, stock awards
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,330,220
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	4,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	4,000
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock-based compensation, option awards
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,497
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,497
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Loss for the period
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(23,550
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(23,550
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance at December 31, 2014
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,832
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	821
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	23,975,358
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	62,550
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(45,829
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	17,544
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Exercise of options and warrants
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	388,052
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	143
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	143
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Conversion of Series C Preferred Stock and associated dividends
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(2,832
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(821
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,627,563
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,071
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	250
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Conversion of Series D Preferred Stock to common stock and accretion
	of deemed dividend
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	4,511,730
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,438
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,439
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock-based compensation
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	588,169
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,833
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,833
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares issued to settle liabilities
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	290,594
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	537
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	537
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares issued for financing costs
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	53,476
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	100
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	100
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Warrants issued in connection with debt financing
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	416
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	416
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Warrants issued in connection with Series D financing
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	758
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	758
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Loss for the period
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(17,157
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(17,157
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance at December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	32,434,942
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	70,846
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(62,986
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	7,863
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	The accompanying notes are an integral
	part of the consolidated financial statements.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V434974_10K_HTM_FIN_005">
</A>
	Immune Pharmaceuticals Inc. and Subsidiaries
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Consolidated Statements of Cash Flows
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	($ in thousands)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the Year Ended
<BR>
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(17,157
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(23,550
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Depreciation and amortization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	328
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Amortization of debt discount and debt issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	318
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Stock-based compensation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,833
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,497
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Non-cash interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,887
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Disposals of property and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Issuance of common stock to consultant
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Derivative liability instrument expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	558
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Warrant amendment expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,145
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Interest amortization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Decrease in long term grants payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(469
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(52
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	(Increase) decrease in other current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Increase in security deposit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(177
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Increase (decrease) in accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,447
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,895
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	Increase (decrease) in accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	591
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT; PADDING-BOTTOM: 1PT">
	Decrease in due to related parties
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(439
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 20.1PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(13,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(13,864
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from investing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Change in restricted cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	140
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Purchase of property and equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(167
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 20.1PT">
	Net cash provided by (used in) investing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(177
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds received from issuance of shares, net of original issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,029
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds from Series D Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds received from exercise of options and warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	251
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds from issuance of debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds received from sale of convertible note
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds received from March 2014 financing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Repayment of loans
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,191
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,486
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Payment of financing fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,593
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Decrease in deposits for future financing
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 20.1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,859
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,465
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net increase (decrease) in cash
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,224
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,718
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,676
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash at end of year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,543
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,767
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Supplemental disclosure of cash flow information:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash paid for interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	378
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	505
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash paid for income taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Supplemental disclosure of non-cash financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deemed dividend
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,959
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	616
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued to Series D Preferred Stock placement agents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	758
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued to July 2015 debt financing placement agent
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	416
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series D Preferred Stock original issue discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Shares issued to settle liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Shares issued for financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Dividend on Series C Preferred stock settled in common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	129
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Conversion of Series C Preferred Stock reclassified from mezzanine to equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	821
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,209
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassification of Series C Preferred Stock from mezzanine to equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,887
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassification of warrants from liability to equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,202
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Intangible assets acquired with note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued dividends on Series C Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Offset of debt in March 2014 financing (See Note 15)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	329
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Conversion of promissory note
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-cash warrants with common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	June warrants issued for Series C Preferred Stock amendment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	441
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	The accompanying notes are an integral
	part of the consolidated financial statements.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V434974_10K_HTM_FIN_006">
</A>
	Immune Pharmaceuticals Inc. and Subsidiaries
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Notes to Consolidated Financial Statements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTE 1.&nbsp;&nbsp; NATURE OF OPERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-INDENT: -14.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Immune Pharmaceuticals Inc., together with
	its subsidiaries (&ldquo;Immune&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo; or the &ldquo;Company&rdquo;), is
	a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics
	in the fields of immuno-inflammation and immuno-oncology. The Company focuses on a precision medicine approach to treatment of
	diseases by incorporating methods for better patient selection in its clinical trials and the potential for development of companion
	diagnostics. The Company&rsquo;s Immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully
	human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products
	and nanocyclo, a topical nanocapsule formulation of cyclosporine A, for the treatment of atopic dermatitis and psoriasis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 2. GOING CONCERN UNCERTAINTY, FINANCIAL
	CONDITION AND MANAGEMENT&rsquo;S PLANS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company believes that its
	available cash as of the date of this filing may not be sufficient to fund its anticipated level of operations for at least
	the next 12 months. The Company&rsquo;s ability to continue as a &ldquo;going concern&rdquo; is dependent on a combination of
	several of the following factors: the Company&rsquo;s ability to raise capital, the potential exercise for cash of
	outstanding warrants and options, the Company&rsquo;s ability to monetize assets, the receipt of grants and access to an
	established line of credit. The Company has limited capital resources and its operations have been funded by the proceeds of
	equity and debt offerings.&nbsp;&nbsp;The Company has devoted substantially all of its cash resources to research and
	development (&ldquo;R&amp;D&rdquo;) programs and incurred significant general and administrative expenses to enable it to
	finance and grow its business and operations. To date, the Company has not generated any significant revenue and may not
	generate any revenue for a number of years, if at all. If the Company is unable to raise additional funds in the future on
	acceptable terms, or at all, it may be forced to curtail its development activities. In addition, the Company could be forced
	to delay or discontinue certain or all product developments, and forego attractive business opportunities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015, the Company had a
	working capital deficit of approximately $1.4 million. Accumulated deficit amounted to $63.0 million and $45.8 million at December
	31, 2015 and 2014, respectively. Net loss for the years ended December 31, 2015 and 2014 was $17.2 million and $23.6 million, respectively.
	Net cash used in operating activities was $13.9 million for both years ended December 31, 2015 and 2014. At December 31, 2015,
	the Company had cash and cash equivalents of $4.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company has historically funded its
	operations primarily through debt, the sale of its securities, including sales of common stock, convertible notes, preferred stock
	and warrants. During July 2015, the Company raised a total of up to $21.5 million through two financing agreements (&ldquo;July
	2015 financings&rdquo;). The first, on July 29, 2015 with Hercules Capital (&ldquo;Hercules&rdquo;), was for a term loan of $4.5
	million with the option to draw down additional capital of up to $5.0 million prior to June 15, 2016, subject to certain clinical
	milestones and other conditions, for which no additional capital has been drawn as of December 31, 2015. The second on July 28,
	2015, was with Discover Growth Fund (&ldquo;Discover&rdquo;) through the issuance and sale of 947 shares of the Company&rsquo;s
	Series D Preferred Stock for total gross proceeds of $9.0 million. On September 29, 2015, pursuant to the Stock Purchase Agreement
	the Company issued and sold an additional 316 shares of its Series D Preferred Stock, for a total gross proceeds of $3.0 million.
	The Company repaid the MidCap Financial Trust (&ldquo;MidCap&rdquo;) $2.1 million of its senior secured term loan and an early
	termination fee of $0.5 million from the proceeds of the July 2015 financings. &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company will require additional financing
	in fiscal 2016 in order to continue at its expected level of operations. If the Company fails to obtain the needed capital, it
	will be forced to delay, scale back, partner out or eliminate some or all of its R&amp;D programs, which could result in an impairment
	of the Company&rsquo;s intangible assets and have a material adverse impact on its financial condition and results of operations.
	There is no assurance that the Company will be successful in any capital-raising efforts that it may undertake to fund operations
	during 2016. The Company anticipate that it will continue to issue equity and/or debt securities as a source of liquidity, when
	needed, until its able to generate positive cash flow to support its operations. The Company cannot give any assurance that the
	necessary capital will be raised or that, if funds are raised, it will be on favorable terms. Any future sales of securities to
	finance the Company will dilute existing stockholders' ownership. The Company cannot guarantee when or if it will ever generate
	positive cash flow. In addition, the Company may partner or license the Company&rsquo;s assets, which may allow for additional
	non-dilutive financing in the future. The Company has previously received government grants in Israel and may receive additional
	grant funding in 2016. The Independent Registered Public Accounting Firms&rsquo; Report issued in connection with the Company&rsquo;s
	audited consolidated financial statements for the year ended December 31, 2015 stated that there is &ldquo;substantial doubt about
	the Company&rsquo;s ability to continue as a going concern.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s strategy to
	fund its operations is to monetize its multiple asset groups either through partnerships, asset-centric subsidiaries or
	joint ventures, raise capital, and the potential exercise for cash of warrants and options. On March 30, 2016, the Company
	executed a binding term sheet with Regatta Select Healthcare LLC (&ldquo;Regatta&rdquo;) whereby Regatta shall purchase up to
	3.5 million shares of the Company&rsquo;s common stock over a twelve-month term at the discretion of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 3.&nbsp;&nbsp; SUMMARY OF SIGNIFICANT
	ACCOUNTING POLICIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -14.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Basis of Presentation and Principles
	of Consolidation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -14.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying consolidated financial
	statements include the accounts of Immune and its wholly-owned subsidiaries: Immune Pharmaceuticals Ltd. (&ldquo;Immune Ltd.&rdquo;),
	Immune Pharmaceuticals USA Corp., Maxim Pharmaceuticals, Inc., Cytovia, Inc. and EpiCept GmbH (closed January 2015). All material
	inter-company transactions and balances have been eliminated in consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On August 25, 2013, the Company closed
	the merger with Immune Ltd. (&ldquo;Merger&rdquo;). After giving effect to the acquisition and the issuance of Immune Pharmaceuticals
	Inc. common stock to the former shareholders of Immune Ltd., the Company had 13,276,037 shares of common stock issued and outstanding,
	with the shareholders of Immune Pharmaceuticals Inc. before August 26, 2013 (&ldquo;Pre-merged Immune Inc.&rdquo;) collectively
	owning approximately 19%, and the former Immune Pharmaceuticals Ltd. stockholders owning approximately 81%, of the outstanding
	common stock of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying consolidated financial
	statements were prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S.
	GAAP&rdquo;) and instructions to Form 10-K. In the opinion of management, all adjustments necessary for a fair presentation of
	the consolidated statements of financial position, consolidated statements of operations and comprehensive loss, consolidated statements
	of stockholders&rsquo; equity and consolidated statements of cash flows, for the periods indicated, have been made. Certain prior
	year amounts have been reclassified to conform to the current year presentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Use of Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In preparing consolidated financial statements
	in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets
	and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and expenses during
	the reported periods. Significant estimates include impairment of long lived assets (including intangible assets and In Process
	R&amp;D (&ldquo;IPR&amp;D&rdquo;)), amortization of intangible assets, stock based compensation, valuation of options, warrants
	and derivative liabilities and valuation of uncertain tax position. Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 15.4PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Cash and Cash Equivalents
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company considers investments with
	original maturities of three months or less to be cash equivalents. Restricted cash primarily represents cash not available for
	immediate and general use by the Company. The Company maintains cash and cash equivalents with certain major financial institutions
	in the U.S. and Israel. At certain times during the year cash may exceed U.S. federally insured limits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Intangible Assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company accounts for the purchases
	of intangible assets in accordance with the provisions of Accounting Standards Classification (&ldquo;ASC&rdquo;) 350, Intangibles.
	Intangible assets are recognized based on their acquisition cost. Intangible assets determined to have indefinite lives are not
	amortized, but rather tested for impairment at least annually or more frequently if events or changes in circumstances indicate
	that the carrying amount may no longer be recoverable. If any of the Company&rsquo;s intangible assets are considered to be impaired,
	the amount of impairment to be recognized is the excess of the carrying amount of the assets over its fair value. Intangible assets
	with definitive lives are also reviewed for impairment only if indicators exist in accordance with ASC 360, Property, Plant and
	Equipment, and are amortized or depreciated over the shorter of their estimated useful lives or the statutory or contractual term, and in the case of patents on a straight-line basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Property and Equipment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Property and equipment are carried at cost,
	less accumulated depreciation. Depreciation is provided principally by use of the straight-line method over the useful lives of
	the related assets, which are depreciated over the terms of their related leases or their estimated useful lives, whichever is
	shorter. Expenditures for maintenance and repairs, which do not improve or extend the expected useful life of the assets, are expensed
	to operations while major repairs are capitalized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 54%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Method
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Estimated Useful
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Life (Years)
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Computers and accessories
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Straight-line
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3 - 5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Equipment
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Straight-line
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3 - 5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Furniture and fixtures
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Straight-line
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3 - 7
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Property and equipment consisted of the
	following ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Computers and accessories
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	85
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	273
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Furniture and fixtures
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	448
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Less accumulated depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(77
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(51
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	371
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Depreciation expense amounted to $26,000
	and $25,000 for the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	In-Process Research and Development
	(&ldquo;IPR&amp;D&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IPR&amp;D represents the estimated
	fair value assigned to R&amp;D projects acquired in a purchased business combination that have not been completed at the date
	of acquisition and which have no alternative future use.&nbsp; IPR&amp;D assets acquired in a business combination are
	capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment
	of the associated R&amp;D efforts. During the period prior to completion or abandonment, these acquired indefinite-lived
	assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances
	indicate that the asset might be impaired. The Company completed an impairment analysis as of December 31, 2015 and 2014 and
	concluded that there was no impairment to IPR&amp;D. This assessment was based on a discounted cash flow valuation analysis
	coupled with qualitative market assumptions performed in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Segment Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.3PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company operates in one reportable
	segment: acquiring, developing and commercializing prescription drug products. Accordingly, the Company reports the accompanying
	consolidated financial statements in the aggregate, including all of its activities in one reportable segment. As of December 31,
	2015 and 2014, approximately 8% and 7%, respectively, of the Company's assets were located outside of the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Research and Development (&ldquo;R&amp;D&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.3PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	R&amp;D expenses consist primarily of the
	cost of the Company&rsquo;s development and operations personnel, the cost of its clinical trials, manufacturing costs, as well
	as the cost of outsourced services and are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Translation into U.S. dollars
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s functional
	currency is the U.S. dollar. The Company conducts certain transactions in foreign currencies, particularly, the Israeli
	Shekel and the Euro, which are recorded at the exchange rate as of the transaction date. All exchange gains and losses from
	re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected as non-operating income or
	expense in the statement of operations, as they arise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Stock-based Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company recognizes compensation expense
	for all equity-based payments. Stock based compensation issued to employees is accounted for under ASC 718, Compensation &ndash;
	Share Compensation (&ldquo;ASC 718&rdquo;). The Company utilizes the Black-Scholes valuation method to recognize compensation expense
	over the vesting period. Certain assumptions need to be made with respect to utilizing the Black-Scholes valuation model, including
	the expected life, volatility, risk-free interest rate and anticipated forfeiture of the stock options. The expected life of the
	stock options were calculated using the short cut method per the provisions of ASC 718. The risk-free interest rate is based on
	the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the options. As the Company
	common stock does not have an adequate length of trading history, coupled with significant changes to the business since the Merger,
	the expected stock price volatility for the Company&rsquo;s common stock was estimated by taking the average historical price volatility
	for industry peers combined with the Company&rsquo;s historical data based on daily price observations. Estimates of pre-vesting
	option forfeitures are based on the Company&rsquo;s experience. The Company adjusts its estimate of forfeitures over the requisite
	service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes
	in estimated forfeitures are recognized through a cumulative catch-up adjustment in the period of change and also impacts the amount
	of compensation expense to be recognized in future periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company accounts for stock-based transactions
	with non-employees in which services are received in exchange for equity instruments based upon the fair value of the equity instruments
	issued, in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Factors that most significantly affect the expense
	related to equity-based payments to non-employees include the estimated fair market value of the common stock underlying the stock
	options and the estimated volatility of such fair market value. The value of such options is re-measured every quarter until performance
	is complete and income or expense is recognized during the vesting terms. Accounting for equity-based payments to non-employees
	granted by the Company requires fair value estimates of the equity instrument granted or sold. When stock-based grants are granted
	in exchange for the receipt of goods or services, the Company estimates the value of the stock-based compensation based upon the
	value of its common stock at the date of grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company accounts for income taxes in
	accordance with ASC 740 &ldquo;Income Taxes&rdquo;. The Company is required to file income tax returns in the appropriate U.S.
	federal, state and local jurisdictions, including New York State, New York City and Israel. All of the tax years from Inception
	to date are still open for the Company and its subsidiaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Income taxes are accounted for under the
	asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized based upon
	the differences arising from carrying amounts of the Company&rsquo;s assets and liabilities for tax and financial reporting purposes
	using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on the deferred tax
	assets and liabilities of a change in tax rates is recognized in the period when the change in tax rates is enacted. A valuation
	allowance is established when it is determined that it is more likely than not that some portion or all of the deferred tax assets
	will not be realized. A full valuation allowance has been applied against the Company&rsquo;s net deferred tax assets as of December
	31, 2015 and 2014, due to projected losses and because it is not more likely than not that the Company will realize future benefits
	associated with these deferred tax assets. The Company&rsquo;s policy is to recognize interest and penalties accrued on any unrecognized
	tax benefits as a component of income tax expense. ASC 740 prescribes how a company should recognize, measure, present and disclose
	in its financial statements uncertain tax positions that a company has taken or expects to take on a tax return. Additionally,
	for tax positions to qualify for deferred tax benefit recognition under ASC 740, the position must have at least a &ldquo;more
	likely than not&rdquo; chance of being sustained upon challenge by the respective taxing authorities, which criteria is a matter
	of significant judgment. The Company had gross liabilities recorded of $50,000 for both years ended December 31, 2015 and 2014
	to account for potential state income tax exposure. The Company&rsquo;s policy is to record interest and penalty related to the
	underpayment of income taxes or unrecognized tax benefits as a component of its income tax provision, of which such amounts were
	immaterial for the years ended December 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Patents
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company expenses external costs, such
	as filing fees and associated attorney fees, incurred to obtain issued patents and patent applications pending. The Company also
	expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recently Issued Accounting Pronouncements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In May 2014, the FASB issued Accounting
	Standards Update No. 2014-09, Revenue from Contracts with Customers. Under the new standard, revenue is recognized at the time
	a good or service is transferred to a customer for the amount of consideration for which the entity expects to be entitled for
	that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of
	adoption. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting
	periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual
	periods beginning after December 15, 2016). The Company is currently evaluating the impact the adoption of this standard will have
	on its consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April 2015, the FASB issued ASU No.
	2015-03
<I>
	, Simplifying the Presentation of Debt Issuance Costs.
</I>
	This standard amends existing guidance to require the presentation
	of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a
	deferred charge. It is effective for annual reporting periods beginning after December 15, 2015, but early adoption is permitted.
	The Company has early adopted this standard effective the third quarter of 2015 in conjunction with the closing of the Hercules
	Loan and recorded $1.3 million of debt issuance costs as a debt discount which will be amortized over the term of the Hercules
	Loan and recorded interest expense of $0.3 million for the year ended December 31, 2015, relating to the amortization of the debt
	discount.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In November 2015, the FASB issued ASU No.
	2015-17,
<I>
	Balance Sheet Classification of Deferred Taxes
</I>
	, to simplify the presentation of deferred taxes. This amendment
	requires that all deferred tax assets and liabilities, along with any related valuation allowances, be classified as noncurrent
	on the balance sheet. However, an entity shall not offset deferred tax liabilities and assets attributable to different tax jurisdictions.
	ASU 2015-17 is effective for annual and interim reporting periods ending after December 15, 2016. Early adoption is permitted,
	and the new guidance may be applied either prospectively or retrospectively. The Company adopted this guidance prospectively as
	of December 31, 2015. Therefore, prior periods have not been adjusted to reflect this adoption. This change in accounting principle
	does not change the Company&rsquo;s results of operations, cash flows or stockholders&rsquo; equity. As of December 31, 2015 and
	2014, no amounts of the Company&rsquo;s deferred tax assets and liabilities were reclassified as current on its consolidated balance
	sheets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 2016, the FASB issued Accounting
	Standards Update No. 2016-02,
<I>
	Leases.
</I>
	The new standard establishes a right-of-use (&ldquo;ROU&rdquo;) model that requires
	a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases
	will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income
	statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those
	fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at,
	or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical
	expedients available. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTE 4. DERIVATIVE FINANCIAL INSTRUMENTS
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company accounts for derivative financial
	instruments in accordance with ASC 815-40, &ldquo;Derivative and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity&rdquo;
	(&ldquo;ASC 815-40&rdquo;), instruments which do not have fixed settlement provisions are deemed to be derivative instruments.
	The Hercules Warrants are classified as liability instruments due to an anti-dilution provision that provides for a reduction to
	the exercise price of the Hercules Warrants if the Company issues additional equity or equity linked instruments within six months
	from the execution of the agreement at an effective price per share less than the exercise price then in effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Hercules Warrants
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On July 29, 2015, the Company and Immune
	Pharmaceuticals USA Corp. entered into a Loan and Security Agreement with Hercules to borrow $4.5 million with a Company option
	to borrow an additional $5.0 million prior to June 15, 2016, subject to the achievement of certain clinical milestones and satisfaction
	of certain other conditions. In connection with the Hercules Loan, the Company has issued to Hercules a five-year warrant to purchase
	an aggregate of 214,853 shares of its common stock (or 279,412 shares if the Company closes on the additional $5.0 million), at
	an exercise price of $1.70 per share, subject to certain adjustments, including, if lower, the effective price of any financing
	occurring six months after the issuance date (the &ldquo;Hercules Warrants&rdquo;) (see Note 9).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company determined the fair value of
	the Hercules Warrants of $0.3 million on July 29, 2015 using the Binomial Lattice pricing model and recorded that amount as part
	of debt discount in the consolidated balance sheets since considered as part of the cost of the financing which will be amortized
	over the life of the loan using the effective interest method. The Hercules Warrants are re-measured at each balance sheet date
	until the expiration of the anti-dilution provision on January 29, 2016. The fair value of the Hercules Warrants as of December
	31, 2015 was $0.1 million and the Company recorded a gain on the change in the estimated fair value of the Hercules Warrants of
	$0.2 million for the year ended December 31, 2015, which was recorded in non-operating expense in the consolidated statements of
	operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Discover Series D Convertible Preferred
	Stock
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company issued Series D Preferred Stock
	to Discover, with a fixed conversion price of $2.50 per share and automatic conversion to common stock at six and a half years.
	Discover can convert at any time and at conversion it will receive a conversion premium equal to the amount of dividends it would
	have received if the shares had been held to term. The Series D Preferred Stock dividend rate includes an adjustment feature that
	fluctuates inversely to the changes in the value of the Company&rsquo;s common stock price. The conversion premium and dividends
	are redeemed upon conversion of the Series D Preferred Stock.&nbsp;&nbsp;The Company determined that the conversion premium and
	dividends with the noted features require liability treatment. Accordingly, the conversion premium and the dividend feature have
	been bifurcated from the convertible preferred stock and are carried as a derivative liability at fair value. Changes in the fair
	value of this derivative liability are recognized in earnings each reporting period. At issuance, the fair value of the total derivative
	liability was $8.0 million, and this amount has been recorded as a deemed dividend. As conversions occur, the associated derivative
	liability will be settled and recorded as a deemed dividend. Discover converted 300 Series D Preferred Stock during the year ended
	December 31, 2015, the associated derivative liability was settled for $1.8 million and has been reflected as a deemed dividend
	in additional paid-in capital. The Company recorded a loss on the change in the estimated fair value of the Discover derivative
	liability of $0.3 million for the year ended December 31, 2015, which was recorded in non-operating expense in the consolidated
	statements of operations. The fair value of the Discover derivative liability as of December 31, 2015 was $6.5 million (see Note
	11).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	March
	2014 Warrants
</I>
</B>
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company's derivative instruments as
	of December 31, 2014 included warrants issued in March 2014 (&ldquo;March 2014 Warrants&rdquo;), which were recorded as a liability
	at fair value. The warrants were revalued at each reporting date through the consolidated statements of operations as non-operating
	expense. The Company recorded a loss on a change in the estimated fair value of the March 2014 Warrants of $0.6 million for the
	year ended December 31, 2014. When the warrants were amended in August 2014, the Company incurred a $3.1 million charge, and the
	warrants were classified as equity instruments in the consolidated balance sheets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The March 2014 Warrants were valued using
	the Monte-Carlo simulation as these warrants included down-round protection clauses. The Hercules Warrants were valued using the
	Binomial Lattice options pricing model.&nbsp;The assumptions used during the years ended December 31, 2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="WIDTH: 70%">
	Fair value of common stock
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$ 0.73 &ndash; 1.18
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4.11
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	Expected life (in years based on the term of the warrants)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	4.58
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.03-2.08
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.33% - 1.66
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.46%-0.52
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	Expected volatility
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	91.55% - 93.16
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	74.8
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	Dividend yield
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Expected volatility is based on an analysis of the Company&rsquo;s
	volatility, as well as the volatilities of peer companies. The risk free interest rate is based on the U.S. Treasury security rates
	for the remaining term of the warrants at the measurement date. The dividend yield is based upon the fact that the Company has
	not historically paid dividends, and does not expect to pay dividends in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Series D Preferred Stock derivative
	liability was valued using the Binomial Lattice options pricing model. The assumptions used at December 31, 2015 were as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,&nbsp;2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT">
	Face value of Series D Preferred Stock
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Conversion price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Dividend period (in years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTE 5. FAIR VALUE MEASUREMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Financial Instruments and Fair Value
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company accounts for financial instruments
	in accordance with ASC 820, &ldquo;Fair Value Measurements and Disclosures&rdquo; (&ldquo;ASC 820&rdquo;). ASC 820 establishes
	a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.&nbsp;&nbsp;The hierarchy
	gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
	and the lowest priority to unobservable inputs (Level 3 measurements).&nbsp;&nbsp;The three levels of the fair value hierarchy
	under ASC 820 are described below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Level 1
</I>
	&ndash; Unadjusted quoted
	prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Level 2
</I>
	&ndash; Quoted prices in
	markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Level 3
</I>
	&ndash; Prices or valuations
	that require inputs that are both significant to the fair value measurement and unobservable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The financial instruments recorded in the Company&rsquo;s consolidated
	balance sheets consist primarily of cash and cash equivalents, restricted cash, debt and accounts payable. The carrying amounts
	of the Company&rsquo;s cash and cash equivalents and accounts payable approximate fair value due to their short-term nature. The
	fair value of the Company&rsquo;s debt approximates its carrying value due to their variable interest rates, which are indexed
	to market, market conditions and variability in pricing from multiple lenders and term of debt and are classified as Level 1 within
	the fair value hierarchy.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In estimating the fair value of the Company&rsquo;s
	Hercules and Discover derivative liabilities, the Company used the Binomial Lattice options pricing model at inception and on each
	subsequent valuation date. Based on the fair value hierarchy, in 2015, the Company classified the Hercules and Discover derivative
	liability within Level 3. In 2014, the Company&rsquo;s derivative liabilities included its March 2014 Warrants and November 2014
	convertible promissory note side letter, all of which had been recorded as a liability at fair value, and were revalued at each
	measurement date until extinguishment of the liability, with changes in the fair value of the instruments included in the consolidated
	statements of operations as non-operating expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table presents the Company&rsquo;s
	liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair
	value hierarchy as of December 31, 2015 ($ in thousands). The Company had no assets or liabilities that were measured at fair value
	as of December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As&nbsp;of&nbsp;December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair&nbsp;Value&nbsp;Hierarchy&nbsp;at&nbsp;December 31,&nbsp;2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total&nbsp;carrying&nbsp;and
<BR>
	estimated&nbsp;fair&nbsp;value
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Quoted&nbsp;prices&nbsp;in
<BR>
	active&nbsp;markets
<BR>
	(Level&nbsp;1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Significant&nbsp;other
<BR>
	observable&nbsp;inputs
<BR>
	(Level&nbsp;2)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Significant
<BR>
	unobservable
<BR>
	inputs&nbsp;(Level&nbsp;3)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Series D Preferred Stock Derivative Liability
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,529
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,529
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Derivative liability related to Hercules Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Hercules Warrants
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table sets forth a summary
	of changes in the estimated fair value of the Company&rsquo;s Hercules Warrant derivative liability for the period from January
	1, 2015 through December 31, 2015 ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 96%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair&nbsp;Value&nbsp;Measurements&nbsp;of
<BR>
	Hercules
<BR>
	Common Stock Warrants
<BR>
	Using Significant
<BR>
	Unobservable Inputs (Level&nbsp;3)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Balance at January 1, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT">
	Warrants issued with July 2015 debt financing
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	315
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in estimated fair value of liability classified warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(231
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Series D Preferred Stock
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table sets forth a summary
	of changes in the estimated fair value of the Company&rsquo;s Series D Preferred Stock derivative liability for the period from
	January 1, 2015 through December 31, 2015 ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 96%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair&nbsp;Value&nbsp;Measurements&nbsp;of
<BR>
	Series D Preferred Stock
<BR>
	Derivative Liability
<BR>
	Using Significant
<BR>
	Unobservable Inputs&nbsp;(Level&nbsp;3)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Balance at January 1, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT">
	Series D Preferred Stock derivative liability at inception- July 28, 2015 ($9.0 million financing)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5,930
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series D Preferred Stock derivative liability at inception- September 29, 2015 ($3.0 million financing)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,077
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series D Preferred Stock conversions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,836
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in estimate fair value of Series D Preferred Stock derivative liability
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	358
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,529
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	March 2014 Warrants
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Until its amendment, on August 13, 2014,
	the March 2014 warrants derivative liability was classified within Level 3 because they were valued using the Monte-Carlo model
	(as these warrants include down-round protection clauses), which utilize significant inputs that are unobservable in the market.
	The following table summarizes the changes in the Company&rsquo;s derivative liability measured at fair value using significant
	unobservable inputs (Level 3) from January 1, 2014 through December 31, 2014 ($ in thousands):&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 96%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Level&nbsp;3
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance at January 1, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT">
	Derivative warrants issued to investors in connection with the March 2014 Financing
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7,404
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassification into additional paid in capital due to Amendment Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,882
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Derivative issued in connection with convertible promissory note
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	670
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Settlement of derivative liability of convertible promissory note
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Fair value adjustment at reclassification, included in statement of operations
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	558
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance at December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The table
	below outlines the key inputs in valuing the March 2014 warrants derivative liability
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE; MARGIN-LEFT: 0.15IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Unobservable inputs
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	As of March 10, 2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	As of August 13, 2014
<BR>
	(Restated
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Warrant Date)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 34%">
<FONT STYLE="FONT-SIZE: 10PT">
	Volatility
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	82.90
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	74.8
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Risk free interest rate
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.40% - 0.60
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.46% - 0.52
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Expected term, in years
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.50
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.03-2.08
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dividend yield
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Probability and timing of down-round triggering event
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	63.5% for on August 1, 2014; 33.5% for on October 1, 2014; and 3% for every six months from September 10, 2014
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	63.5% for on September 1, 2014; 33.5% for on October 1, 2014; and 3% for every six months from September 10, 2014
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Stock Price
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.04
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.11
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During November 2014, the Company issued
	a convertible promissory note and side letter to an existing investor (See Note 15). As a result of this transaction the Company
	recognized a derivative liability of $0.7 million. The initial fair value was determined by calculating the probability and timing
	of future scenarios. Unobservable inputs included 100% of the volume weighted average price (&ldquo;VWAP&rdquo;) over a set period
	of time as well as 5% discount off VWAP over the same period of time. On November 20, 2014, the date the derivative liability was
	extinguished (See Note 15), the Company used the known closing price of the financing of $2.50 per share to calculate fair value
	on that date and recognized an increase in the derivative liability of $80,000 which was recorded in the consolidated statement
	of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Sensitivity of Level 3 measurements to changes in significant
	unobservable inputs
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The inputs to estimate the fair value of
	the Company&rsquo;s derivative liabilities at December 31, 2015, included the risk-free interest rate, expected volatility, dividend
	yield, dividend period, expected life and the market price of the Company&rsquo;s stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 15.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Significant changes in any of these inputs
	in isolation can result in a significant change in the fair value measurement.&nbsp;Generally, a positive change in the market
	price of the Company&rsquo;s shares of common stock, and an increase in the volatility of the Company&rsquo;s shares of common
	stock, or an increase in the remaining term of the warrant or Series D Preferred Stock, or an increase of a probability of a down-round
	triggering event would each result in a similar change in the estimated fair value of the Company&rsquo;s warrants and Series D
	Preferred Stock and thus an increase in the associated derivative liabilities and vice-versa.&nbsp;An increase in the risk-free
	interest rate or a decrease in the positive differential between the warrant&rsquo;s exercise price and the market price of the
	Company&rsquo;s shares of common stock would result in a decrease in the estimated fair value measurement of the warrants and thus
	a decrease in the associated derivative liability.&nbsp;The Company has not, nor plans to, declare dividends on its shares of common
	stock, and thus, there is no change in the estimated fair value of the warrants or Series D Preferred Stock due to the dividend
	assumption.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTE 6. LICENSING AGREEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Yissum Research Development Company
	of The Hebrew University of Jerusalem Ltd. (&ldquo;Yissum&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Yissum &ndash; AmiKet Nano
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On June 25, 2015, the Company entered into
	a definitive research and license agreement with Yissum. Under the license, the Company has obtained an exclusive, worldwide license
	from Yissum, with certain sublicensing rights, to make commercial use of certain of Yissum&rsquo;s patents and know-how in connection
	with a topical nano-formulated delivery of AmiKet for the development, manufacturing, marketing, distribution and commercialization
	of products based on the technology. In consideration for the license, the Company will pay Yissum the following payments throughout
	the term of the license:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual maintenance fee of $30,000 commencing on June 25, 2020, which maintenance fee shall increase
	by 30% each year, up to a maximum annual maintenance fee of $0.1 million and may be credited against royalties or milestone payments
	payable in the same calendar year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	royalties on net sales of products (as such term is defined in the license) by the Company in the
	amount of up to 3%, subject to certain possible reductions in certain jurisdictions;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	milestones payments of up to approximately $4.5 million upon the achievement of certain regulatory,
	clinical development and commercialization milestone; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reimbursement of related patent fees.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Furthermore, the Company
	will fund an annual research program in the amount of approximately $0.4 million annually, plus VAT and any applicable taxes, commencing
	on October 1, 2015 (or such other time as mutually agreed between the parties). The results of the research, including any patents
	or patent applications shall automatically be licensed to the Company. During the year ended December 31, 2015, the Company accrued
	the first installment of the annual research fee of $0.2 million, which was paid in the first quarter of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Atlante Biotech SAS (&ldquo;Atlante&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 28, 2015, the Company entered
	into an exclusive license with Atlante, to the patents and know-how for a new format of bispecific antibodies. The R&amp;D work
	on the bispecific antibodies will be performed at the Company&rsquo;s recently established Immunology R&amp;D unit at the Alexandria
	Center for Life Sciences in New York City, under the leadership of Dr. Boris Shor, Executive Director of R&amp;D of Immune. In
	recently presented data, the platform prototype bispecific antibody was shown to retain effector functions and mediate redirect
	killing of target cells by cytokine induced killer T cells. The bispecific antibody demonstrated direct anti-cancer effects in
	vitro, as well as in vivo anti-tumor activity and improved survival in a mouse xenograft model of disseminated leukemia. A collaborative
	European consortium led by Dr. Kadouche and funded by a European grant developed the novel platform for production of tetravalent
	IgG1-like bispecific antibodies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Dr. Jean Kadouche and Alan Razafindrastita
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2011, Dr. Jean Kadouche, a related
	party (see Note 16), sold, assigned and transferred to Immune the entire right, title and interest for all countries, in and to
	any and all patents and inventions related to mice producing human antibodies and a method of preparation of human antibodies,
	collectively, the Human Antibody Production Technology Platform. Immune Ltd paid Dr. Kadouche a total consideration of: (i) $20,000
	in cash, and (ii) 800,000 ordinary shares of Immune Ltd, which were valued at approximately $0.7 million. Through the Human Antibody
	Production Technology Platform and additional laboratory work, human immune systems and specific cell lines are introduced in mice,
	enabling them to produce human mAbs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Endo Pharmaceuticals Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; COLOR: #222222">
	On
	July 7, 2015, the Company amended its 2003 Licensing Agreement with Endo. As a result, Immune transferred to Endo its previously
	licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo granted to Immune a royalty-free,
	non-exclusive, fully transferable license to those patents. Endo will make undisclosed milestone payments to Immune if Endo receives
	a back pain indication for a lidocaine-based product, as per the original 2003 Licensing Agreement. Immune re-gained full exclusive
	rights to develop, commercialize and license LidoPAIN. The company is assessing strategic alternatives for this non-core asset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Dalhousie University (&ldquo;Dalhousie&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In connection with the Merger, the Company
	maintains a direct license agreement with Dalhousie University under which the Company has an exclusive license to certain patents
	for the topical use of tricyclic anti-depressants and
<FONT STYLE="COLOR: #222222; BACKGROUND-COLOR: WHITE">
	N
</FONT>
	-methyl-D-aspartate
	(&ldquo;NMDA&rdquo;) receptor antagonists as topical analgesics for neuralgia. These, and other patents, cover the combination
	treatment consisting of amitriptyline and ketamine in AmiKet.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company has been granted worldwide
	rights to make, use, develop, sell and market products utilizing the licensed technology in connection with passive dermal applications.
	The Company is obligated to make payments to Dalhousie upon achievement of specified milestones and to pay royalties based on annual
	net sales derived from the products incorporating the licensed technology. The Company is further obligated to pay Dalhousie an
	annual maintenance fee until the license agreement expires or is terminated, or a New Drug Application (&ldquo;NDA&rdquo;) for
	AmiKet is filed with the FDA, or Dalhousie will have the option to terminate the contract. The license agreement with Dalhousie
	terminates upon the expiration of the last to expire licensed patent. On April 3, 2014, the Company entered into a Waiver and Amendment
	to the license agreement pursuant to which Dalhousie agreed to irrevocably waive the Company&rsquo;s obligation to pay the $0.5
	million maintenance fee that was due on August 27, 2012 and August 27, 2013 and in any subsequent year. In addition, the Company
	has agreed to pay Dalhousie royalties of 5% of net sales of licensed technology in countries in which patent coverage is available
	and 3% of net sales in countries in which data protection is available. The parties have also agreed to amend the timing and increase
	the amounts of the milestone payments payable under the license agreement. As of December 31, 2015 and 2014, no amounts were due
	to Dalhousie. Additional milestones payments will become due upon sub licensing and receipt of certain approvals, none of which
	have yet been met or received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Shire BioChem (&ldquo;Shire&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In connection with the Merger, the Company
	acquired a license agreement for the rights to the MX2105 series of apoptosis inducer anti-cancer compounds from Shire BioChem,
	Inc. (formerly known as BioChem Pharma, Inc.). Under the agreement, the Company is required to provide Shire BioChem a portion
	of any sublicensing payments the Company receives, if the Company relicenses the series of compounds or make milestone payments
	to Shire BioChem totaling up to $26.0 million assuming the successful commercialization of the compounds by the Company for the
	treatment of a cancer indication, as well as pay a royalty on product sales. As of December 31, 2015 and 2014, no amounts were
	due to Shire.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Lonza Sales AG (&ldquo;Lonza&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On May 2, 2012, Lonza granted Immune a
	sub-licensable, non-exclusive worldwide license under certain know-how and patent rights to use, develop, manufacture, market,
	sell, offer, distribute, import and export bertilimumab, as it is produced through the use of Lonza&rsquo;s system of cell lines,
	vectors and know-how. If Lonza is to manufacture bertilimumab, the Company is required to pay Lonza a royalty of 1% of the net
	selling price of the commercial product but no annual license fee as described below. If Immune or one of its strategic partners
	manufactures bertilimumab, Immune is required to pay Lonza approximately $0.1 million annually during the course of the license
	agreement (first payable upon commencement of Phase II clinical trials) plus a royalty of 1.5% of the net selling price of the
	product, and if any other party manufactures bertilimumab, The Company is also required to pay Lonza approximately $0.5 million,
	or, per sublicense annually during the duration of such sublicense plus a royalty of 2% of the net selling price of the product.
	In addition, the Company is required to pay Lonza approximately $3,000 or, for the supply of certain cell lines, if it uses such
	cell lines. Notwithstanding the foregoing, Immune is not obligated to manufacture bertilimumab through the use of Lonza&rsquo;s
	system. The royalties are subject to a 50% reduction based on the lack of certain patent protections, including the expiration
	of patents, on a country-by-country basis. Unless earlier terminated (including, but not limited to, the reasons set forth below),
	the license agreement continues until the expiration of the last enforceable valid claim to the licensed patent rights, which began
	to expire in 2014 and will continue to expire between 2015 and 2016. As of December 31, 2015 and 2014, no amounts were due under
	the license agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	MabLife SAS (&ldquo;MabLife&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2012, Immune Ltd. acquired from
	MabLife, through an assignment agreement, all rights, titles and interests in and to the patent rights, technology and deliverables
	related to the anti-Ferritin mAb, AMB8LK, including its nucleotide and protein sequences, its ability to recognize human acid and
	basic ferritins, or a part of its ability to recognize human acid and basic ferritins The consideration was as follows: (i)&nbsp;$0.6
	million payable in six equal installments of which $0.2 million had been paid through December 31, 2015; and (ii)&nbsp;royalties
	of 0.6% of net sales of any product containing AMB8LK or the manufacture, use, sale, offering or importation of which would infringe
	on the patent rights with respect to AMB8LK.&nbsp; The Company is required to assign the foregoing rights back to MabLife if it
	fails to make any of the required payments, are declared insolvent or bankrupt or terminate the agreement. In February 2014, the
	Company acquired from MabLife, through an irrevocable, exclusive, assignment of all rights, titles and interests in and to the
	secondary patent rights related to the use of anti-ferritin monoclonal antibodies in the treatment of some cancers, Nucleotide
	and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies
	or antibody-like molecules comprising these sequences for $0.1 million (see Notes 7 and 9). During the first quarter of 2015, MabLife
	informed the Company that it had filed for bankruptcy. The Company is considering its options relating to the MabLife assignment
	agreement. As of December 31, the bankruptcy had no impact on the Company&rsquo;s Anti-ferritin Antibody intangible asset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	iCo Therapeutics Inc. (&ldquo;iCo&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In December 2010, iCo granted Immune Ltd.
	an option to sub-license the use of bertilimumab from iCo, which obtained certain exclusive license rights to intellectual property
	relating to bertilimumab pursuant to a license agreement with Cambridge Antibody Technology Group Plc, and to which Immune became
	a party. In June 2011, Immune exercised its option and obtained a worldwide license from iCo for the use and development of bertilimumab
	for all human indications, other than ocular indications, pursuant to a product sub-license agreement. iCo retained the worldwide
	exclusive right to the use of bertilimumab for all ocular applications. Under the agreement, Immune Ltd. paid an initial consideration
	of $1.7 million comprised of (i) $0.5 million in cash, (ii) 600,000 ordinary shares, which were valued at approximately $1 million
	(or $1.72 per share) and (iii) 200,000 warrants, which were valued at approximately $0.2 million (or $0.95 per warrant). In addition
	to this consideration, iCo received anti-dilution rights equal to 6.14% of the Company&rsquo;s issued and outstanding share capital
	on a fully diluted basis. iCo will be subject to dilution up to 2.5% (on a fully diluted and as converted basis) upon, and at any
	time following, any future issuance of securities in connection with a financing made at a Company pre-money valuation that is
	higher than $30 million. This right was to lapse upon the earlier of: the consummation of an initial public offering involving
	the listing of the Company's shares on an internationally-recognized stock exchange, or a Deemed Liquidation event, as defined
	in the Immune Ltd.&rsquo;s Amended and Restated Articles of Association. The Company believes that the Merger qualified as a Deemed
	Liquidation event, therefore the anti-dilution rights have lapsed. Upon initial valuation, the anti-dilution shares were determined
	to be a derivative liability with a fair value of approximately $0.8 million. At both December 31, 2015 and 2014, the derivative
	liability was $0. During the years ended December 31, 2015 and 2014, no expenses were charged to the consolidated statements of
	operations, respectively. As of December 31, 2015 and 2014, after giving effect to the Merger, iCo holds 654,486 shares of common
	stock and 123,649 warrants of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	iCo may receive from Immune up to $32.0
	million in milestone payments plus royalties. These milestones include the first dosing in a Phase III clinical trial, filing a
	Biologics License Application/Marketing Authorization Application, (&ldquo;BLA/MMA&rdquo;), approval of a BLA/MAA and the achievement
	of $100.0 million in aggregate sales of licensed products. The term of the license lasts until the expiration of all payment obligations
	on a country-by-country basis, at which point the license will be deemed fully paid, perpetual and irrevocable with respect to
	that country. As of December 31, 2015 and 2014, no milestones requiring payments had been reached.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 7. INTANGIBLE ASSETS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The value of the Company&rsquo;s intangible
	assets including gross asset value and carrying value is summarized below ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 15.4PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 96%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Human
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Anti-ferritin
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Bertilimumab
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	NanomAbs
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Antibodies
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Antibody
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	iCo
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Yissum
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Kadouche
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	MabLife
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD">
	Balance as of December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,087
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	567
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	568
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	385
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,607
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Addition
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(167
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(46
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(47
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(43
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(303
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance, December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,920
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	521
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	521
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	453
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,415
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(167
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(46
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(46
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(45
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(304
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance, December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,753
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	475
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	475
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	408
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,111
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Gross asset value
</B>
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,509
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	694
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	700
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	547
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,450
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Accumulated amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(756
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(219
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(225
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(139
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,339
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Carrying value December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,753
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	475
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	475
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	408
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,111
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 15.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	See Note 6 for a discussion
	of specific rights acquired in connection with the purchase of each intangible asset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s intangible
	assets above were determined by its management to have a useful life between 7 and 15 years. Amortization expense amounted to $0.3
	million each for the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Estimated amortization expense
	for each of the five succeeding years, based upon the Company&rsquo;s intangible assets owned at December 31, 2015 is as follows
	($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 55%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	Period Ending December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	305
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2020
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	2021 and thereafter
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,586
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,111
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 8. ACCRUED EXPENSES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Accrued&nbsp;expenses
	consist&nbsp;of&nbsp;the&nbsp;following ($ in thousands):&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.3PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Professional fees
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	549
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,934
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Salaries and employee benefits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	545
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	488
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Rent
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	691
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	631
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Provision for a claim (see Note 13)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Severance
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	287
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued dividend for Series C Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Franchise taxes payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	307
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	201
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,660
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,133
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 9. NOTES AND LOANS PAYABLE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company is party
	to loan agreements as follows ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.3PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Loan and security agreement,
<B>
</B>
	net of original issue discount of $1.0 million
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,496
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Senior secured term loan
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Note payable
<SUP>
	(3) (4)
</SUP>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	387
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total notes and loans payable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,883
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,575
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes and loans payable, current portion
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,011
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Notes and loans payable, long-term
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,886
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,564
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Total notes and loans payable,
</B>
<B>
	net
	of original issue discount of $1.0 million and $0
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,883
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,575
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Repayments under the
	Company&rsquo;s existing debt agreements consist of the following ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 55%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	Period Ending December 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,444
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,926
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,496
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	2019
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,887
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Loan and Security Agreement (1)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On July 29, 2015, the Company and Immune
	Pharmaceuticals USA Corp. entered into a Loan and Security Agreement (the &ldquo;Loan Agreement&rdquo;) with Hercules to borrow
	$4.5 million with a Company option to borrow an additional $5.0 million prior to June 15, 2016, subject to the achievement of certain
	clinical milestones and other conditions. The Company did not record the additional $5.0 million loan availability as a liability
	until the cash is received due to its contingent nature. The Hercules Loan&rsquo;s maturity date is September 1, 2018 and includes
	a nine month interest-only payment period following the closing in which escalating principal payments of $0.1 million per month
	will begin on April 1, 2016. Interest expense for the year ended December 31, 2015, was approximately $0.3 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Loan Agreement includes customary representations,
	warranties and restrictive covenants, including certain restrictions on the Company&rsquo;s ability to incur liens and indebtedness.&nbsp;
	In connection with the Loan, the Company issued to Hercules a five-year warrant to purchase an aggregate of 214,853 shares of its
	common stock (or 279,412 shares if the Company closes on the additional $5.0 million), at an exercise price of $1.70 per share,
	subject to certain adjustments, including, if lower, the effective price of any financing occurring six months after the issuance
	date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Loan Agreement is collateralized by
	a first priority perfected security interest in all tangible and intangible assets of the Company and its subsidiaries, senior
	to all indebtedness. The interest rate on the Hercules Loan is calculated at the greater of 10% or the prime rate plus 5.25%. The
	Company may prepay the Hercules Loan at any time, subject to certain prepayment penalties.&nbsp; Hercules may convert up to $1.0
	million of the loan in any subsequent institutionally led Company financing on the same terms, conditions and pricing of such subsequent
	financing. This option to convert would be at the then fair value, as it will be at the same term and pricing as the new investors,
	therefore it is deemed to have minimal value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Loan Agreement includes an end of term
	charge of $0.5 million payable on the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays
	the outstanding Secured Obligations in full, or (iii) the date that the secured obligations become due and payable in full (as
	defined in the Loan Agreement). The Company will accrue this charge as of each reporting period accruing up to the $0.5 million
	charge over the 37-month term of the Loan Agreement because this charge is a cost of the debt and the Company is obligated to make
	this payment in the future. For the year ended December 31, 2015, the Company recorded a charge of approximately $0.1 million,
	which has been recorded in non-operating expense in the consolidated statements of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The placement agent for the Loan Agreement
	received $0.3 million upon the closing of the Hercules Loan and warrants to purchase an aggregate of 350,000 shares of common stock,
	at an exercise price of $1.78 per share, exercisable commencing six months following the issuance date and ending five years following
	the issuance date. The Company valued the warrants issued to the Hercules placement agent using the Black-Scholes options-pricing
	model and calculated a fair value of $0.4 million on the date of grant, which has been recorded as part of the debt issuance costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company early adopted ASU 2015-03
<I>
	Simplifying
	the Presentation of Debt Issuance Costs
</I>
	and recorded debt issuance costs of $1.3 million relating to placement agent fees,
	legal fees, closing costs and the fair value of the placement agent warrants as a debt discount in the consolidated balance sheet
	as of December 31, 2015. ASU 2015-03 requires the use of the effective interest method for the amortization of the debt discount.
	The Company will amortize the debt discount costs over the term of the Loan, which expires on September 1, 2018. The Company has
	recorded interest expense of $0.3 million for the year ended December 31, 2015, relating to the amortization of the debt discount,
	which is recorded in non-operating expense in the consolidated statements of operations. The Company recognized interest expense
	of approximately $0.3 million for the year ended December 31, 2015 related to the Hercules loan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Senior Secured Term Loan (2)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In connection with the Merger, the Company
	assumed a senior secured term loan, collateralized by substantially all assets of the Company, from MidCap.&nbsp;The senior secured
	term loan contained customary affirmative and negative covenants and events of default applicable to the Company. The affirmative
	covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver
	certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on the Company
	transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other
	distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain
	exceptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Third Amendment entered into in August
	2013, restructured the Company's loan in connection with the completed Merger. In addition to providing MidCap&rsquo;s consent
	to the Merger, the amendment fixed the outstanding principal balance of the initial borrowing (&ldquo;Tranche 1&rdquo;) of the
	loan at approximately $4.4 million. Principal repayments on the Tranche 1 amount was set to commence on December 1, 2013 and was
	later amended under the Fourth Amendment to commence on May 1, 2014. Principal repayments became due in approximately equal monthly
	installments commencing on the first repayment date. The scheduled maturity date of the loan is August 1, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Third Amendment also provided availability
	for a second borrowing (&ldquo;Tranche 2&rdquo;) of $1.0 million, which was to be available for drawing by the Company through
	August 1, 2014, at the Company&rsquo;s discretion. The Company did not draw any amounts under Tranche 2. Interest on the Tranche
	1 loan accrues at the rate of 11.5% per annum and is paid monthly in arrears.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As part of the Third Amendment, in consideration
	for the restructuring of the loan, subsequent to the closing of the Merger, the Company granted to MidCap five-year warrants to
	purchase 101,531 shares of the Company&rsquo;s common stock at $3.50 per share having a grant date fair value of approximately
	$0.3 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2014, in connection with the issuance
	of the Preferred C Stock and the March 2014 Warrants (see Note 15), the Company signed a Fourth Amendment to a senior secured term
	loan agreement (the &ldquo;Fourth Amendment&rdquo;). This amendment fixed the amortization schedule for the Tranche 1. According
	to the new schedule, principal payments of approximately $0.2 million each were to resume monthly as of May 1, 2014. In addition,
	the parties agreed to waive defaults that had occurred since the consummation of the Merger. The overall accounting impact of the
	Fourth Amendment was not material. On May 1, 2014, the Company commenced repayments of principal, as per the new schedule.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In conjunction with the July 2015 financing
	transactions, the Company repaid the MidCap $2.1 million senior secured term loan and paid early termination fees of $0.5 million
	in connection with the repayment of the senior secured term loan which was recorded as a loss on extinguishment of debt in the
	consolidated statements of operations for the year ended December 31, 2015. &nbsp; Interest expense recognized for the senior secured
	term loan was $0.2 million and $0.3 million for the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	MabLife Notes Payable (3)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2012, the Company acquired from
	MabLife through an assignment agreement, all rights, titles and interests in and to the patent rights, technology and deliverables
	related to the anti-Ferritin mAb, AMB8LK, including its nucleotide and protein sequences and its ability to recognize human acid
	and basic ferritins. The consideration was as follows: (i) $0.6 million payable in six annual installments (one of such installments
	being an upfront payment made upon execution of the agreement), and (ii) royalties of 0.6% of net sales of any product containing
	AMB8LK or the manufacture, use, sale, offering or importation of which would infringe on the patent rights with respect to AMB8LK.
	The Company is required to assign the foregoing rights back to MabLife, if it fails to make any of the required payments, is declared
	insolvent or bankrupt or terminates the agreement. In February 2014, the parties revised the payment arrangement for the purchase
	of the original assignment rights. Remaining payments of $0.1 million per year are due each year in 2016 and 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 2014, the Company acquired
	from MabLife, through an irrevocable, exclusive, assignment of all rights, titles and interests in and to the secondary patent
	rights related to the use of anti-ferritin monoclonal antibodies in the treatment of some cancers, nucleotide and protein sequences
	of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules
	comprising these sequences. As full consideration for the secondary patent rights, the Company will pay a total of $150,000 of
	which $15,000 was paid in 2014 and $25,000 will be paid on the first through fourth anniversary of the agreement and an additional
	$35,000 on the fifth anniversary of the agreement. Interest expense recognized on the first and secondary patents for the year
	ended December 31, 2015 and 2014, aggregated to $0 and $45,000 respectively. As a result of the purchase of the patent rights,
	the Company recorded an intangible asset of $0.5 million at December 31, 2014 (see Note 7).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Revolving Line of Credit (4)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April 2014, the Company entered into
	a three-year, $5.0 million revolving line of credit with Melini Capital Corp. (&ldquo;Melini&rdquo;), an existing stockholder who
	is related to the Chairman of the Company&rsquo;s Board of Directors. Borrowings under this revolving line of credit incur interest
	at a rate of 12% per year, payable quarterly. Drawdowns are available to the Company within four weeks of an official request.
	The revolving line of credit is unsecured and subordinated to the Loan Agreement. Either party to the revolving line of credit
	has the right to terminate this line of credit upon completion of a capital raise in excess of $5.0 million. On April 14, 2015,
	the revolving line of credit was amended to extend the line of credit and to provide Melini the right to terminate the line of
	credit on the earlier of (i) one year from the amendment date, or (ii) the completion of a capital raise in excess of $5.0 million.
	The revolving line of credit was further amended upon the completion of the July 2015 financings in which the Company completed
	a capital raise greater than $5.0 million. On August 7, 2015, Melini agreed to extend the line of credit until September 30, 2015
	and on October 14, 2015, Melini agreed to extend the line of credit until November 30, 2016. In October 2015, the Company paid
	Melini $0.3 million as reimbursement for direct financial and administrative expenses incurred for the maintenance of the revolving
	line of credit from April 2014 to March 2016. To date, no amounts have been drawn under the revolving line of credit. Any amounts
	borrowed under the revolving line of credit must be repaid upon the maturity date of November 30, 2016 (see Note 16).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 10. STOCKHOLDERS&rsquo; EQUITY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(a)
	Stock options and stock award activity
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table illustrates
	the common stock options granted for the years ended December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Grant date
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	No. of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	options
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exercise
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	price
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Share
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	price at
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	grant date
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Vesting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	terms
</B>
</P>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Assumptions used in Black-Scholes
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	option pricing model
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 11%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management, Directors and Employees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 12%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	January &ndash; December 2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 8%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,762,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 8%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$0.69-$2.20
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 8%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$1.25-$2.20
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 9%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0 to 3.0 years
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 18%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Volatility
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 13%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	84.33% -96.49%
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk free interest rate
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.23%-2.17%
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Expected term, in years
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6.00-10.00
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dividend yield
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.00%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consultants
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	May 2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	160,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$1.98-$2.01
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$1.89-$2.01
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.0 years
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Volatility
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	91.55%
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk free interest rate
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.23% -0.27%
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Expected term, in years
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6.00
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dividend yield
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.00%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Grant date
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	No. of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	options
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exercise
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	price
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Share
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	price at
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	grant date
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Vesting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	terms
</B>
</P>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Assumptions used in Black-Scholes
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	option pricing model
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 11%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management, Directors and Employees
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	February - August 2014
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,603,630
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$2.38 - $3.58
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$2.38 - $3.58
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Over 1.0-3.0 years
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Volatility
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	87.53%-89.00%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk free interest rate
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.65%-2.82%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Expected term, in years
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dividend yield
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.00%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consultants
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	February - September 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,050,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$2.38-$4.00
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$2.38-$4.00
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Over 1.0-3.0 years
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Volatility
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	84.33%-87.21%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk free interest rate
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.17%-2.68%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Remaining expected term, in years
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9.09-10.00
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dividend yield
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.00%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table illustrates
	the stock awards granted for the years ended December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 16.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.3PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Title
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant date
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	No. of
<BR>
	stock
<BR>
	awards
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share
<BR>
	price at
<BR>
	grant date
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vesting
<BR>
	terms
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="WIDTH: 40%">
	Employees
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 14%; TEXT-ALIGN: CENTER">
	January - December 2015
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	14,000
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
	$2.47
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 14%; TEXT-ALIGN: CENTER">
	Immediately
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	Consultants
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	January &ndash; December 2015
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	744,469
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$1.16-$2.00
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Immediately to 1 Year
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="WIDTH: 40%">
	Consultants
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 14%; TEXT-ALIGN: CENTER">
	January-December 2014
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,357,588
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$1.70-$4.82
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 14%; TEXT-ALIGN: CENTER">
	Over 0.0-3.0 years
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table summarizes information about
	stock awards and stock option activity for the year ended December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="18" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Aggregate
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Average
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Average
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Intrinsic
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise&nbsp;Price
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Grant Date
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Value
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	of Options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Range
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair Value
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	(000)s
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD">
	Outstanding at January 1, 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,192,849
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3.81
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.04&nbsp;-&nbsp;$5,648.40
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1.67
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,940
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,653,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.98
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.38&nbsp;-&nbsp;$4.00
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(20,012
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.99
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	$0.99
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Forfeited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(372,724
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.99 - $4.00
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.95
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(106,889
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	88.73
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.04 - $5,648.40
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Outstanding at January 1, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,346,854
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1.70
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	$0.04&nbsp;-&nbsp;$4.00
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1.95
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,266
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,922,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.69-$2.20
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(635,350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.04-$0.71
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Forfeited/Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,644,516
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4.92
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.38-$4.00
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Outstanding at December 31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,988,988
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1.56
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.04-$4.00
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1.97
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	527
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Exercisable at December 31, 2015
</B>
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,733,767
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1.34
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.04-$4.00
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1.66
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	526
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Stock&nbsp;awards
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number of
<BR>
	Stock
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
<BR>
	Average
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Awards
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair&nbsp;Value
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Unvested at January 1, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%">
	Granted
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,357,588
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3.27
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Vested
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,196,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Forfeited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Unvested at December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	160,702
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4.06
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	650,135
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.69
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Vested
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(758,469
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.73
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Forfeited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(52,368
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Unvested at December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Stock-based compensation expense
	for the years ended December 31, 2015 and 2014 was $2.8 million and $6.5 million, respectively, which has not been tax-effected
	due to the recording of a full valuation allowance against net deferred tax assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(b) Warrants
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.3PT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table summarizes
	information about warrants outstanding at December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Average
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number of
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Price
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Range
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Warrants outstanding and exercisable January 1, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,005,684
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	16.23
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	$1.85-$124.20
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issued in connection with March 2014 Financing (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,361,904
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$4.25-$5.10
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjustment to amount of warrants issued in connection with March 2014 Financing (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,468,832
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.53
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$3.39-$4.07
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued for amendment of Preferred C Stock (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	427,179
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issuance to lead investors (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	134,004
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued in connection with private placements (5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	412,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.44
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$3.75-$5.00
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued to March 2014 Financing placement agent (6)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	295,366
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$3.00-$3.50
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issued in connection with November 2014 Financing (7)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,078,725
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Exercised (8)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(77,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(180,029
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	94.04
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$3.00-$124.20
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Warrants outstanding and exercisable at December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,926,385
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5.06
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	$1.85-$65.60
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Warrants issued to consultants (9)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	160,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.98
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.98
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued to Hercules as part of July 2015 debt financing (10)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	214,853
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued to July 2015 debt financings placement agent (10)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	350,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued to placement agents in connection with Series D financing (11)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	778,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrants issued in conjunction with Series C Exchange (12)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	431,457
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(168,557
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	Warrants outstanding at December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,692,138
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3.93
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	$1.66-$65.60
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	Warrants exercisable at December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,917,828
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4.23
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	$1.66-$65.60
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	As part of the units given to participants in the March 2014 Financing, the Company granted its investors with (i) a five-year warrant to purchase 50% or 100% (as per the agreement made with each investor) of the shares of common stock issuable for conversion of Preferred C stock shares, at an exercise price equal to the lower of $4.25 and 125% of the conversion price of the Preferred C Stock then in effect, and a five-year warrant to purchase 50% or 100% (as per the agreement made with each investor) of a share of common stock at an exercise price equal to the lower of $5.10 and 150% of the conversion price of the Preferred C Stock then in effect.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	On April 25, 2014, the Company filed a Registration Statement on Form S-1 to register the resale of the shares of common stock underlying the Preferred C Stock, the shares of common stock underlying the March 2014 Warrants and certain shares of common stock that may be issuable as payment for dividends on the Preferred C Stock, which registration statement was declared effective by the SEC. Subsequently, and in accordance with the terms of the Preferred C Stock, such registration triggered a reduction of the conversion price of the Preferred C Stock from $3.40 to $2.71 and the exercise price of the warrants was reduced from $4.75 to $3.39 and from $5.10 to $4.07, as applicable. In addition, according to the warrant agreements, the number of warrants was increased, so that an additional 427,983 March 2014 Warrants at an exercise price of $3.39 and 427,983 at an exercise price of $4.07 were issued. Furthermore, on August 13, 2014, pursuant to an Amendment Agreement, the exercise prices of the March 2014 Warrants were reduced from $3.39 to $3.00 and from $4.07 to $3.50, and the number of warrants was increased from 2,108,938 to 2,381,342 and from 2,108,938 to 2,449,380, respectively. See Note 15.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	On June 23, 2014, in connection with the amendment of its Certificate of Designations, the Company issued the June Warrants to purchase up to an aggregate of 427,179 shares of the Company&rsquo;s Common Stock to the original purchasers of the Preferred C Stock. See Note 15.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	On February 24, 2014, the Company&rsquo;s Board of Directors approved an amendment to 2012 and 2013 warrant grants to investors of pre-Merger Immune Ltd. Such investors were originally granted with the option to purchase 20% instead of 50% of the shares of Immune Ltd. Therefore, as a remedy, the Company issued an additional 134,004 warrants, at an exercise price of $5.04. The total fair value of $0.3 million was determined using the Black-Scholes option-pricing model, with an expected term of 1.95-4.48 years, volatility of 90%, risk-free interest rate of 0.27%-1.43%. Because the issuance reflects a correction to previous grant, these warrants were accounted for within equity, following the accounting for the original transaction. The impact on current, as well as on any prior financial period was determined not to be material.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	On August 13, 2014, the Company entered into an investment agreement with one of its investors. Pursuant to the agreement, the Company received a total of $2 million upon closing. As consideration, the Company issued the investor 500,000 shares of its common stock, at $4.00 per share, and granted the investor 250,000 warrants, at an exercise price of $5.00 with a term of five years. The fair value of the issued warrants is $0.6 million, which was determined using the Black-Scholes option pricing model, using the following assumptions: stock price of $4.11, expected term of 5.0 years, volatility of 83.44%, risk-free interest rate of 1.72%.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	In September 2014, the Company
	entered into an agreement with one of its investors. According to the agreement, in consideration for $0.4 million, received by
	the Company in April 2014, it issued the investor 96,000 shares of its common stock and 162,000 warrants at an exercise price of
	$4.00 and term of five years. The fair value of the issued warrants is $0.4 million, which was determined using the Black-Scholes
	option pricing model, using the following assumptions: stock price of $3.92, expected term of 5.0 years, volatility of 83.44%,
	risk-free interest rate of 1.72%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Prior to its March 2014 Financing, the Company entered into an agreement with its placement agent, according to which it was obligated to pay the agent 7% in cash and 7% in warrants of the total amount sold in the March 2014 Financing, as placement agent compensation. The warrants were to bear the same terms and conditions as the March 2014 Warrants. Although the cash fees were paid, the warrants due to the placement agent were inadvertently neither issued nor accounted for. The overall impact in prior periods, of such issuance, was: (i) an additional expense of $0.3 million, $0.1 million and $0.2 million in the statement of operations, in the three month periods ended March 31, 2014, June 30, 2014 and the six month period ended June 30, 2014, respectively; (ii) a total of $0.3 million and $0.3 million decrease in stockholders&rsquo; equity as of March 31, 2014 and June 30, 2014; (iii) a total of $0.4 million and $0.3 million increase in a long term derivative liability as of March 31, 2014 and June 30, 2014; The impact is deemed to be not material to the periods and therefore was recorded during the three month period ended September 30, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	As of December
	31, 2014, the Company accounted for the placement agent warrants, at a total fair value of $0.5 million, which was determined using
	the Black-Scholes option pricing model, with an expected term of 2.25 years, volatility of 74.4%, risk free interest rate of 0.71%.
	These warrants were accounted for following the accounting method used for the original transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 58.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In connection with the November 2014 Offering (see Note 15), the Company issued warrants to purchase 1,078,725 shares of common stock exercisable immediately for a period of three years with a total exercise price of $3.75 per share. The fair value of the issued warrants is $1.4 million, which was determined using the Black-Scholes option pricing model, using the following assumptions: stock price of $2.75, expected term of 3.0 years, volatility of 84.66%, risk-free rate of 0.94%.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2014, the Company&rsquo;s
	Board of Directors agreed to extend the expiration date of 235,333 warrants, originally issued in connection with a financing
	transaction, at an exercise price of between $3.36 and $4.20, and original expiration dates of between September 2014 and February
	2015, until December 31, 2015. As a result, the Company recorded an incremental value of $0.2 million, as a deemed dividend. Such
	value was determined using the Black-Scholes option-pricing model, with an expected term of 1.32 years, volatility of 75%, risk-free
	interest rate of 1.50%. Furthermore, the Company entered into agreements with certain warrant holders, according to which, a total
	of 162,288 warrants at an exercise prices ranging from $4.20 to $5.04 and remaining term of between one and four years, were exchanged
	for 162,288 warrants at an exercise price of $3.00 and expiration on October 30, 2014. As of December 31, 2014, a total of 77,280
	were exercised and the remaining warrants expired. The modification did not have an impact on the Company&rsquo;s consolidated
	financial statements, since the fair value of the new warrants was less than the fair value of the existing warrants prior to
	the modification.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1PT; TEXT-ALIGN: JUSTIFY">
	In June 2015, the Company
	issued 160,000 shares to a consultant for services performed, at an exercise price of $1.98 per share, exercisable commencing
	six months from the date of issuance and ending five years following the issuance date.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1PT; TEXT-ALIGN: JUSTIFY">
	In connection with the
	Loan Agreement with Hercules, the Company issued to Hercules a five-year warrant to purchase an aggregate of 214,853 shares of
	its common stock at an exercise price of $1.70 per share, subject to certain adjustments, including, if lower, the effective price
	of any financing occurring six months after the issuance date. The placement agent for the Loan Agreement received $0.3 million
	upon the closing of the Hercules Loan and warrants to purchase an aggregate of 350,000 shares of common stock, at an exercise
	price of $1.78 per share, exercisable commencing six months following the issuance date and ending five years following the issuance
	date.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11)
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Upon closing of the $9.0 million
	Discover financing, the co-placement agents received an aggregate of $0.6 million upon closing and each received warrants to purchase
	an aggregate of 275,000 shares of the Company&rsquo;s common stock, for a total of 550,000 shares of common stock, at an exercise
	price of $2.50 per share, exercisable commencing six months following the issuance date and ending five years following the issuance
	date. Upon closing of the additional $3.0 million Discover financing, the co-placement agents received an aggregate of $0.2 million
	in cash and each received warrants to purchase an aggregate of 114,000 shares of the Company&rsquo;s common stock, for a total
	of 228,000 shares of common stock, at an exercise price of $2.50 per share, exercisable six months following the issuance date
	and ending five years following the issuance date.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;In July 2015, in connection with the Exchange Agreement with Holders of all of the
	shares of Series C Preferred Stock, the Company agreed to issue the Holders an aggregate of 2,238,282 shares of its common
	stock and five-year warrants to purchase an aggregate of up to 431,457 shares of the Company&rsquo;s common stock, at an
	exercise price of $3.00 per share and exercisable commencing six months following the date of issuance. See Note 10(d).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(c) Performance Based Options
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On May 6, 2015, the Company&rsquo;s Board
	of Directors, pursuant to the recommendation of the Compensation Committee of the Board of Directors of the Company (&ldquo;Compensation
	Committee&rdquo;), granted an option to purchase up to 250,000 shares of the Company&rsquo;s common stock to Dr. Daniel G. Teper,
	the Company&rsquo;s Chief Executive Officer, as performance-based compensation.&nbsp; The performance-based options were granted
	at an exercise price of $1.87 per share and will vest upon the Company&rsquo;s achievement of certain operational, financing and
	partnership objectives that were determined by the Compensation Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In connection with the granting of the
	performance-based options to Dr. Teper, the Company recorded a charge to stock compensation expense of $0.2 million for the year
	ended December 31, 2015 because the Company determined that the achievement of the performance options vesting criteria was deemed
	to be probable. The Company is amortizing the expense over the expected term of the performance options (see Note 16).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	(d) Series C Preferred Stock
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In July 2015, the Company entered into
	Securities Exchange Agreements (&ldquo;Exchange Agreement&rdquo;) with certain holders (&ldquo;Holders&rdquo;) of all of their
	shares of Series C 8% Convertible Preferred Stock (&ldquo;Series C Preferred Stock&rdquo;), pursuant to which the Company agreed
	to issue the Holders an aggregate of 2,238,282 shares of its common stock and five-year warrants to purchase an aggregate of up
	to 431,457 shares of the Company&rsquo;s common stock, at an exercise price of $3.00 per share and exercisable commencing six months
	following the date of issuance. In exchange, the Holders&rsquo; agreed to exchange an aggregate of 2,286 shares of Series C Preferred
	Stock, originally issued by the Company on March 14, 2014, including any accrued but unpaid dividends payable thereon (the &ldquo;Exchange&rdquo;),
	pro rata to each Holder&rsquo;s Preferred Stock ownership. As of December 31, 2015, 0 shares of the Company&rsquo;s Series C Preferred
	Stock remained outstanding. The Exchange Agreement was considered to be an inducement in accordance with ASC 470 and as a result,
	the Company recorded the excess of (i) the fair value of all securities and other consideration transferred by the Company to the
	Series C Preferred Stock holders and (ii) the fair value of securities issuable pursuant to the original conversion terms are added
	to the Company&rsquo;s net loss to arrive at loss available to common stockholders in the calculation of loss per share. Prior
	to the Exchange Agreement, the Company issued 389,281 shares of its common stock in exchange for the conversion of 546 shares of
	Series C Preferred Stock. For the year ended December 31, 2015, the Company charged to additional paid-in capital approximately
	$1.6 million in deemed dividend related to the Series C Preferred Stock. See Note 15.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	(e) 10b5-1 Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On September 1, 2015, Dr. Daniel G. Teper,
	the Company&rsquo;s Chief Executive Officer, purchased 7,569 shares of the Company&rsquo;s common stock at $1.29 per share. On
	September 15, 2015, Dr. Teper, established a stock trading plan (the &ldquo;10b5-1 Plan&rdquo;) with respect to purchases in the
	open market of up to an aggregate of $0.3 million worth of the Company&rsquo;s common stock in accordance with Rule 10b5-1 under
	the Securities and Exchange Act of 1934, as amended (the &ldquo;Act&rdquo;) and other applicable federal securities laws and regulations
	adopted by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Through March 2016, Dr. Teper had purchased $0.3 million
	worth of the Company&rsquo;s common stock in purchases under the 10b5-1 Plan. On September 14, 2015, the Chairman of the Company&rsquo;s
	Board of Directors purchased 50,000 shares of the Company&rsquo;s common stock at $1.47 per share and on December 7, 2015 purchased
	an additional 240,623 shares of the Company&rsquo;s common stock at a price of $0.79.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(f) Equity Incentive Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s 2005 Equity Incentive
	Plan, as amended and restated, expired in September 2015. On December 9, 2015, the 2015 Equity Incentive Plan (&ldquo;2015 Plan)
	was approved at the Company&rsquo;s 2015 Annual Meeting of Stockholders. The 2015 Plan provides for the grant of incentive stock
	options, within the meaning of Section 422 of the Internal Revenue Code to the Company&rsquo;s employees and its parent and subsidiary
	corporations&rsquo; employees, and for the grant of non-statutory stock options, restricted stock, restricted stock units, performance-based
	awards and cash awards to its employees, directors and consultants and its parent and subsidiary company&rsquo;s employees and
	consultants. The Company&rsquo;s Board of Directors determines the terms of the 2015 Plan such as vesting period. A total of 5,000,000
	shares of the Company&rsquo;s common stock is reserved for issuance pursuant to the 2015 Plan. No optionee may be granted an option
	to purchase more than 1,500,000 shares in any fiscal year. Options issued pursuant to the 2015 Plan have a maximum maturity of
	10 years.&nbsp; The 2015 Plan will expire on November 12, 2025. On December 24, 2015, the Company filed a Registration Statement
	on Form S-8 (Registration No. 333-208754), which registered the 5,000,000 common shares that may be issued or sold under the plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(g) Employee Stock Purchase Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 16.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo;)
	is implemented by offerings of rights to all eligible employees from time to time. Unless otherwise determined by the Company&rsquo;s
	Board of Directors, common stock is purchased for accounts of employees participating in the ESPP at a price per share equal to
	the lower of (i) 85% of the fair market value of a share of the Company's common stock on the first day of offering or (ii) 85%
	of the fair market value of a share of the Company's common stock on the last trading day of the purchase period. Each offering
	period will have six-month duration. There were no shares issued under the ESPP during the year ended December 31, 2015, and no
	expense has been recorded. A total of 998,043 shares are available for issuance under the ESPP as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTE 11. SERIES D PREFERRED STOCK
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On July 28, 2015, the Company entered into
	Stock Purchase Agreements (the &ldquo;Purchase Agreements&rdquo;) with mutual fund Discover pursuant to which the Company agreed
	to issue and sell up to an aggregate of 947 shares of the Company&rsquo;s newly designated Series D Redeemable Convertible Preferred
	Stock (&ldquo;Series D Preferred Stock&rdquo;) of the Company, par value $0.0001 per share, convertible into shares of the Company&rsquo;s
	Common Stock, at a fixed conversion price of $2.50 per share (the &ldquo;Conversion Price&rdquo;), at a purchase price of $10,000
	per share, for total gross proceeds of $9.0 million after taking into account a 5% original issue discount, or the sale of approximately
	$9.47 million. Original issue discount of approximately $0.4 million was recorded as a reduction of the Series D Preferred Stock
	in the consolidated balance sheets as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company sold 444 shares of the Series
	D Preferred Stock to Discover pursuant to a prospectus supplement to the Company's &ldquo;shelf&rdquo; registration statement on
	Form S-3 (File No. 333-198647), which became effective on October 28, 2014. The Company sold the remaining 503 shares to Discover
	pursuant to section Regulation 4(a)(2) of the securities act governing private placements. The Company has filed a registration
	statement on Form S-3 with the SEC covering the resale of the shares of common stock issuable upon conversion of the Series D Preferred
	Stock issued in the private placement as well as any dividends payable in shares of common stock which registration statement became
	effective on September 25, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company agreed to issue and sell an
	additional 316 shares of Series D Preferred Stock for gross proceeds of $3.0 million (with a 5% original issue discount) upon the
	satisfaction of certain customary closing conditions for transactions of this type as well as (i) approval by the Company&rsquo;s
	stockholders of issuance of shares of Common Stock in accordance with the requirements of NASDAQ Listing Rule 5635(d) and (ii)
	a registration statement registering the shares of common stock issuable under the terms of the Series D Preferred Stock being
	declared effective by the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On September 24, 2015, the Company held
	a Special Meeting of Stockholders (the &ldquo;Special Meeting&rdquo;) to vote on a proposal to approve the potential issuance of
	more than 19.99% of the Company&rsquo;s outstanding common stock upon conversion of the Series D Preferred Stock, together with
	certain additional shares the Company issued pursuant to other transactions that are aggregated under the NASDAQ Listing Rules
	in accordance with the stock purchase agreements between the Company and Discover dated July 28, 2015. This proposal was approved
	at the Special Meeting. On September 29, 2015, pursuant to the Stock Purchase Agreement and the satisfaction of the closing conditions
	included therein, the Company issued and sold 316 shares of the Company&rsquo;s Series D Preferred Stock to Discover for total
	gross proceeds of $3.0 million, after taking into account a 5% original issue discount, or the sale of approximately $3.16 million
	of Series D Preferred Stock. The Company received the additional $3.0 million on September 29, 2015. Total original issue discount
	of $0.2 million was recorded as a reduction of the Series D Preferred Stock in the consolidated balance sheets as of December 31,
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Series D Preferred Stock is convertible
	at a fixed price of $2.50 per share and has a six and a half year maturity term, at which time it will convert automatically into
	common stock at $2.50 per share. The Series D Preferred Stock bears an accrued annual dividend rate of 8.0%, which may range from
	0% to 15%, based on certain adjustments and conditions, including changes in the volume weighted average price of the Company&rsquo;s
	common stock. Upon conversion, the Company shall pay the holders of the Series D Preferred Stock being converted a conversion premium
	equal to the amount of dividends that such shares would have otherwise been issued if they had been held through the maturity date
	(&ldquo;Conversion Premium&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The dividends and conversion premium may
	be paid in cash or, at the Company&rsquo;s option, shares of common stock. If the Company elects to pay the dividends or conversion
	premium amount in the form of common stock, the number of shares to be issued is calculated as follows: (i) if there is no triggering
	event (as such term is defined in the Certificate of Designations), 90.0% of the average of the five lowest individual daily volume
	weighted average prices during the applicable measurement period, which may be non-consecutive, less $0.05 per share of common
	stock, not to exceed 100% of the lowest sales price on the last day of such measurement period, less $0.05 per share of common
	stock, or (ii) following any triggering event, 80.0% of the lowest daily volume weighted average price during any measurement period,
	less $0.05 per share of common stock, not to exceed 80.0% of the lowest sales price on the last day of any measurement period,
	less $0.05 per share of common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The face value of the Series D Preferred
	Stock of $12.6 million, inclusive of $0.6 million in debt discount, has been accounted for as mezzanine equity in the consolidated
	balance sheets at December 31, 2015 in accordance with ASC 480 &ldquo;Distinguishing Liabilities from Equity&rdquo;, as upon liquidation,
	the Company will be required to redeem the outstanding Series D Preferred Stock for cash. The beneficial conversion feature relating
	to the Series D Preferred Stock resulted in a deemed dividend of $3.0 million on the date of issuance of the Series D Preferred
	Stock and was reflected as a reduction of the net loss attributable to common stockholders as the effective conversion price of
	the Series D Preferred Stock was below the Company&rsquo;s stock price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The conversion premium and the dividends
	associated with the Series D Preferred Stock contain an anti-dilution feature within the dividend rate, which fluctuates inversely
	to the changes in the value of the Company&rsquo;s stock price. The conversion premium and dividends with the noted features are
	redeemed upon conversion of the Series D Preferred Stock.&nbsp;&nbsp;The Company&rsquo;s management analyzed the conversion premium
	and dividends with the noted features and determined that they required liability treatment. Accordingly, the conversion premium
	and the dividends have been bifurcated from the Series D Preferred Stock. Initial and subsequent measurement of this derivative
	liability will be at fair value, with changes in fair value recognized in earnings on a quarterly basis. The Company calculated
	the fair value of the total derivative liability of $8.0 million at inception of the two tranches of the Series D Preferred Stock
	issued to Discover, which have been recorded as a reduction of the Series D Preferred Stock in the consolidated balance sheet since
	redemption is not currently deemed to be probable. A proportionate amount of the derivative liability that was recorded at inception
	of each tranche of the issuance of the Series D Preferred Stock will be reflected as a deemed dividend as the conversions occur.
	The Discover derivative liability was reduced by $1.8 million upon the Series D Preferred Stock conversions during the year ended
	December 31, 2015. The Company recorded a loss on the change in the estimated fair value of the derivative liability of $0.3 million
	for the year ended December 31, 2015, which was recorded in non-operating expense in the consolidated statements of operations.
	The fair value of the Discover derivative liability as of December 31, 2015 was $6.5 million (see Note 5).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Upon closing of the $9.0 million Discover
	financing, the co-placement agents received an aggregate of $0.6 million upon the closing and each received warrants to purchase
	an aggregate of 275,000 shares of the Company&rsquo;s common stock, for a total of 550,000 shares of common stock, at an exercise
	price of $2.50 per share, exercisable commencing six months following the issuance date and ending five years following the issuance
	date. The Company valued the warrants issued to the placement agents using the Black-Scholes options-pricing model and calculated
	a fair value of $0.6 million, which has been recorded as a reduction to the Series D Preferred Stock in the consolidated balance
	sheet. Upon closing of the additional $3.0 million Discover financing, the co-placement agents received an aggregate of $0.2 million
	in cash and each received warrants to purchase an aggregate of 114,000 shares of the Company&rsquo;s common stock, for a total
	of 228,000 shares of common stock, at an exercise price of $2.50 per share, exercisable six months following the issuance date
	and ending five years following the issuance date. The Company valued the 114,000 warrants issued to placement agents using the
	Black-Scholes options-pricing model and calculated a fair value of $0.2 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, the Company paid legal fees
	of $0.1 million, which were recorded as a reduction of the Series D Preferred Stock in the consolidated balance sheet. Total Series
	D Preferred Stock issuance costs of approximately $1.7 million were recorded as a reduction of the Series D Preferred Stock in
	the consolidated balance sheet as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the year ended December 31, 2015,
	Discover converted 300 shares of Series D Preferred Stock into a total of 1,200,000 of the Company&rsquo;s common stock. In addition,
	the Company issued an additional 3,311,730 of common stock to Discover as payment of dividends and conversion premium. The Company
	recorded a proportionate amount of the Series D Preferred Stock as a deemed dividend of $2.4 million upon conversion, which was
	charged to additional paid-in capital. In addition, during the year ended December 31, 2015, $3.0 million was credited to additional
	paid-in capital from the conversion of the 300 shares of Series D Preferred Stock. Subsequent to December 31, 2015, Discover converted
	an additional 100 shares of Series D Preferred Stock for a total of 400,000 common shares and the Company issued an additional
	2,604,434 common stock as payment of dividends and conversion premium.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Below is the activity for the Company&rsquo;s
	Series D Preferred Stock issuances for the periods presented ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Issuance of Series D Preferred Stock
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,263
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	12,632
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series D Preferred Stock original issue discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series D Preferred Stock derivative liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,007
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Conversion of Series D Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accretion of Series D Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,398
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Series D Preferred Stock issuance costs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,732
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	963
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,659
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 12. LOSS PER SHARE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Basic and diluted loss per share is computed
	by dividing loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during
	the period. Diluted weighted average shares outstanding for the years ended December 31, 2015 and 2014 excludes shares underlying
	stock options and warrants and convertible preferred, since the effects would be anti-dilutive. Accordingly, basic and diluted
	loss per share is the same.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Such excluded shares are summarized as
	follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Common stock options
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,988,988
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5,346,854
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Restricted stock units (unvested)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	160,702
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Common shares issuable upon conversion of Series C Preferred Stock (not including dividends)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,165,351
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Common shares issuable upon conversion of Series D Preferred Stock (not including dividends and conversion premium paid in common stock)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,852,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,464,138
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,926,385
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Total shares excluded from calculation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	19,305,126
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	15,599,292
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 13. COMMITMENTS AND CONTINGENCIES
<U>
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(a) Leases
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 2015, the Company&rsquo;s corporate
	headquarters was relocated to New York, NY under a lease agreement with Alexandria Real Estate, which expires in 2020. On August
	31, 2015, the Company signed an amendment to the New York, NY lease agreement with Alexandria Real Estate for lab space and offices
	for an additional 1,674 square feet commencing on September 1, 2015 and ending in 2020. The total base rent for offices and lab
	space, as amended, is $30,000 per month, subject to annual rent escalations. On January 15, 2016, the Company signed a one year
	lease agreement with an option for an additional year for new office space in Israel. For the years ended December 31, 2015 and
	2014, the Company recorded rent expense of $0.4 million and $0.2 million, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Future minimum lease payments under non-cancelable
	leases for office space, as of December 31, 2015, are as follows ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.75IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	Period Ending
<BR>
	December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	432
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	378
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	392
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	405
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	2020
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	139
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,746
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(b) Licensing Agreements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company is a party to a number of research
	and licensing agreements, including iCo, MabLife, Yissum, Dalhousie, Lonza and Shire, which may require the Company to make payments
	to the other party upon the other party attaining certain milestones as defined in the agreements. The Company may be required
	to make future milestone payments under these agreements. See also Note 6.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	(c) Litigation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Immune Pharmaceuticals Inc. was the defendant
	in litigation involving a dispute with the plaintiffs Kenton L. Cowley and John A. Flores. The complaint alleges breach of contract,
	breach of covenant of good faith and fair dealing, fraud and rescission of contract with respect to the development of a topical
	cream containing ketamine and butamben, known as EpiCept NP-2. A summary judgment in Immune&rsquo;s favor was granted in January
	2012 and the plaintiffs filed an appeal in the United States Court of Appeals for the Ninth Circuit in September 2012. A hearing
	on the motion occurred in November 2013. In May 2014, the court scheduled the trial in November 2014 and a mandatory settlement
	conference in July 2014. In July 2014, the parties failed to reach a settlement at the mandatory settlement conference. The case
	was tried by a jury, which rendered a decision on March 23, 2015, in favor of the Company on all causes of action. During the year
	ended December 31, 2015, in connection with the trial, the Company incurred approximately $0.5 million of legal costs, $0.2 million
	which were settled in cash, and 116,594 shares of stock, with a fair value of $0.2 million which is included in general and administrative
	expenses in the consolidated statements of operations. The Company issued an additional 40,000 shares on April 1, 2015, with a
	fair value of $70,000 to settle current outstanding legal costs. In April 2015, the plaintiffs filed a motion for a new trial,
	which was heard by the Court on June 8, 2015. In October 2015, the court denied the plaintiff&rsquo;s motion for a new trial and
	on October 9, 2015; the plaintiffs filed a notice of appeal to the court. No ruling has been made by the court on plaintiff&rsquo;s
	motion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In October 2014, the Company received a
	written demand from a former lender (&ldquo;Lender&rdquo;), for $9.1 million, which was based on an agreement with Immune Ltd.,
	from 2011, relating to a loan of $0.3 million, which was repaid in full in 2011. The Lender demands to receive certain warrants
	to purchase shares of the Company&rsquo;s common stock, to participate in a future public offering or merger of the Company, with
	certain discounted terms and cash damages. The Company currently estimates that its future loss would range between $0.3 million
	(as accrued for) to $1.0 million, which if determined to be payable to Lender, the Company believes would be likely to be settled
	in equity. The Company intends to vigorously defend itself against those demands, if and when official legal proceedings relating
	to this matter will be initiated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	From time to time the Company is involved
	in legal proceedings arising in the ordinary course of business. The Company believes there is no other litigation pending that
	could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 14. INCOME TAXES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company recorded a deferred tax liability
	of $10.9 million as of December 31, 2015 and 2014 related to the purchase of the AmiKet IPR&amp;D. This deferred tax liability
	was recorded to account for the book vs. tax basis difference related to the IPR&amp;D intangible asset, which was recorded in
	connection with the Merger. This deferred tax liability was excluded from sources of future taxable income, as the timing of its
	reversal cannot be predicted due to the indefinite life of this IPR&amp;D. As such, this deferred tax liability cannot be used
	to offset the valuation allowance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Deferred income taxes reflect the net
	effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the
	amounts used for income tax purposes. The Company&rsquo;s deferred tax assets relate primarily to its net operating loss carryforwards
	and other balance sheet basis differences. In accordance with ASC 740, &ldquo;Income Taxes,&rdquo; the Company recorded a valuation
	allowance to fully offset the gross deferred tax asset, because it is not more likely than not that the Company will realize future
	benefits associated with these deferred tax assets at December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31 2015, the Company had
	deferred tax assets of $22.5 million, against which a full valuation allowance of $22.5 million had been recorded. The
	determination of this valuation allowance did not take into account the Company&rsquo;s deferred tax liability for
	IPR&amp;D assigned an indefinite life for book purposes, also known as a &ldquo;naked credit&rdquo;, in the amount of $10.9
	million at December 31, 2015. The change in the valuation allowance for the year ended December&nbsp;31, 2015 was an increase
	of $3.5 million. The increase in the valuation allowance for the year ended December 31, 2015 was mainly attributable to an
	increase in net operating losses, which resulted in an increase in the deferred tax assets with a corresponding
	valuation allowance. Significant components of the Company&rsquo;s deferred tax assets at December&nbsp;31, 2015 and 2014 are
	as follows ($ in thousands):&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Deferred tax assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Property, plant &amp; equipment
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	688
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Patents and other intangible assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	359
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	119
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Net operating loss carryforwards &ndash; U.S.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,511
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Net operating loss carryforwards &ndash; Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,757
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,655
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Stock-based&nbsp;compensation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,659
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,616
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Gross deferred tax assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,476
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,018
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(22,476
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(19,018
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Gross deferred tax assets after valuation allowance
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Deferred tax liability &ndash; AmiKet IPR&amp;D assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,870
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,870
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Net deferred tax liability
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(10,870
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(10,870
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A reconciliation of the federal
	statutory tax rate and the effective tax rates for the years ended December 31, 2015 and 2014 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	U.S. federal statutory tax rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	State income taxes, net of federal benefit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	U.S. vs. foreign tax rate differential
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equity-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Change in valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(35.5
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(33.4
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Effective tax rate
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	90
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company had approximately
	$81.2 million and $67.1 million of gross net operating loss (&ldquo;NOL&rdquo;) carryforwards (federal, state and Israel) as
	of December 31, 2015 and 2014, respectively. Sections 382 and 383 of the Internal Revenue Code, and similar state
	regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year
	upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event
	of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that
	the Company may utilize in any one year may be limited. The Company reduced its tax attributes (NOL&rsquo;s and tax credits)
	as a result of the Company&rsquo;s ownership changes in 2007, 2009, 2013 and 2015 and the limitation placed on the
	utilization of its tax attributes, as a substantial portion of the NOL&rsquo;s and tax credits generated prior to the
	ownership changes will likely expire unused. The most significant reduction in tax attributes occurred in 2013 as a result of
	the Merger. The Company does not have any material foreign earnings, due to a history of losses in its foreign subsidiary. A
	reconciliation of the Company&rsquo;s NOLs for the years ended December 31, 2015 and 2014 is as follows ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	U.S. Federal NOL's
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	29,100
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	24,300
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	U.S. State NOL's
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Israel NOL's
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	23,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	18,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total NOL&rsquo;s
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	81,200
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	67,100
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s federal and state NOL&rsquo;s
	of $29.1 million each begin to expire after 2030 through 2033. The Company&rsquo;s Israel NOL of $23.0 million&nbsp;does not expire.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company has adopted guidance on accounting
	for uncertainty in income taxes which clarified the accounting for income taxes by prescribing the minimum threshold a tax position
	is required to meet before being recognized in the financial statements as well as guidance on de-recognition, measurement, classification
	and disclosure of tax positions. The Company has gross liabilities recorded of $50,000 for both years ended December&nbsp;31, 2015
	and 2014, to account for potential state income tax exposure.&nbsp; The Company is obligated to file income tax returns in the
	U.S. federal jurisdiction and Israel and various states.&nbsp; Since the Company had losses in the past, all prior years that generated
	NOL&rsquo;s are open and subject to audit examination in relation to the NOL generated from those years.&nbsp; A reconciliation
	of the beginning and ending amount of unrecognized tax benefits is as follows ($ in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Balance at January 1,
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	40
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Additions related to tax positions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Reductions related to tax positions
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Balance at December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On May 1, 2015, the Company received a
	notice from New York State relating to audits of the 2011 to 2013 tax years. The Company has provided requested information to
	New York State and the Company does not expect this to have a material effect on the Company&rsquo;s unrecognized tax benefits.
	As of December 31, 2015, the Company has not recorded any liabilities as a result of the audits. In addition, during the third
	quarter of 2015, the Company received tax notices from the Israeli Tax Authority relating to the 2010 to 2014 tax years. As of
	December 31, 2015, the Company has not recorded any liabilities as a result of the Israel tax notices as the Company is unable
	to determine whether any amounts will be due as a result of the receipt of the Israeli tax notices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 15. 2014 FINANCINGS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.3PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	March 2014 Financing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2014, the Company signed agreements
	to raise $11.7 million (&ldquo;March 2014 Financing&rdquo;) through the sale of its newly designated Series C 8% Convertible Preferred
	Stock (&ldquo;Series C Preferred Stock&rdquo;), convertible into shares of the Company&rsquo;s common stock, at an initial conversion
	price per share equal to the lower of $3.40 and 85% of the offering price in a future public equity offering of at least $10 million,
	a five-year warrant to purchase 50% or 100% (as per the agreement with each investor) of a share of common stock at an exercise
	price equal to the lower of $4.25 and 125% of the conversion price of the Preferred C Stock then in effect, and a five-year warrant
	to purchase 50% or 100% (as per the agreement with each investor) of its shares of common stock, at an exercise price equal to
	the lower of $5.10 and 150% of the conversion price of the Series C Preferred Stock then in effect (collectively, the &ldquo;March
	2014 Warrants&rdquo;).&nbsp;One investor defaulted on payments of $1 million under a short-term promissory note, resulting in rejection
	by the Company of the investor&rsquo;s participation in the March 2014 Financing. A total of approximately $0.4 million received
	from that investor during the second quarter of 2014 was applied for participation in later financing done by the Company (refer
	to Note 15 (d) (5)). In addition, two board members who participated in the March 2014 Financing and paid for their securities
	by fees earned for service as members of the Board of Directors, reduced their subscriptions by $20,000 each, resulting in the
	cancellation of an aggregate of 40 shares of the Series C Preferred Stock and the related warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	91
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Series C Preferred Stock carries a
	dividend of 8% per annum, based on the stated value of $1,000 per share, payable in cash or, at the option of the Company and subject
	to the satisfaction of certain conditions, in shares of common stock. Dividends on the Series C Preferred Stock accrue from the
	date of issuance and are paid on the date of conversion thereof. As of December 31, 2015 and 2014, a total of $0 and $0.3 million,
	respectively, was recorded for dividend liability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In total, the Company issued 10,680 shares
	of Series C Preferred Stock, 1,680,945 March 2014 Warrants at an exercise price of $4.25 and 1,680,945 March 2014 Warrants at an
	exercise price of $5.10, for $1,000 per share. The Company received total net proceeds of approximately $10.2 million after deduction
	of related fees and expenses of $0.2 million, which were allocated to the value of the Series C Preferred Stock, and $0.3 million
	which was offset against existing debt to the Company&rsquo;s employees, consultants, officers and directors. Additional offering
	expenses of $0.4 million were allocated to the March 2014 Warrants and recorded in the consolidated statement of operations during
	the year ended December 31, 2014. Included in net proceeds, was a deposit of $0.5 million the Company received in November and
	December 2013. Furthermore, in the third quarter of 2014, the Company accounted for the value of additional warrants to be issued
	to its placement agent. See Note 10.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 16.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The March 2014 Warrants were accounted
	for as a derivative liability, as both the exercise price and the number of warrants issued were subject to certain anti-dilution
	adjustments. See Notes 5 and 10. Therefore, on March 10, 2014 (agreement date), the March 2014 Warrants were recorded at their
	fair value of $7.4 million. The Series C Preferred Stock was recorded as the difference between overall consideration and the fair
	value of the March 2014 Warrants on grant date. Initially, a total amount of $3.1 million was recorded as mezzanine equity according
	to
<I>
	ASC 480 &ldquo;Distinguishing Liabilities from Equity&rdquo;,
</I>
	as such shares bear clauses allowing for a future adjustment
	to the number of shares issued to investors. As per above, such adjustment may only increase the number of shares issued, as the
	conversion price may only be reduced from the initially set level of $3.40.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In connection with the March 2014 Financing,
	the Company filed a Registration Statement on Form S-1 (Registration No. 333-195251) to register the resale of the shares of common
	stock underlying the Series C Preferred Stock, the shares of common stock underlying the March 2014 Warrants and certain shares
	of common stock that may be issuable as payment for dividends on the Series C Preferred Stock, which registration statement was
	declared effective by the SEC on April 25, 2014. Subsequently, and in accordance with the terms of the Series C Preferred Stock,
	such registration triggered a reduction of the conversion price of the Series C Preferred Stock from $3.40 to $2.71 and the exercise
	price of the warrants was reduced from $4.75 to $3.39 and from $5.10 to $4.07, as applicable. In addition, the number of March
	2014 Warrants was adjusted to reflect the decrease in exercise price. Consequently, as of May 2, 2014, an additional 786,977 shares
	of common stock may be issuable upon the conversion of the Series C Preferred Stock, an additional 62,958 shares may be issuable
	as payment for dividends thereon (the dividend amount represents the annual 8% accrual for the additional common stock to be issued
	due to ratchet triggering event) and additional 427,983 March 2014 Warrants at an exercise price of $3.39 and 427,983 additional
	March 2014 Warrants at an exercise price of $4.07 were issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the three month period ended June
	30, 2014, prior to its reclassification out of mezzanine into equity, 4,168 shares of the Series C Preferred Stock were converted
	into 1,529,262 shares of the Company&rsquo;s common stock. In addition, during the six-month period ended December 31, 2014, after
	reclassification from mezzanine into equity, certain investors elected to convert an additional 3,680 shares of the Series C Preferred
	Stock. As a result, 1,446,057 shares of common stock were issued by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On June 23, 2014, the holders of the Series
	C Preferred Stock agreed to amend the Company&rsquo;s Certificate of Designation of Preferences, Rights and Limitations of the
	Series C Preferred Stock (&ldquo;Certificate of Designations&rdquo;). Pursuant to the amendment, the holders of the Series C Preferred
	Stock were entitled, subject to the limitations on beneficial ownership contained in the Certificate of Designation, to vote on
	all matters as to which holders of the Company&rsquo;s shares of common stock are entitled to vote. Each share of the Series C
	Preferred Stock entitles its holder to such number of votes per share equal to the number of shares of common stock, which would
	be obtained upon the conversion of such share of the Series C Preferred Stock as if converted at market value of the common stock
	on the date of issuance. In addition, pursuant to the amendment, in the event of future adjustments, the conversion price of the
	Series C Preferred Stock will not be less than $0.25. As a result of the amendment, which limited the down round ratchet provision
	and fixed the maximum number of shares to be issued upon conversion, all then outstanding Series C Preferred Stock, in the total
	value of $1.9 million, was reclassified from mezzanine equity into stockholders equity of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In consideration for the consent of the
	Series C Preferred Stockholders to amend the Certificate of Designation, and pursuant to the consent of greater than 67% of the
	holders of the securities issued in the Company&rsquo;s March 2014 Financing allowing issuance of new securities by the Company,
	on June 23, 2014, the Company agreed to issue two-year warrants (the &ldquo;June Warrants&rdquo;) to purchase up to an aggregate
	of 427,179 shares of the Company&rsquo;s common stock to the original purchasers of the Series C Preferred Stock, at an exercise
	price of $3.00 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	92
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The June Warrants were valued at approximately
	$0.4 million, using the Black-Scholes option pricing model, using the following assumptions: volatility of 81.38%, risk free interest
	rate of 0.45%, grant date stock price of $2.60, expected term of 2 years and 0% dividend yield. The June Warrants were accounted
	for within the Company&rsquo;s equity. The Company accounted for the amendment of its Series C Preferred Stock, classified as mezzanine
	equity prior to such amendment, as a modification of terms, as the additional fair value granted to investors for such modification
	was less than 10% of pre-amendment value of the Series C Preferred Stock. As such, as of December 31, 2014, the Company recognized
	approximately $0.4 million, which was the total value of its June Warrants, as a deemed dividend.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On August 13, 2014, pursuant to an amendment
	agreement, the Company and all of the holders of March 2014 Warrants agreed to amend and restate the March 2014 Warrants to remove
	all anti-dilution provisions, and make certain other changes, in consideration for which, the exercise prices were reduced from
	$3.39 to $3.00 and from $4.07 to $3.50, and the number of warrants was increased from 2,108,938 to 2,381,342 and from 2,108,938
	to 2,449,380, respectively. In addition, the Company issued to such holders a total of 224,127 of its unregistered shares of common
	stock, in consideration for their consent to modify such warrants (the &ldquo;Amendment Agreement&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company accounted for the Amendment
	Agreement using the guidance in ASC 815 &ldquo;
<I>
	Derivatives and Hedging
</I>
	&rdquo; and ASC 470-50 &ldquo;
<I>
	Debt - Modifications
	and Extinguishments
</I>
	&rdquo;. Under ASC 470-50-40, as the overall modification was significant, extinguishment accounting was
	applied. As such, the difference between the fair value of the March 2014 Warrants just prior to the amendment and the fair value
	of the restated warrants and the restricted shares of common stock issued to investors, is to be recognized as a gain or a loss.
	As of August 13, 2014, the fair value of the original March 2014 Warrants was determined to be $7.9 million, the fair value of
	the restated warrants was determined to be $10.2 million and the value of the unregistered shares of common stock was approximately
	$0.8 million. As a result, a non-operating expense of $3.1 million was recorded in the consolidated statement of operations to
	reflect the extinguishment. Additionally, a total non-operating expense of $2.3 million was recorded in the third quarter of 2014,
	representing the revaluation of the March 2014 Warrants derivative liability to its fair value just prior to its amendment on August
	13, 2014. Since the warrants no longer contain the anti-dilution protection provisions after the amendment, they were no longer
	classified as liabilities, and therefore the fair value of the restated March 2014 Warrants of $10.2 million was reclassified to
	stockholders&rsquo; equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The fair value of the March 2014 Warrants
	was estimated using the Monte Carlo simulation and the Black-Scholes Model. The following assumptions were used to value the original
	warrants: volatility: 74.80%, share price: $4.11, risk free interest rate: 0.46%-0.52%, expected term: 2.50 years and dividend
	yield: 0%. The following assumptions were used to value the restated warrants: volatility: 74.40%, share price: $4.11, risk free
	interest rate: 0.71%, expected term: 2.03-2.08 years and dividend yield: 0%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On August 22, 2014, the Company filed a
	registration statement on Form S-3 (Registration No. 333-198309) to register for resale the additional shares of common stock issuable
	upon conversion of shares of the Series C Preferred Stock based on the adjusted conversion price of $2.71 per share, shares of
	common stock that may be issued as payment for dividends on the additional Series C Preferred Stock, payable through May 2, 2015,
	shares of common stock issuable upon exercise of the June Warrants, and the shares of its common stock issuable upon exercise of
	the Company&rsquo;s restated warrants. This registration statement on Form S-3 was declared effective on October 28, 2014, and
	subsequently, as a result, and in accordance with the terms of the Series C Preferred Stock, such registration triggered a reduction
	of the conversion price of the Series C Preferred Stock from $2.71 to $2.43. See Note 10 (b). In addition, as of December 31, 2014,
	the Company had paid $68,000 for its obligation to compensate its holders for the delayed filing of its registration statement,
	and $54,000 remained accrued for potential future obligations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	August 2014 Financing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In August 2014, the Company entered into
	an investment agreement with one of its investors. Pursuant to the agreement, the Company received gross proceed of $2.0 million
	upon closing. As consideration, the Company issued the investors 500,000 shares of its common stock, at $4.00 per share, and granted
	the investor 250,000 warrants (see Note 10 (b)(5)). Total issuance costs related to this financing were insignificant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	September 2014 Financing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2014, the Company entered
	into an investment agreement with one of its investors. Pursuant to the agreement, the Company received gross proceed of approximately
	$0.4 million upon closing. As consideration, the Company issued the investors 96,000 shares of its common stock, at $4.00 per share,
	and granted the investor 162,000 warrants (see Note 10 (b)(5)). Total issuance costs related to this financing were insignificant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	93
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	November 2014 Convertible Promissory
	Note
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 12, 2014, the Company received
	$1.0 million in cash proceeds resulting from a bridge financing (&ldquo;Bridge&rdquo;) by an investor who previously invested $2.0
	million in August 2014. Under the agreement, the Company issued to the investor a convertible promissory note (the &ldquo;Note&rdquo;),
	bearing an annual interest rate of 12%. The Note was subordinated to the Company&rsquo;s senior secured term loan from its lender,
	MidCap. If the Company completed an offering of common stock prior to November 6, 2019, the maturity date of the Note, the balance
	remaining outstanding under the Note would automatically convert into shares of its common stock, at the price per share of common
	stock sold in its next financing transaction.&nbsp;In addition, as consideration for the bridge financing, the Company entered
	into a side letter and agreed that if the price per share in its next public offering was less than $4.00 per share (the subscription
	price paid by such investor in the August 2014 Financing), it will issue additional shares of common stock to the investor in an
	amount such that the total subscription price paid in August 2014, when divided by the total number of shares issued to such investor
	will result in an actual price paid per share of common stock equal to such lower price. As a result, on November 12, 2014, the
	Company recognized a derivative liability, and a debt discount, in the same amount of approximately $0.7 million, to be accreted
	to interest expense through the maturity date of the Note, or upon conversion, if earlier.&nbsp; The derivative liability would
	be marked to market through the consolidated statement of operations at each reporting period until the next financing transaction
	of common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Furthermore, in connection with the Note,
	the Company accelerated the vesting of 433,333 restricted shares held by Melini, a related party (see Note16), and of 433,333 restricted
	shares previously granted to another existing investor, as a fee for assisting the Company in obtaining the Bridge. Upon the acceleration
	of vesting, $2.2 million of previously unrecognized expense relating to these restricted shares was recorded as debt issuance costs
	which will be amortized as interest expense over the term of the debt, or to conversion, if earlier.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 20, 2014, the Company completed
	an underwritten offering of common stock that triggered the conversion of the Note, re-measurement and reclassification of the
	derivative liability and the expensing of the related debt discount and debt issuance costs. Prior to the reclassification of the
	derivative liability into equity the derivative was revalued and a derivative liability expense of $80,000 was recorded in the
	consolidated statement of operations. Subsequently, the total derivative liability of approximately $0.8 million was re-classified
	to equity. Additionally, the total debt discount of approximately $0.7 million and debt issuance costs of $2.2 million were amortized
	to interest expense in November 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 14.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	November 2014 Underwritten Offering
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 20, 2014, the &ldquo;Company&rdquo;
	entered into an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with National Securities Corporation, as representative
	of the several underwriters named in Schedule VI to the Underwriting Agreement (the &ldquo;Underwriters&rdquo;), relating to an
	underwritten public offering of 3,450,000 units, with each unit consisting of (i) one share of the Company&rsquo;s common stock,
	par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), and (ii) a warrant to purchase 0.25 of a share of Common Stock, at
	a public offering price of $2.50 per unit, less underwriting discounts and commissions (the &ldquo;Offering&rdquo;). Under the
	terms of the Underwriting Agreement, the Company has granted the Underwriters an option, exercisable for 30 days subsequent to
	the closing of the transaction to purchase up to an additional 517,500 units to cover over-allotments, if any.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The warrants issued in the offering are
	exercisable for a period of three years following the issuance, at an exercise price of $3.75 per share. The warrants were not
	be listed on The NASDAQ Capital Market or any other exchange and no trading market for the warrants is expected to develop. The
	shares of Common Stock and warrants will be mandatorily separable immediately upon issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 26, 2014, the Company announced
	the completion of the underwriter&rsquo;s partial exercise of the over-allotment option to purchase 459,697 units, each consisting
	of (i) one share of common stock of the Company and (ii) a warrant to purchase 0.25 of a share of common stock of the Company,
	at a public offering price of $2.50 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The gross proceeds received by the Company
	from the primary offering, the partial exercise of overallotment shares and conversions of board fees owed for past services was
	$9.8 million. Underwriting commissions of approximately $0.7 million as well as additional financing fees of approximately $0.4
	million offset the total gross proceeds. The offering resulted in the issuance of 3,909,697 shares of common stock and 1,078,725
	warrants. The fair value of the issued warrants was approximately $1.4 million, which was determined using the Black-Scholes option
	pricing model, using the following assumptions: stock price of $2.75, expected term of 3.0 years, volatility of 84.66%, risk-free
	rate of 0.94%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 13.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	94
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 16. RELATED-PARTY TRANSACTIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD>
<B>
<I>
	(a) Dr. Daniel G. Teper
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2011, Immune Ltd. entered
	into an employment agreement with Dr. Teper under which he continued as Immune Ltd.&rsquo;s Chief Executive Officer. Immune Ltd.
	agreed to compensate Dr. Teper with a monthly salary of approximately $10,000 plus benefits and reimbursement of certain expenses.
	Dr. Teper was eligible for an annual bonus of up to 50% of his annual salary, based 50% upon successful achievement of personal
	objectives and the overall performance of his duties and obligations, and 50% on general corporate performance. The agreement was
	cancelable by Dr. Teper with six months&rsquo; prior notice and by Immune Ltd. with twelve months&rsquo; prior notice. On June
	1, 2014, Immune Ltd., and Dr. Teper entered into an amendment to an employment agreement, according to which, Dr. Teper&rsquo;s
	compensation is to be adjusted to reflect an annual compensation of $0.1 million per annum. Effective January 1, 2015, Dr. Teper&rsquo;s
	employment agreement with Immune Ltd. was terminated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On June 1, 2014, Dr. Teper entered into
	an additional employment agreement with Immune Inc. According to the agreement between Immune Inc. and Dr. Teper, an annual total
	compensation of $0.3 million is to be paid to Dr. Teper by the Company. In addition, the Company agreed to pay Dr. Teper a sign-on
	bonus for the services provided prior to the date of this agreement. Moreover, Dr. Teper is entitled for an annual incentive award,
	in cash or in equity, based on mutually agreed goals. Effective January 1, 2015, concurrent with his terminated agreement Dr. Teper&rsquo;s
	employment agreement with the Immune Inc. was amended to increase total compensation to $0.4 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In June 2011, Immune Pharmaceuticals Corporation,
	Inc., a wholly owned subsidiary of Immune Ltd., entered into a services agreement with 21 West Partners LLC (&ldquo;21 West&rdquo;),
	a company owned and controlled by Dr. Teper, a founder and CEO of Immune Ltd, under which, the Company agreed to pay $0.2 million
	annually for services rendered plus reimbursement for certain expenses. The agreement with 21 West was terminated by the parties
	in December 2013. In addition, Dr. Teper offset $60,000 of the amounts due to him under the service agreement with 21 West for
	participation in the March 2014 Financing. Total expenses recorded for 21 West Partners LLC and Dr. Teper in the aggregate amounted
	to $0, and $0.2 million in each of the years ended December 31, 2015 and 2014, respectively. As of December 31, 2015 and 2014 no
	amounts were due to Dr. Teper.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 2014, the Company granted Dr.
	Teper 750,000 options to the Company&rsquo;s shares of common stock, at an exercise price of $2.38. These options will vest quarterly
	over a three-year period. Total fair value at grant date was approximately $1.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	(b)
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Dr. Jean Kadouche, Ph.D.
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In July 2010, Immune Ltd. issued Dr. Kadouche
	shares of its ordinary stock, so that at the time of the transaction, Dr. Kadouche became a 50% owner of Immune Ltd. Immune Ltd.
	assigned no value to the shares issued in this transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In August 2013, Immune Ltd. and Dr. Kadouche
	entered into a consulting agreement, pursuant to which, Dr. Kadouche agreed to serve as Immune Ltd.&rsquo;s Vice President Biologics
	Research and Development and as a member of the Scientific Advisory Board. In consideration for his services, Immune Ltd. agreed
	to pay a consulting fee of up to $10,000 per any calendar month plus reimbursement of expenses if and when services are provided.
	Dr. Kadouche is also eligible to receive bonus compensation in any calendar year at the discretion of the Company&rsquo;s Board
	of Directors. In 2013, Immune Ltd. issued 22,917 of its ordinary shares to Dr. Kadouche as compensation for any past services rendered
	for which payment had not already been made. The shares were valued at $55,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Total expenses recorded for Dr. Kadouche
	in the aggregate amounted to $0.1 million and $15,000 for the years ended December 31, 2015 and 2014, respectively. As of December
	31, 2015 and 2014, no amounts were due to Dr. Kadouche.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	(c)
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Isaac Kobrin
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In October 2013, in connection with his
	board service, the Company awarded Dr. Kobrin ten-year options to purchase 100,000 ordinary shares at an exercise price of $2.50
	per share. Half of the options were immediately vested and half of the options vest within a three year period. The fair value
	of the options, based on the Black-Scholes option-pricing model, was approximately $0.2 million. In addition, in October 2013,
	the Company agreed to pay Dr. Isaac Kobrin $60,000 per year for his board services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In July 2014, Dr. Kobrin resigned from
	the Company&rsquo;s Board of Directors and signed a consulting agreement, under which he will be paid monthly fees of $5,000 for
	his services to the Company. In addition, his options continue to vest under their original terms. The related modification charge
	was insignificant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Total expenses recorded for Dr. Kobrin
	in the aggregate amounted to $0 and $30,000 in each of the years ended December 31, 2015 and 2014, respectively. In addition, Dr.
	Kobrin participated in the March 2014 financing by converting $60,000 owed to him by the Company. As of December 31, 2015 and 2014,
	$0 and $30,000 was due to Dr. Kobrin, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	95
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	(d)
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Mark E. Rothenberg, M.D., Ph.D.
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Mark E. Rothenberg, M.D., Ph.D. was the
	co-chairman of Immune Ltd.&rsquo;s Scientific Advisory Board. In March 2011, Immune Ltd. agreed to compensate Dr. Rothenberg $5,000
	per month for consulting services if and when services are provided plus 400,000 ordinary shares. The share grant was valued at
	$0.3 million based on the fair value of the share as of the date of grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In December 2013, in connection with his
	board service, Immune Ltd. awarded Dr. Rothenberg options to purchase 50,000 ordinary shares at an exercise price of $2.35 per
	share. The options were immediately vested. The fair value of the options, based on the Black-Scholes option pricing formula, was
	approximately $0.1 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Total expenses recorded for Dr. Rothenberg
	in the aggregate amounted to $0 and $20,000 for the years ended December 31, 2015 and 2014, respectively. In addition, Dr. Rothenberg
	participated in the March 2014 Financing by converting $39,000 into shares of the Company&rsquo;s Series C Preferred Stock for
	consulting fees due to him. As of December 31, 2015 and 2014, there were no amounts due to Dr. Rothenberg.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	(e)
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Daniel Kazado and Melini Capital Corp (&ldquo;Melini&rdquo;).
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Mr. Kazado originally served on the Board
	of Directors of Immune Ltd. and is now Chairman of Immune&rsquo;s Board of Directors. In January 2014, the Company entered into
	a consulting agreement with Melini, to which Mr. Kazado is related. In accordance with the agreement, Melini received a grant of
	600,000 restricted shares of common stock of the Company, to vest monthly over three years. The vesting of these restricted shares
	was accelerated in connection with the November 2014 Note (see Note 15). In connection with this grant, and acceleration, the Company
	recorded an expense of approximately $1.6 million for the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2012, Melini had previously received
	options to purchase an aggregate of 750,000 shares of the Company&rsquo;s common stock. As of December 31, 2015, those options
	were fully vested. The options had a grant date fair value aggregating approximately $1.2 million based on the Black-Scholes option-pricing
	model.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April 2014, the Company entered into
	a three-year, $5.0 million revolving line of credit with Melini, an existing stockholder, who is related to the Chairman of the
	Board of Directors. Borrowings under this revolving line of credit incur interest at a rate of 12% per year, payable quarterly.
	Drawdowns are available to the Company within four weeks of an official request. The revolving line of credit is unsecured and
	subordinated to the Loan Agreement. Either party to the revolving line of credit has the right to terminate this credit facility
	upon completion of a capital raise in excess of $5.0 million. On April 14, 2015, the revolving line of credit was amended to remove
	Melini&rsquo;s right to terminate the line of credit and extended to provide Melini the right to terminate the line of credit on
	the earlier of (i) one year from the amendment date, or (ii) the completion of a capital raise in excess of $5.0 million. The revolving
	line of credit was further amended upon the completion of the July 29, 2015 financings in which the Company completed a capital
	raise greater than $5.0 million. On August 7, 2015, Melini agreed to extend the revolving line of credit until September 30, 2015
	and on October 14, 2015, Melini agreed to extend the line of credit until November 30, 2016. In October 2015, the Company paid
	Melini $0.3 million as reimbursement for direct financial and administrative expenses accrued for the maintenance of the revolving
	line of credit from April 2014 to March 2016. To date, no amounts have been drawn under the revolving line of credit. Any amounts
	borrowed by the Company under the revolving line of credit become due upon the maturity date of November 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Mr. Kazado offset $20,000 of existing debt
	by the Company for participation in the March 2014 Financing. As of December 31, 2015 and 2014, $30,000 and $0 were due to Mr.
	Kazado for his board services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN; TEXT-INDENT: 0; PADDING-LEFT: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	(f)
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Soho Mavericks LLC
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 34.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2014, the Company entered
	into a consulting agreement with Soho Mavericks LLC, which was founded, and is being managed by Mr. Benjamin Teper, the son of
	the Company&rsquo;s CEO, Dr. Daniel Teper. According to the agreement, the Company is to pay a $5,000 monthly retainer for services
	received. In December 2014, the Company terminated the agreement with Soho Mavericks LLC. No expense was incurred under this agreement
	during the year ended December 31, 2015. &nbsp;During the year ended December 31, 2014, total payment under the consulting agreement
	of $20,000 was recorded. The Company paid $7,500 to Soho Mavericks LLC for media services performed during the year ended December
	31, 2015 unrelated to the 2014 consulting agreement. &nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 22.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	96
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_SUBSEQUENT_EVENTS>
<A NAME="FIS_SUBSEQUENT_EVENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTE 17.&nbsp;&nbsp;Subsequent Events
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	BioNanoSim Ltd - Nano Cyclosporine-A
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On January 1, 2016, the Company, through
	its wholly owned subsidiary, Immune Pharmaceuticals Ltd. entered into a definitive research and license agreement (the &ldquo;License&rdquo;)
	with BioNanoSim Ltd., (&ldquo;BNS&rdquo;). The License was entered into pursuant to an existing binding MOU, dated June 10, 2015,
	by and between the Company and Yissum. Under the License, the Company obtained from BNS an exclusive, worldwide sublicense, with
	a right to further sublicense, for the development, manufacturing and commercialization of certain inventions and research results
	regarding Yissum&rsquo;s patents in connection with nanoparticles for topical delivery of cyclosporine-A (&ldquo;Nanocyclo&rdquo;),
	for all topical skin indications. In consideration for the License, the Company will pay BNS the following payments throughout
	the term of the License:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
	an annual maintenance fee of $30,000, commencing on January 1, 2021, which
	maintenance fee shall increase by 30% each year, up to a maximum annual maintenance fee of $0.1 million and may be credited against
	royalties or milestone payments payable in the same calendar year;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
	a license fee in the amount of $0.5 million, to be paid in four equal installments
	to be made between January 4, 2016 and October 1, 2016; and
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
	royalties on net sales of products (as such term is defined in the License)
	by the Company in the amount of up to 5%, subject to certain possible reductions in certain jurisdictions;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
	sublicense fees in the amount of 18% of any non-sales related consideration
	received by the Company from a sublicense or an option to receive a sublicense for the products and/or the licensed technology
	(as such terms are defined in the license); and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
	milestones payments of up to approximately $4.5 million and 250,000 shares
	of the Company&rsquo;s common stock upon the achievement of certain regulatory, clinical development and commercialization milestones,
	though in the event that the Company receives consideration from a sublicensee for any such milestones, the Company will pay to
	BNS the higher of either (a) the amount of the particular milestone payment or (b) the amount of the sublicense fees that are due
	for such sublicensee consideration paid to the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, the Company
	shall reimburse BNS within 60 days for expenses relating to patent fees and will sponsor a 12-month research program to prepare
	the program for investigational new drug (&ldquo;IND&rdquo;) submission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Unless earlier terminated
	by the Company or by BNS pursuant to the provisions of the License, the License shall terminate on a country-by-country, product-
	by-product basis, upon the later of
<FONT STYLE="COLOR: #131315">
	(i) the date of expiration of the last valid claim included in
	the licensed technology that covers the particular product; (ii) the end of any exclusivity on the product granted by a regulatory
	or government body; or (iii) the end of a period of 15 years from the date of the first commercial sale of the particular product
	(as such terms
</FONT>
	are defined in the License)
<FONT STYLE="COLOR: #131315">
	. Should the periods referred to in (i) or (ii) expire
	prior to 15 years from the date of the first commercial sale in a particular country or countries, the license in that country
	or those countries shall be deemed a license to the know-how. At the end of the later of the periods as set forth above, the Company
	shall have a fully paid nonexclusive license to the licensed technology.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	97
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SUBSEQUENT_EVENTS>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage101"></A>
<A NAME="V434974_EX10-44_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.44
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_001.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_002.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_003.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_004.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_005.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_006.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_007.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_008.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_009.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_010.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_011.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_012.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_013.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_014.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_015.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_016.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_017.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; OPTIONS: LAST -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage118"></A>
<A NAME="V434974_EX10-45_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.45
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_018.JPG" ALT="" STYLE="HEIGHT: 124PX; WIDTH: 400PX">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	November 2, 2015
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	To: Monica Luchi
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	293 St. David Court
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Mount Laurel, NJ 08054
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dear Monica,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The purpose of this letter is to provide
	you with an employment offer specifying the terms and conditions of your employment with Immune Pharmaceuticals Inc. as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&#9;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Position and Duties:
</U>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	You will function as the Executive
	Vice President and Chief Medical Officer of Immune Pharmaceuticals Inc., and will perform all duties as determined necessary by
	Company&rsquo;s Board of Directors (the &quot;Board&quot;). This is a full-time position for which you agree to devote 100% of
	your working hours, provided that you may see patients one half day per week and the Company shall reimburse you for associated
	malpractice insurance at commercially reasonable rates as mutually agreed from time to time. You may be required to travel in accordance
	with Company&rsquo;s business needs, in accordance with Company's travel policy, as may be amended from time to time. It is understood
	that you may serve on the board of business entities, trade associations and charitable organizations, and engage in charitable
	activities and community affairs, provided that these activities do not materially interfere with the proper performance of your
	duties and responsibilities to Company, or create a conflict of interest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
<U>
	Term
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The term of your employment shall be effective as of November 19, 2015 or such other date as mutually agreed in writing and shall continue, unless terminated by either you or Company as set forth in Section 7 below (all periods of your employment with Company under this letter agreement, the &quot;Term&quot;). Please note that
<B>
</B>
	neither this letter agreement nor any other oral or written representations constitute a contract of employment with Company for any guaranteed specific period of time, and that Company shall have the discretion to determine whether or not you will be required to continue to perform your regular duties and/or report to work during any relevant notice period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Compensation:
</U>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Your annual base salary shall be $360,000; less required and authorized deductions (the &quot;Base Salary&quot;), with such Base Salary paid to you on a monthly basis in accordance with Company&rsquo;s regular payroll practices. It is agreed that during the Term your Base Salary shall not be decreased at any time without your prior written consent. As you know, your position is classified as exempt for purposes of federal wage-hour law and therefore you are not entitled to overtime pay.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In addition to the Base Salary, you will have the opportunity to earn additional compensation via an Incentive Plan, attached to this letter agreement as Schedule A, as may be amended from time to time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD>
<U>
	Paid Time Off and Benefits:
</U>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	You will be eligible to participate
	in all employee benefit plans, programs and arrangements, and all fringe benefits and perquisites that are made available to senior
	executives of Immune Pharmaceuticals Inc., including but not limited to health insurance coverage in accordance with the terms
	of the Immune Pharmaceuticals health insurance plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	You are entitled to take 21
	days of paid time off per calendar year (prorated, for partial years of employment), in addition to Company-designated holidays,
	in each case, in accordance with Company policy and in coordination with the Board. Please note that you shall be permitted to
	carryover up to 10 days from one calendar year to the next, and shall forfeit any accrued but unused vacation days above such amount.
	Upon your termination of employment for any reason you shall be entitled to payment for a maximum of 20 accrued but unused days.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In accordance with Company policy,
	you are entitled to reimbursement for those expenses reasonably incurred by you in connection with your employment duties, upon
	your submission of an expense report together with invoices to the financial department of Company, provided that such invoices
	are in form and in substance satisfactory to Company, and are submitted within thirty days of your incurring such expenses and
	provided further that such expenses are in line with Company's expense policy, as may be amended from time to time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Company Property
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	During the Term, Immune Pharmaceuticals
	may provide you with the benefit of using Company property, such as a laptop and/or cell phone. Your use of such Company property
	must be in accordance with Company guidelines, and you are obligated to return any such property to Company upon its request, and
	in any case upon the termination of your employment for any reason.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	6.
</TD>
<TD>
<U>
	Confidentiality and Insider Trading Policy
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Your continued employment is
	dependent upon your signing and complying with the terms of the Non-Disclosure and Non-Competition Agreement (&quot;NDNC&quot;)
	attached to this letter agreement as Schedule B, as well as complying with the insider trading policy of the Company from time
	to time according to the terms set forth in the Insider Trading Policy attached to this letter agreement as Schedule C.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	7.
</TD>
<TD>
<U>
	Termination
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	You employment may be terminated at any time as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Termination upon Death or Disability
</U>
	. The Term shall automatically end upon your death or
	Disability. For purposes of this letter agreement, &quot;Disability&quot; shall be defined as your failure to perform your regular
	duties on account of a physical or mental illness for a period of thirty consecutive work days, or forty-five days in any six-month
	period.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Termination for Cause
</U>
	. At any time, Company has the right to immediately terminate your
	employment for Cause. For purposes of this letter agreement, &quot;Cause&quot; shall be defined as your (i) failure to substantially
	perform the duties of your position for a period of at least fifteen calendar days following Company&rsquo;s written notice of
	such failure; (ii) engaging in conduct, which in Company&rsquo;s sole discretion, is demonstrably and materially injurious to Company,
	and which does not cease immediately following your receipt of written notice from Company specifying the nature of such conduct;
	(iii) acting in a manner which constitutes gross negligence or willful misconduct with respect to your duties to Company; (iv)
	misappropriating corporate assets or corporate opportunities, or any other acts of dishonesty or breach of fiduciary obligations
	to Immune Pharmaceuticals or its affiliated corporate entities; (v) committing a felony, or a misdemeanor involving moral turpitude
	(including the entry of a plea of
<I>
	nolo contendre
</I>
	); (vi) engaging in theft, embezzlement, self-dealing, or an act which causes
	material damage to Company and/or any of its related corporate entities, officers or directors, or (vii) materially violating this
	Agreement or your signed Non-Disclosure Non-Competition Agreement (&quot;NDNC&quot;).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Termination for Good Reason
</U>
	. You shall be entitled to terminate your employment with Company
	for &quot;Good Reason,&quot; which shall be defined as a: (i) material change to your role at Company which was not agreed upon
	with you; (ii) material breach by Company or any of its affiliated corporate entities of their material obligations to you; or
	(iii) failure of Company to obtain the assumption in writing of its obligations under this letter agreement by any successor to
	all or substantially all of its business or assets within fifteen days after any merger, sale, liquidation or dissolution of Company,
	in each case absent your consent. In order to qualify as a termination for Good Reason, you must give written notice to the Board
	of Company within fourteen calendar days of the occurrence of one of the above events, and Company must fail to cure within thirty
	calendar days of receiving such notice from you.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Termination without Cause.
</U>
	Your employment may be terminated by Company without Cause upon
	written notice from Company to you. Upon such termination, you shall be entitled to three months Base Salary, upon your signing
	of a release in form and in substance satisfactory to Company. In the event of a termination without Cause, Company shall in its
	discretion determine based on its business needs, the appropriate notice period and whether or not you will be obligated to report
	to work during such notice period. Upon termination for a change of control, you shall be entitled to six months Base Salary.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Termination without Good Reason
</U>
	. Your employment may be terminated by you for any reason
	at any time upon three months&rsquo; written notice from you to Company. In the event of such termination, Company shall have the
	right to determine whether or not you will be obligated to report to work during such notice period.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Notice of Termination
</U>
	. In the event of a termination of your employment for any reason,
	written notice of such termination must be given by one party to the other
<B>
</B>
	via certified or registered mail, email, fax,
	or by hand, and such notice shall be deemed to have been received three days after mailing, twenty-four hours after sending an
	email or fax, or immediately upon confirmation of receipt.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Transition
</U>
	. Regardless of the circumstances surrounding your termination of employment,
	it is agreed that upon such termination, you will return to Company all Company property and will make every effort to facilitate
	the orderly transition of your duties and responsibilities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	8.
</TD>
<TD>
<U>
	Dispute Resolution
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In the event of a dispute between
	you and Company arising out of or related to your employment with Immune Pharmaceuticals (with the exception of disputes arising
	under the NDNC), it is agreed that any such dispute shall be settled by means of arbitration administered under New York law by
	the American Arbitration Association (&quot;AAA&quot;) located in the State of New York and conducted in accordance with the AAA&rsquo;s
	Employment Rules. In such arbitration, the arbitrator (i) shall not amend or modify the terms of this letter agreement or of any
	Company policy, and (ii) shall render a decision within ten business days from the closing statements or submission of post-hearing
	briefs by the parties. The arbitration award shall be final and binding, and any state or federal court shall have jurisdiction
	to enter a judgment on such award. This requirement to arbitrate disputes shall apply to all claims and demands, including, without
	limitation, any rights you may assert under any federal, state, or local laws or regulations applicable to your employment with
	Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Section 409A of the Internal Revenue Code of 1986, as amended
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The intent
	with respect to any and all payments and benefits under this letter agreement (including Schedule A), is that such payments and
	benefits either: (i) do not constitute &quot;nonqualified deferred compensation&quot; within the meaning of Section 409A of the
	Internal Revenue Code (&quot;Section 409A&quot;), and therefore are exempt from Section 409A, or (ii) are subject to a &quot;substantial
	risk of forfeiture&quot; and are exempt from Section 409A under the &quot;short&minus;term deferral rule&quot; set forth in Treasury
	Regulation &sect;1.409A&minus;1(b)(4). In any event, it is confirmed that the intent is to have all provisions of this letter agreement
	(including Schedule A) construed, interpreted and administered in a manner consistent with the requirements for avoiding taxes
	or penalties under Section 409A.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During your employment with Company, you
	will be expected to abide by all Company policies, as established from time to time. Please note that the terms of your employment,
	as well as your post-employment obligations, will be governed by such Company policies, the NDNC, and the terms of this letter
	agreement, which supersedes any prior agreements, whether oral or written, between you and Company. In addition, all matters related
	to your relationship with Company shall be governed by New York law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To signify your agreement with the terms
	of employment as set forth in this letter agreement, please sign below where indicated, and send a copy of the signed letter agreement
	(including signed Schedule B) to Daniel Teper, CEO (daniel.teper@immunepharma.com). Please note that the terms of this letter agreement
	may be amended only via a writing signed by both you and an officer of Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We are confident in your ability to continue
	to contribute to Company's growth and success, and are happy to continue to have you as a valuable member of the Immune Pharmaceuticals
	team.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
	Sincerely,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 60%; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 35%; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<B>
	IMMUNE PHARMACEUTICALS INC.
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	By:&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING: 0; TEXT-INDENT: 0">
	Daniel G. Teper
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Name:
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Dr. Daniel G. Teper
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Title:
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Chief Executive Officer
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2IN; PADDING: 0; TEXT-INDENT: 0">
	Acknowledged and Accepted by:
</TD>
<TD STYLE="WIDTH: 2IN; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING: 0; TEXT-INDENT: 0">
	Monica Luchi
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<B>
	Monica Luchi
</B>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Date: November 2, 2015
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Schedule A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Incentive Plan:
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Equity
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Effective October 28, 2015, you
	have been granted an option to purchase 400,000 shares of Company&rsquo;s common stock, at a price per share equal to the market
	share price on the date of grant by the Board, whereas 33.33% shall vest on the first year anniversary of the date of grant (the
	&ldquo;Anniversary&rdquo;), and the remainder 66.66% shall vest in equal portions at the end of each three month period over the
	course of a two (2) year period commencing on the Anniversary, subject to acceleration in the event of Change of Control.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Incentive Award
</U>
	:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	You will be eligible for an annual
	incentive award for each calendar year of the Term, upon your achievement of mutually agreed upon goals, of up to $180,000, which
	may be granted in cash or in equity equivalent (with such equivalent value to be determined as of the date of the equity grant).
	The Board or any designated compensation committee shall have the sole discretion to determine whether you have met the mutually
	agreed upon set of goals, and the amount of such incentive award to be granted to you. The incentive award shall be paid to you
	in accordance with Company's annual incentive award payment practices and schedule for senior executives of Company. Please note
	that in order to receive such incentive award, you must be employed by Company, without notice of any termination having been given,
	on the date that such incentive award is scheduled to be paid to you.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Schedule B
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Non-Disclosure and Non-Competition
	Agreement:
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_019.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_020.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_021.JPG" ALT="">
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001144204-16-091621_IMAGE_022.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage127"></A>
<A NAME="V434974_EX21-1_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SUBSIDIARIES>
<A NAME="FIS_SUBSIDIARIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;21.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Subsidiaries of Immune Pharmaceuticals
	Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following are the subsidiaries of Immune Pharmaceuticals
	Inc.:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 39%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 59%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Jurisdiction of Incorporation
</B>
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immune Pharmaceuticals USA Corp.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Delaware
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immune Pharmaceuticals Ltd.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Israel
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Maxim Pharmaceuticals, Inc.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Delaware
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Cytovia, Inc.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Delaware
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EpiCept GmbH (closed January 2015)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Germany
</FONT>
</TD>
</TR>
</TABLE>
</EFX_SUBSIDIARIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage128"></A>
<A NAME="V434974_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;23.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	Consent of Independent
	Registered Public Accounting Firm
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: FUCHSIA">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Immune Pharmaceuticals
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	New York, New York
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: FUCHSIA">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We hereby consent to the
	incorporation by reference in the Registration Statements on Form S-8 (No. 333-195251) and Form S-3 (No. 333-198647) of Immune
	Pharmaceuticals, Inc. of our report dated March 30, 2016 relating to the financial statements of Immune Pharmaceuticals, Inc.,
	which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company&rsquo;s ability to continue
	as a going concern.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: FUCHSIA">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ BDO USA, LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: FUCHSIA">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	New York, New York
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: FUCHSIA">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	March 30, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: FUCHSIA">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage129"></A>
<A NAME="V434974_EX23-2_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;23.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We consent to the incorporation by reference
	in the Registration Statements of Immune Pharmaceuticals, Inc. on Form&nbsp;S-8 (Nos. 333-198521, 333-156438, 333-151150, 333-130865,
	333-130861 and 333-130860) and Form S-3 (Nos. 333-198309 and 333-198647) of our report dated April 15, 2015, on our audit of the
	consolidated financial statements as of December&nbsp;31, 2014 and for the year then ended, which report is included in this Annual
	Report on Form 10-K to be filed on or about March 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ EisnerAmper LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Iselin, New Jersey
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 30, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage130"></A>
<A NAME="V434974_EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;31.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
	PURSUANT TO
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	SECTION 302(a) OF THE SARBANES-OXLEY ACT
	OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	I, Dr. Daniel G. Teper, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	1. I have reviewed
	this Annual Report on Form&nbsp;10-K of Immune Pharmaceuticals Inc.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	2. Based on my knowledge,
	this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
	made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
	this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	3. Based on my knowledge,
	the financial statements, and other financial information included in this report, fairly present in all material respects the
	financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	4. The registrant&rsquo;s
	other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
	in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
	13a-15(f) and 15d-15(f)) for the registrant and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	a) designed such disclosure
	controls and procedures, or caused such disclosure controls and procedures to be designed under the Company&rsquo;s supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	b) designed such internal
	control over financial reporting, or caused such internal control over financial reporting to be designed under the Company&rsquo;s
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	c) evaluated the effectiveness
	of the registrant&rsquo;s disclosure controls and procedures and presented in this report the Company&rsquo;s conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	d) disclosed in this
	report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
	most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	5. The registrant&rsquo;s
	other certifying officer(s) and I have disclosed, based on the Company&rsquo;s most recent evaluation of internal control over
	financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or
	persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	a) all significant
	deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
	likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	b) any fraud, whether
	or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
	over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Date:&nbsp;&nbsp;&nbsp;&nbsp;March 30, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;Daniel G. Teper
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Daniel G. Teper
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chief Executive Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Executive Officer)
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage131"></A>
<A NAME="V434974_EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;31.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION PURSUANT TO
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	SECTION 302(a) OF THE SARBANES-OXLEY ACT
	OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	I, John Militello, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	1. I have reviewed
	this Annual Report on Form&nbsp;10-K of Immune Pharmaceuticals Inc.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	2. Based on my knowledge,
	this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
	made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
	this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	3. Based on my knowledge,
	the financial statements, and other financial information included in this report, fairly present in all material respects the
	financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	4. The registrant&rsquo;s
	other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
	in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
	13a-15(f) and 15d-15(f)) for the registrant and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	a) designed such disclosure
	controls and procedures, or caused such disclosure controls and procedures to be designed under the Company&rsquo;s supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	b) designed such internal
	control over financial reporting, or caused such internal control over financial reporting to be designed under the Company&rsquo;s
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	c) evaluated the effectiveness
	of the registrant&rsquo;s disclosure controls and procedures and presented in this report the Company&rsquo;s conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	d) disclosed in this
	report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
	most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	5. The registrant&rsquo;s
	other certifying officer(s) and I have disclosed, based on the Company&rsquo;s most recent evaluation of internal control over
	financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or
	persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	a) all significant
	deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
	likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 29.7PT">
	b) any fraud, whether
	or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
	over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Date:&nbsp;&nbsp;&nbsp;March 30, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;John Militello
</FONT>
</TD>
<TD STYLE="WIDTH: 51%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	John Militello
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	VP of Finance, Controller and Chief Accounting Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Financial Officer and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Principal Accounting Officer)
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage132"></A>
<A NAME="V434974_EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;32.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	PURSUANT TO 18 U.S.C. SECTION 1350,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	AS ADOPTED PURSUANT TO
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	SECTION 906 OF THE SARBANES-OXLEY ACT OF
	2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	In connection with
	the Annual Report of Immune Pharmaceuticals Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December&nbsp;31,
	2015 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Daniel G. Teper, Chief
	Executive Officer of the Company, certify, pursuant to 18 U.S.C &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes
	&ndash;Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	1)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 33.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -16.55PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	2)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;Daniel G. Teper
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Daniel G. Teper
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chief Executive Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Executive Officer)
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage133"></A>
<A NAME="V434974_EX32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit&nbsp;32.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	PURSUANT TO 18 U.S.C. SECTION 1350,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	AS ADOPTED PURSUANT TO
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	SECTION 906 OF THE SARBANES-OXLEY ACT OF
	2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.5PT">
	In connection with
	the Annual Report of Immune Pharmaceuticals Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December&nbsp;31,
	2015 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, John Militello, Principal
	Financial Officer of the Company, certify, pursuant to 18 U.S.C &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes
	&ndash;Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	1)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 33.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -16.55PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	2)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;John Militello
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	John Militello
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	VP of Finance, Controller and Chief Accounting Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Principal Financial Officer and
<BR>
	Principal Accounting Officer)
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	March 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
